[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fOLVpnOYbtE-ZaCpKbziO638TBywxVcbC-hSNYAOdEDo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":9,"truncated":10,"activeTrials":11,"phase3Count":12,"totalEnrollment":13,"activePrograms":14,"nonDrugCount":15,"topConditions":16,"upcomingReadouts":40,"phaseBuckets":89,"rows":96},"Indiana University",[4,6,7,8],"Indiana University Health Ball Memorial Hospital Rehabiliation Services","Indiana University Health","Indiana University Health Methodist Hospital",1045,false,233,42,1064149,47,760,[17,20,23,26,29,32,35,37],{"name":18,"count":19},"Depression",32,{"name":21,"count":22},"Anxiety",28,{"name":24,"count":25},"Breast Cancer",18,{"name":27,"count":28},"Alzheimer Disease",17,{"name":30,"count":31},"Asthma",16,{"name":33,"count":34},"Dementia",14,{"name":36,"count":34},"Gastroparesis",{"name":38,"count":39},"Hypertension",13,[41,46,51,56,61,65,70,74,79,84],{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT07030725","Menthol Stimulation of Brown Adipose Tissue in Humans: Aim 1","2026-03","Menthol Gel",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06411938","A Cervical Cancer Prevention Program in Kenya","2026-05-01","Gardisil-9",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT03507257","Longitudinal Early-onset Alzheimer's Disease Study Protocol","2026-05-31","Flortaucipir",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT04160910","5HTP Regulation Of Asthma In Children","2026-06-30","5-Hydroxytryptophan",{"nctId":62,"briefTitle":63,"date":59,"intervention":64},"NCT05435547","Preoperative Corticosteroids in Autoimmune Thyroid Disease","Dexamethasone",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT06996951","Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy","2026-07","CONTINUE NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID",{"nctId":71,"briefTitle":72,"date":68,"intervention":73},"NCT05821309","Evaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush Regimen","PEG 3350",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT05789173","Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK","2026-08-15","Methadone and Tizanidine",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT03827460","Sex Differences in the Response to Abstinence From Alcohol.","2026-08-31","Intravenous Alcohol",{"nctId":85,"briefTitle":86,"date":87,"intervention":88},"NCT07243275","SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease","2026-09-30","SYSTANE® PRO",[90,91,92,93,94,95],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[97,150,191,217,235,257,275,300,325,358,381,399,417,444,466,492,510,537,555,588,609,632,657,683,709,735,762,786,813,831,876,902,923,944,966,984,1010,1037,1055,1082,1114,1140,1158,1184,1208,1226,1244,1274,1333,1389,1419,1459,1505,1537,1577,1611,1644,1680,1713,1747,1779,1801,1819,1847,1865,1883,1901,1919,1949,1967,1985,2003,2021,2039,2061,2079,2106,2131,2149,2173,2201,2219,2244,2262,2288,2306,2324,2342,2367,2392,2410,2428,2451,2475,2500,2523,2547,2572,2599,2617,2642,2666,2689,2707,2731,2755,2773,2799,2817,2839,2866,2884,2906,2933,2951,2974,2998,3023,3048,3072,3090,3108,3134,3158,3180,3198,3223,3241,3263,3287,3309,3333,3359,3383,3408,3426,3490,3524,3566,3603,3625,3652,3670,3688,3715,3733,3751,3777,3795,3821,3839,3857,3880,3898,3921,3943,3968,3986,4009,4035,4053,4071,4097,4115,4138,4162,4185,4208,4226,4250,4268,4286,4304,4322,4340,4358,4376,4423,4462,4493,4527,4554,4587,4626,4660,4702,4727,4751,4769,4794,4816,4839,4864,4888,4911,4936,4957,4981,5007,5032,5054,5078,5096,5119,5148,5172,5190,5214,5232,5256,5281,5305,5323,5350,5374,5396,5422,5440,5463,5490,5508,5530,5554,5572,5597,5615,5639,5661,5685,5710,5728,5746,5770,5793,5811,5829,5855,5878,5907,5925,5948,5966,5998,6016,6038,6069,6099,6117,6140,6169,6187,6205,6223,6246,6268,6293,6315,6336,6359,6383,6408,6426,6458,6488,6512,6541,6559,6577,6602,6625,6649,6675,6702,6725,6749,6767,6789,6812,6849,6891,6921,6959,6987,7017,7051,7085,7107,7134,7165,7187,7218,7239,7263,7281,7306,7324,7342,7366,7384,7402,7426,7444,7462,7480,7506,7524,7542,7565,7583,7606,7632,7655,7677,7698,7720,7744,7762,7786,7804,7822,7844,7862,7883,7906,7930,7951,7979,7997,8015,8033,8051,8078,8096,8114,8137,8161,8179,8201,8225,8249,8267,8289,8313,8337,8355,8373,8397,8421,8443,8461],{"intervention":64,"totalTrials":98,"cells":99},3,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":109,"NA":148},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[],{"trials":106,"activeCount":102},[],{"trials":108,"activeCount":102},[],{"trials":110,"activeCount":147,"soonestReadout":59},[111,124,134],{"nctId":112,"briefTitle":113,"status":114,"phases":115,"primaryCompletion":116,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":122},"NCT02436265","Low Dose IV Dexamethasone in Prolonging Caudal Anesthesia in Children Undergoing Genitourinary Surgery","TERMINATED",[94],"2017-06-23","2017-12","2015-02",8,[121],"Surgery",[64,123],"Ropivacaine",{"nctId":62,"briefTitle":63,"status":125,"phases":126,"primaryCompletion":59,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":133},"RECRUITING",[94],"2026-12-30","2023-06-16",76,[131,132],"Graves Disease","Hashimoto Disease",[64],{"nctId":135,"briefTitle":136,"status":137,"phases":138,"primaryCompletion":139,"completion":139,"start":140,"enrollment":141,"conditions":142,"interventions":145},"NCT03822182","Single Shot Liposomal Bupivicaine in Rotator Cuff Surgery","COMPLETED",[94],"2020-01-22","2018-10-24",78,[143,144],"Rotator Cuff Tear","Pain, Postoperative",[146,64],"liposomal bupivicaine",1,{"trials":149,"activeCount":102},[],{"intervention":151,"totalTrials":152,"cells":153},"Surfactant",2,{"EARLY_PHASE1":154,"PHASE1":156,"PHASE2":158,"PHASE3":160,"PHASE4":162,"NA":189},{"trials":155,"activeCount":102},[],{"trials":157,"activeCount":102},[],{"trials":159,"activeCount":102},[],{"trials":161,"activeCount":102},[],{"trials":163,"activeCount":147,"soonestReadout":179},[164,175],{"nctId":165,"briefTitle":166,"status":137,"phases":167,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":174},"NCT05714865","Implementing LISA Surfactant in Nigeria",[94],"2025-03-30","2023-06-25",349,[172,173],"Respiratory Distress Syndrome","Neonatal Death",[151],{"nctId":176,"briefTitle":177,"status":125,"phases":178,"primaryCompletion":179,"completion":180,"start":181,"enrollment":182,"conditions":183,"interventions":188},"NCT06554522","Pragmatic Evaluation of Respiratory Distress Syndrome Treatment in Africa",[94],"2027-09-30","2027-12-30","2025-01-01",1512,[184,185,186,187],"Respiratory Distress Syndrome in Premature Infant","RDS of Prematurity","Surfactant Deficiency Syndrome Neonatal","Premature Birth",[151],{"trials":190,"activeCount":102},[],{"intervention":192,"totalTrials":147,"cells":193},"sufentanil",{"EARLY_PHASE1":194,"PHASE1":196,"PHASE2":198,"PHASE3":200,"PHASE4":202,"NA":215},{"trials":195,"activeCount":102},[],{"trials":197,"activeCount":102},[],{"trials":199,"activeCount":102},[],{"trials":201,"activeCount":102},[],{"trials":203,"activeCount":147,"soonestReadout":208},[204],{"nctId":205,"briefTitle":206,"status":125,"phases":207,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":213},"NCT06784999","Sufentanil Infusion vs Intravenous Methadone for Postoperative Analgesia Following Head and Neck Dissection With Free Flap or Rotational Reconstruction",[94],"2027-11-04","2025-01-10",128,[212],"Free Flap Reconstruction",[192,214],"methadone",{"trials":216,"activeCount":102},[],{"intervention":214,"totalTrials":147,"cells":218},{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":225,"PHASE4":227,"NA":233},{"trials":220,"activeCount":102},[],{"trials":222,"activeCount":102},[],{"trials":224,"activeCount":102},[],{"trials":226,"activeCount":102},[],{"trials":228,"activeCount":147,"soonestReadout":208},[229],{"nctId":205,"briefTitle":206,"status":125,"phases":230,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":231,"interventions":232},[94],[212],[192,214],{"trials":234,"activeCount":102},[],{"intervention":88,"totalTrials":147,"cells":236},{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":243,"PHASE4":245,"NA":255},{"trials":238,"activeCount":102},[],{"trials":240,"activeCount":102},[],{"trials":242,"activeCount":102},[],{"trials":244,"activeCount":102},[],{"trials":246,"activeCount":147,"soonestReadout":87},[247],{"nctId":85,"briefTitle":86,"status":125,"phases":248,"primaryCompletion":87,"completion":87,"start":249,"enrollment":250,"conditions":251,"interventions":253},[94],"2026-02-18",260,[252],"Dry Eye Disease (DED)",[88,254],"MIEBO™",{"trials":256,"activeCount":102},[],{"intervention":254,"totalTrials":147,"cells":258},{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":265,"PHASE4":267,"NA":273},{"trials":260,"activeCount":102},[],{"trials":262,"activeCount":102},[],{"trials":264,"activeCount":102},[],{"trials":266,"activeCount":102},[],{"trials":268,"activeCount":147,"soonestReadout":87},[269],{"nctId":85,"briefTitle":86,"status":125,"phases":270,"primaryCompletion":87,"completion":87,"start":249,"enrollment":250,"conditions":271,"interventions":272},[94],[252],[88,254],{"trials":274,"activeCount":102},[],{"intervention":276,"totalTrials":147,"cells":277},"Ondansetron 8mg",{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":284,"PHASE4":286,"NA":298},{"trials":279,"activeCount":102},[],{"trials":281,"activeCount":102},[],{"trials":283,"activeCount":102},[],{"trials":285,"activeCount":102},[],{"trials":287,"activeCount":147,"soonestReadout":292},[288],{"nctId":289,"briefTitle":290,"status":125,"phases":291,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":295,"interventions":297},"NCT05844501","Ondansetron for the Management of Atrial Fibrillation",[94],"2027-12-31","2025-04-22",80,[296],"Atrial Fibrillation",[276],{"trials":299,"activeCount":102},[],{"intervention":301,"totalTrials":147,"cells":302},"Heliox inspirate",{"EARLY_PHASE1":303,"PHASE1":305,"PHASE2":307,"PHASE3":309,"PHASE4":311,"NA":323},{"trials":304,"activeCount":102},[],{"trials":306,"activeCount":102},[],{"trials":308,"activeCount":102},[],{"trials":310,"activeCount":102},[],{"trials":312,"activeCount":147,"soonestReadout":317},[313],{"nctId":314,"briefTitle":315,"status":125,"phases":316,"primaryCompletion":317,"completion":317,"start":318,"enrollment":319,"conditions":320,"interventions":322},"NCT07424014","The Role of Heliox in Respiratory Control",[94],"2027-05-31","2026-02-03",15,[321],"Work of Breathing",[301],{"trials":324,"activeCount":102},[],{"intervention":326,"totalTrials":147,"cells":327},"Trimethoprim Sulfamethoxazole",{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":334,"PHASE4":336,"NA":356},{"trials":329,"activeCount":102},[],{"trials":331,"activeCount":102},[],{"trials":333,"activeCount":102},[],{"trials":335,"activeCount":102},[],{"trials":337,"activeCount":147,"soonestReadout":342},[338],{"nctId":339,"briefTitle":340,"status":125,"phases":341,"primaryCompletion":342,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":355},"NCT06982105","Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections",[94],"2027-06","2025-05-20",100,[346,347,348,349,350,351,352,353,354],"Methicillin Resistant Staphylococcus Aureus","Osteomyelitis Acute","Septic Arthritis","Orbital Cellulitis","Facial Cellulitis","Mastoiditis","Cervical Adenitis","Retropharyngeal Abscess","Peritonsillar Abscess",[326],{"trials":357,"activeCount":102},[],{"intervention":73,"totalTrials":147,"cells":359},{"EARLY_PHASE1":360,"PHASE1":362,"PHASE2":364,"PHASE3":366,"PHASE4":368,"NA":379},{"trials":361,"activeCount":102},[],{"trials":363,"activeCount":102},[],{"trials":365,"activeCount":102},[],{"trials":367,"activeCount":102},[],{"trials":369,"activeCount":147,"soonestReadout":68},[370],{"nctId":71,"briefTitle":72,"status":125,"phases":371,"primaryCompletion":68,"completion":68,"start":372,"enrollment":373,"conditions":374,"interventions":376},[94],"2023-06-08",65,[375],"Constipation",[73,377,378],"PEG-3350 with electrolytes","Glycerin",{"trials":380,"activeCount":102},[],{"intervention":377,"totalTrials":147,"cells":382},{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":389,"PHASE4":391,"NA":397},{"trials":384,"activeCount":102},[],{"trials":386,"activeCount":102},[],{"trials":388,"activeCount":102},[],{"trials":390,"activeCount":102},[],{"trials":392,"activeCount":147,"soonestReadout":68},[393],{"nctId":71,"briefTitle":72,"status":125,"phases":394,"primaryCompletion":68,"completion":68,"start":372,"enrollment":373,"conditions":395,"interventions":396},[94],[375],[73,377,378],{"trials":398,"activeCount":102},[],{"intervention":378,"totalTrials":147,"cells":400},{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":405,"PHASE3":407,"PHASE4":409,"NA":415},{"trials":402,"activeCount":102},[],{"trials":404,"activeCount":102},[],{"trials":406,"activeCount":102},[],{"trials":408,"activeCount":102},[],{"trials":410,"activeCount":147,"soonestReadout":68},[411],{"nctId":71,"briefTitle":72,"status":125,"phases":412,"primaryCompletion":68,"completion":68,"start":372,"enrollment":373,"conditions":413,"interventions":414},[94],[375],[73,377,378],{"trials":416,"activeCount":102},[],{"intervention":418,"totalTrials":147,"cells":419},"Netarsudil Ophthalmic Solution",{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":426,"PHASE4":428,"NA":442},{"trials":421,"activeCount":102},[],{"trials":423,"activeCount":102},[],{"trials":425,"activeCount":102},[],{"trials":427,"activeCount":102},[],{"trials":429,"activeCount":147,"soonestReadout":435},[430],{"nctId":431,"briefTitle":432,"status":433,"phases":434,"primaryCompletion":435,"completion":435,"start":436,"enrollment":437,"conditions":438,"interventions":441},"NCT07588152","Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension","NOT_YET_RECRUITING",[94],"2028-05","2026-05",50,[439,440],"Glaucoma","Ocular Hypertension",[418],{"trials":443,"activeCount":102},[],{"intervention":69,"totalTrials":147,"cells":445},{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":452,"PHASE4":462,"NA":464},{"trials":447,"activeCount":102},[],{"trials":449,"activeCount":102},[],{"trials":451,"activeCount":102},[],{"trials":453,"activeCount":147,"soonestReadout":68},[454],{"nctId":66,"briefTitle":67,"status":125,"phases":455,"primaryCompletion":68,"completion":68,"start":456,"enrollment":457,"conditions":458,"interventions":461},[93],"2025-07-02",64,[459,460],"Cystic Fibrosis (CF)","Chronic Rhinosinusitis (CRS)",[69],{"trials":463,"activeCount":102},[],{"trials":465,"activeCount":102},[],{"intervention":467,"totalTrials":147,"cells":468},"Inrathecal Morphine",{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":475,"PHASE4":488,"NA":490},{"trials":470,"activeCount":102},[],{"trials":472,"activeCount":102},[],{"trials":474,"activeCount":102},[],{"trials":476,"activeCount":147,"soonestReadout":481},[477],{"nctId":478,"briefTitle":479,"status":125,"phases":480,"primaryCompletion":481,"completion":481,"start":482,"enrollment":483,"conditions":484,"interventions":486},"NCT06593665","Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.",[93],"2026-12-31","2024-09-10",142,[485],"Testicular Cancer",[467,487],"Intravenous Methadone",{"trials":489,"activeCount":102},[],{"trials":491,"activeCount":102},[],{"intervention":487,"totalTrials":147,"cells":493},{"EARLY_PHASE1":494,"PHASE1":496,"PHASE2":498,"PHASE3":500,"PHASE4":506,"NA":508},{"trials":495,"activeCount":102},[],{"trials":497,"activeCount":102},[],{"trials":499,"activeCount":102},[],{"trials":501,"activeCount":147,"soonestReadout":481},[502],{"nctId":478,"briefTitle":479,"status":125,"phases":503,"primaryCompletion":481,"completion":481,"start":482,"enrollment":483,"conditions":504,"interventions":505},[93],[485],[467,487],{"trials":507,"activeCount":102},[],{"trials":509,"activeCount":102},[],{"intervention":511,"totalTrials":147,"cells":512},"Cervical ripening with a double balloon catheter plus misoprostol",{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":519,"PHASE4":533,"NA":535},{"trials":514,"activeCount":102},[],{"trials":516,"activeCount":102},[],{"trials":518,"activeCount":102},[],{"trials":520,"activeCount":147,"soonestReadout":525},[521],{"nctId":522,"briefTitle":523,"status":433,"phases":524,"primaryCompletion":525,"completion":526,"start":527,"enrollment":528,"conditions":529,"interventions":531},"NCT07576881","Impact of Standardization on Outcomes Following Cervical Ripening",[92,93],"2027-12","2028-04","2026-06",1158,[530],"Pregnancy",[511,532],"Usual-care control group",{"trials":534,"activeCount":102},[],{"trials":536,"activeCount":102},[],{"intervention":532,"totalTrials":147,"cells":538},{"EARLY_PHASE1":539,"PHASE1":541,"PHASE2":543,"PHASE3":545,"PHASE4":551,"NA":553},{"trials":540,"activeCount":102},[],{"trials":542,"activeCount":102},[],{"trials":544,"activeCount":102},[],{"trials":546,"activeCount":147,"soonestReadout":525},[547],{"nctId":522,"briefTitle":523,"status":433,"phases":548,"primaryCompletion":525,"completion":526,"start":527,"enrollment":528,"conditions":549,"interventions":550},[92,93],[530],[511,532],{"trials":552,"activeCount":102},[],{"trials":554,"activeCount":102},[],{"intervention":556,"totalTrials":152,"cells":557},"Slow Release DHEA",{"EARLY_PHASE1":558,"PHASE1":560,"PHASE2":562,"PHASE3":582,"PHASE4":584,"NA":586},{"trials":559,"activeCount":102},[],{"trials":561,"activeCount":102},[],{"trials":563,"activeCount":147,"soonestReadout":577},[564,573],{"nctId":565,"briefTitle":566,"status":137,"phases":567,"primaryCompletion":568,"completion":568,"start":569,"enrollment":25,"conditions":570,"interventions":572},"NCT05623059","Evaluate Pharmacokinetics and Safety of Slow Release DHEA",[91,92],"2025-04-24","2023-03-03",[30,571],"Genotype",[556],{"nctId":574,"briefTitle":575,"status":433,"phases":576,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":581},"NCT07179952","Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA )",[92],"2028-09-30","2027-01-01",30,[30],[556],{"trials":583,"activeCount":102},[],{"trials":585,"activeCount":102},[],{"trials":587,"activeCount":102},[],{"intervention":60,"totalTrials":147,"cells":589},{"EARLY_PHASE1":590,"PHASE1":592,"PHASE2":594,"PHASE3":603,"PHASE4":605,"NA":607},{"trials":591,"activeCount":102},[],{"trials":593,"activeCount":102},[],{"trials":595,"activeCount":147,"soonestReadout":59},[596],{"nctId":57,"briefTitle":58,"status":125,"phases":597,"primaryCompletion":59,"completion":59,"start":598,"enrollment":599,"conditions":600,"interventions":602},[92],"2021-02-11",20,[601],"Mild or Moderate Asthma With Allergic Sensitization",[60],{"trials":604,"activeCount":102},[],{"trials":606,"activeCount":102},[],{"trials":608,"activeCount":102},[],{"intervention":610,"totalTrials":147,"cells":611},"Extended Release Niacin",{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":626,"PHASE4":628,"NA":630},{"trials":613,"activeCount":102},[],{"trials":615,"activeCount":102},[],{"trials":617,"activeCount":147,"soonestReadout":622},[618],{"nctId":619,"briefTitle":620,"status":125,"phases":621,"primaryCompletion":622,"completion":622,"start":623,"enrollment":579,"conditions":624,"interventions":625},"NCT06582706","Nicotinic Acid for the Treatment of Alzheimer's Disease",[91,92],"2026-12","2024-12-19",[27],[610],{"trials":627,"activeCount":102},[],{"trials":629,"activeCount":102},[],{"trials":631,"activeCount":102},[],{"intervention":633,"totalTrials":147,"cells":634},"SAMe 400 mg",{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":651,"PHASE4":653,"NA":655},{"trials":636,"activeCount":102},[],{"trials":638,"activeCount":102},[],{"trials":640,"activeCount":147,"soonestReadout":645},[641],{"nctId":642,"briefTitle":643,"status":125,"phases":644,"primaryCompletion":645,"completion":645,"start":646,"enrollment":647,"conditions":648,"interventions":650},"NCT04250259","SAMe Trial for Patients With Alcoholic Cirrhosis",[92],"2027-03-01","2020-10-22",196,[649],"Alcoholic Cirrhosis",[633],{"trials":652,"activeCount":102},[],{"trials":654,"activeCount":102},[],{"trials":656,"activeCount":102},[],{"intervention":658,"totalTrials":147,"cells":659},"Alkaline glycine",{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":677,"PHASE4":679,"NA":681},{"trials":661,"activeCount":102},[],{"trials":663,"activeCount":102},[],{"trials":665,"activeCount":147,"soonestReadout":671},[666],{"nctId":667,"briefTitle":668,"status":669,"phases":670,"primaryCompletion":671,"completion":671,"start":672,"enrollment":673,"conditions":674,"interventions":676},"NCT04738422","Determining Airway pH by Compartmental Exhaled Nitric Oxide Levels During Alkaline Buffer Challenge","ENROLLING_BY_INVITATION",[92],"2028-07-15","2020-09-11",150,[675],"Airway Disease",[658],{"trials":678,"activeCount":102},[],{"trials":680,"activeCount":102},[],{"trials":682,"activeCount":102},[],{"intervention":684,"totalTrials":147,"cells":685},"Guanfacine Extended Release",{"EARLY_PHASE1":686,"PHASE1":688,"PHASE2":690,"PHASE3":703,"PHASE4":705,"NA":707},{"trials":687,"activeCount":102},[],{"trials":689,"activeCount":102},[],{"trials":691,"activeCount":147,"soonestReadout":696},[692],{"nctId":693,"briefTitle":694,"status":125,"phases":695,"primaryCompletion":696,"completion":697,"start":698,"enrollment":699,"conditions":700,"interventions":702},"NCT06629259","Guanfacine for Alcohol Use Disorder (AUD)",[92],"2029-08-31","2029-09-07","2025-10-03",200,[701],"Alcohol Use Disorder",[684],{"trials":704,"activeCount":102},[],{"trials":706,"activeCount":102},[],{"trials":708,"activeCount":102},[],{"intervention":710,"totalTrials":147,"cells":711},"Psilocybin",{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":729,"PHASE4":731,"NA":733},{"trials":713,"activeCount":102},[],{"trials":715,"activeCount":102},[],{"trials":717,"activeCount":147,"soonestReadout":722},[718],{"nctId":719,"briefTitle":720,"status":433,"phases":721,"primaryCompletion":722,"completion":723,"start":724,"enrollment":437,"conditions":725,"interventions":728},"NCT07499583","Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder",[91,92],"2031-01-01","2031-02-28","2026-08-01",[726,727],"Treatment Resistant Depression","Substance Use Disorders",[710],{"trials":730,"activeCount":102},[],{"trials":732,"activeCount":102},[],{"trials":734,"activeCount":102},[],{"intervention":736,"totalTrials":147,"cells":737},"Optate",{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":756,"PHASE4":758,"NA":760},{"trials":739,"activeCount":102},[],{"trials":741,"activeCount":102},[],{"trials":743,"activeCount":147,"soonestReadout":749},[744],{"nctId":745,"briefTitle":746,"status":747,"phases":748,"primaryCompletion":749,"completion":749,"start":750,"enrollment":751,"conditions":752,"interventions":755},"NCT05799521","A Nasal Treatment for COVID-19","ACTIVE_NOT_RECRUITING",[92],"2027-03-30","2023-06-27",24,[753,754],"COVID-19","Healthy",[736],{"trials":757,"activeCount":102},[],{"trials":759,"activeCount":102},[],{"trials":761,"activeCount":102},[],{"intervention":763,"totalTrials":147,"cells":764},"Tapinarof",{"EARLY_PHASE1":765,"PHASE1":767,"PHASE2":769,"PHASE3":780,"PHASE4":782,"NA":784},{"trials":766,"activeCount":102},[],{"trials":768,"activeCount":102},[],{"trials":770,"activeCount":147,"soonestReadout":292},[771],{"nctId":772,"briefTitle":773,"status":125,"phases":774,"primaryCompletion":292,"completion":292,"start":775,"enrollment":776,"conditions":777,"interventions":779},"NCT06561321","Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma",[92],"2024-10-30",6,[778],"Palmoplantar Keratoderma",[763],{"trials":781,"activeCount":102},[],{"trials":783,"activeCount":102},[],{"trials":785,"activeCount":102},[],{"intervention":787,"totalTrials":147,"cells":788},"Zanzalintinib",{"EARLY_PHASE1":789,"PHASE1":791,"PHASE2":793,"PHASE3":807,"PHASE4":809,"NA":811},{"trials":790,"activeCount":102},[],{"trials":792,"activeCount":102},[],{"trials":794,"activeCount":147,"soonestReadout":799},[795],{"nctId":796,"briefTitle":797,"status":125,"phases":798,"primaryCompletion":799,"completion":800,"start":801,"enrollment":802,"conditions":803,"interventions":805},"NCT06937866","Maintenance Zanzalintinib With Etoposide After HDCT in GCT",[91,92],"2030-03","2031-09","2025-11-12",38,[804],"Germ Cell Tumor",[787,806],"Etoposide",{"trials":808,"activeCount":102},[],{"trials":810,"activeCount":102},[],{"trials":812,"activeCount":102},[],{"intervention":806,"totalTrials":147,"cells":814},{"EARLY_PHASE1":815,"PHASE1":817,"PHASE2":819,"PHASE3":825,"PHASE4":827,"NA":829},{"trials":816,"activeCount":102},[],{"trials":818,"activeCount":102},[],{"trials":820,"activeCount":147,"soonestReadout":799},[821],{"nctId":796,"briefTitle":797,"status":125,"phases":822,"primaryCompletion":799,"completion":800,"start":801,"enrollment":802,"conditions":823,"interventions":824},[91,92],[804],[787,806],{"trials":826,"activeCount":102},[],{"trials":828,"activeCount":102},[],{"trials":830,"activeCount":102},[],{"intervention":832,"totalTrials":152,"cells":833},"Lacosamide",{"EARLY_PHASE1":834,"PHASE1":836,"PHASE2":856,"PHASE3":870,"PHASE4":872,"NA":874},{"trials":835,"activeCount":102},[],{"trials":837,"activeCount":147,"soonestReadout":842},[838],{"nctId":839,"briefTitle":840,"status":125,"phases":841,"primaryCompletion":842,"completion":842,"start":843,"enrollment":751,"conditions":844,"interventions":855},"NCT05603702","STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis",[91],"2027-03-31","2023-03-17",[845,846,847,848,849,850,851,852,853,854],"Chronic Pain","Chronic Pain Syndrome","Chronic Pancreatitis","Hyperalgesia","Opioid Use Disorder","Opioid-Related Disorders","Opioid Dependence","Chronic Abdominal Pain","ERCP","Pancreatic Surgery",[832],{"trials":857,"activeCount":102},[858],{"nctId":859,"briefTitle":860,"status":861,"phases":862,"primaryCompletion":863,"completion":863,"start":864,"enrollment":102,"conditions":865,"interventions":869},"NCT02342977","Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty:","WITHDRAWN",[92],"2016-08","2014-11",[866,867,868],"Osteoarthritis","Rheumatoid Arthritis","Avascular Necrosis",[832],{"trials":871,"activeCount":102},[],{"trials":873,"activeCount":102},[],{"trials":875,"activeCount":102},[],{"intervention":877,"totalTrials":147,"cells":878},"Caffeine citrate",{"EARLY_PHASE1":879,"PHASE1":881,"PHASE2":894,"PHASE3":896,"PHASE4":898,"NA":900},{"trials":880,"activeCount":102},[],{"trials":882,"activeCount":147,"soonestReadout":887},[883],{"nctId":884,"briefTitle":885,"status":433,"phases":886,"primaryCompletion":887,"completion":342,"start":888,"enrollment":579,"conditions":889,"interventions":893},"NCT07570121","Pharmacokinetics and Placental Transfer of Caffeine",[91],"2027-03","2026-04",[890,187,891,172,892],"Preterm Labor With Preterm Delivery","Apnea of Prematurity","Bronchopulmonary Dysplasia",[877],{"trials":895,"activeCount":102},[],{"trials":897,"activeCount":102},[],{"trials":899,"activeCount":102},[],{"trials":901,"activeCount":102},[],{"intervention":83,"totalTrials":147,"cells":903},{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":915,"PHASE3":917,"PHASE4":919,"NA":921},{"trials":905,"activeCount":102},[],{"trials":907,"activeCount":147,"soonestReadout":82},[908],{"nctId":80,"briefTitle":81,"status":125,"phases":909,"primaryCompletion":82,"completion":910,"start":911,"enrollment":912,"conditions":913,"interventions":914},[91],"2028-08-31","2019-04-10",160,[701],[83],{"trials":916,"activeCount":102},[],{"trials":918,"activeCount":102},[],{"trials":920,"activeCount":102},[],{"trials":922,"activeCount":102},[],{"intervention":45,"totalTrials":147,"cells":924},{"EARLY_PHASE1":925,"PHASE1":934,"PHASE2":936,"PHASE3":938,"PHASE4":940,"NA":942},{"trials":926,"activeCount":147,"soonestReadout":44},[927],{"nctId":42,"briefTitle":43,"status":125,"phases":928,"primaryCompletion":44,"completion":929,"start":930,"enrollment":751,"conditions":931,"interventions":933},[90],"2026-09","2025-03-27",[932],"Regulation of Energy Expenditure",[45],{"trials":935,"activeCount":102},[],{"trials":937,"activeCount":102},[],{"trials":939,"activeCount":102},[],{"trials":941,"activeCount":102},[],{"trials":943,"activeCount":102},[],{"intervention":78,"totalTrials":147,"cells":945},{"EARLY_PHASE1":946,"PHASE1":956,"PHASE2":958,"PHASE3":960,"PHASE4":962,"NA":964},{"trials":947,"activeCount":147,"soonestReadout":77},[948],{"nctId":75,"briefTitle":76,"status":125,"phases":949,"primaryCompletion":77,"completion":481,"start":950,"enrollment":951,"conditions":952,"interventions":954},[90],"2023-10-06",60,[953],"Drug-Drug Interaction",[78,955],"Efavirenz, Methadone and Tizanidine",{"trials":957,"activeCount":102},[],{"trials":959,"activeCount":102},[],{"trials":961,"activeCount":102},[],{"trials":963,"activeCount":102},[],{"trials":965,"activeCount":102},[],{"intervention":955,"totalTrials":147,"cells":967},{"EARLY_PHASE1":968,"PHASE1":974,"PHASE2":976,"PHASE3":978,"PHASE4":980,"NA":982},{"trials":969,"activeCount":147,"soonestReadout":77},[970],{"nctId":75,"briefTitle":76,"status":125,"phases":971,"primaryCompletion":77,"completion":481,"start":950,"enrollment":951,"conditions":972,"interventions":973},[90],[953],[78,955],{"trials":975,"activeCount":102},[],{"trials":977,"activeCount":102},[],{"trials":979,"activeCount":102},[],{"trials":981,"activeCount":102},[],{"trials":983,"activeCount":102},[],{"intervention":985,"totalTrials":147,"cells":986},"ICI Therapy",{"EARLY_PHASE1":987,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1006,"NA":1008},{"trials":988,"activeCount":147,"soonestReadout":525},[989],{"nctId":990,"briefTitle":991,"status":433,"phases":992,"primaryCompletion":525,"completion":525,"start":527,"enrollment":294,"conditions":993,"interventions":999},"NCT07389525","Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study",[90],[994,995,996,997,998],"Gastrointestinal Neoplasms","Genitourinary Cancer","Thoracic Cancer","Sarcoma","Melanoma",[985],{"trials":1001,"activeCount":102},[],{"trials":1003,"activeCount":102},[],{"trials":1005,"activeCount":102},[],{"trials":1007,"activeCount":102},[],{"trials":1009,"activeCount":102},[],{"intervention":1011,"totalTrials":147,"cells":1012},"[18F]-AraG radiotracer",{"EARLY_PHASE1":1013,"PHASE1":1027,"PHASE2":1029,"PHASE3":1031,"PHASE4":1033,"NA":1035},{"trials":1014,"activeCount":147,"soonestReadout":342},[1015],{"nctId":1016,"briefTitle":1017,"status":433,"phases":1018,"primaryCompletion":342,"completion":1019,"start":1020,"enrollment":1021,"conditions":1022,"interventions":1025},"NCT07168785","[18F]-AraG PET Imaging in LA HNSCC",[90],"2027-10","2025-10-01",5,[1023,1024],"Head and Neck Squamous Cell Carcinoma (HNSCC)","Locally Advanced Head and Neck Squamous Cell Carcinoma",[1011,1026],"Chemotherapy",{"trials":1028,"activeCount":102},[],{"trials":1030,"activeCount":102},[],{"trials":1032,"activeCount":102},[],{"trials":1034,"activeCount":102},[],{"trials":1036,"activeCount":102},[],{"intervention":1026,"totalTrials":147,"cells":1038},{"EARLY_PHASE1":1039,"PHASE1":1045,"PHASE2":1047,"PHASE3":1049,"PHASE4":1051,"NA":1053},{"trials":1040,"activeCount":147,"soonestReadout":342},[1041],{"nctId":1016,"briefTitle":1017,"status":433,"phases":1042,"primaryCompletion":342,"completion":1019,"start":1020,"enrollment":1021,"conditions":1043,"interventions":1044},[90],[1023,1024],[1011,1026],{"trials":1046,"activeCount":102},[],{"trials":1048,"activeCount":102},[],{"trials":1050,"activeCount":102},[],{"trials":1052,"activeCount":102},[],{"trials":1054,"activeCount":102},[],{"intervention":1056,"totalTrials":147,"cells":1057},"Carbon Dioxide",{"EARLY_PHASE1":1058,"PHASE1":1072,"PHASE2":1074,"PHASE3":1076,"PHASE4":1078,"NA":1080},{"trials":1059,"activeCount":147,"soonestReadout":1064},[1060],{"nctId":1061,"briefTitle":1062,"status":125,"phases":1063,"primaryCompletion":1064,"completion":1064,"start":1065,"enrollment":1066,"conditions":1067,"interventions":1071},"NCT07420530","Respiratory and Real-time Dynamics in Exercise-Induced Paradoxical Vocal Fold Motion",[90],"2032-01-20","2026-04-20",120,[1068,1069,1070],"Exercise-Induced Vocal Cord Dysfunction","Paradoxical Vocal Fold Motion","Vocal Cord Dysfunction",[1056],{"trials":1073,"activeCount":102},[],{"trials":1075,"activeCount":102},[],{"trials":1077,"activeCount":102},[],{"trials":1079,"activeCount":102},[],{"trials":1081,"activeCount":102},[],{"intervention":50,"totalTrials":152,"cells":1083},{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1090,"PHASE4":1092,"NA":1094},{"trials":1085,"activeCount":102},[],{"trials":1087,"activeCount":102},[],{"trials":1089,"activeCount":102},[],{"trials":1091,"activeCount":102},[],{"trials":1093,"activeCount":102},[],{"trials":1095,"activeCount":152,"soonestReadout":49},[1096,1106],{"nctId":1097,"briefTitle":1098,"status":433,"phases":1099,"primaryCompletion":1100,"completion":1100,"start":1101,"enrollment":1102,"conditions":1103,"interventions":1105},"NCT07240220","The Mother-Daughter Project: Merck-4",[95],"2028-08-01","2026-02-01",2500,[1104],"Cervical Dysplasia",[50],{"nctId":47,"briefTitle":48,"status":747,"phases":1107,"primaryCompletion":49,"completion":49,"start":1108,"enrollment":1109,"conditions":1110,"interventions":1113},[95],"2024-04-02",2300,[1111,1112],"Cervical Cancer Prevention","Cervical Cancer",[50],{"intervention":1115,"totalTrials":147,"cells":1116},"FET F-18",{"EARLY_PHASE1":1117,"PHASE1":1119,"PHASE2":1121,"PHASE3":1123,"PHASE4":1125,"NA":1127},{"trials":1118,"activeCount":102},[],{"trials":1120,"activeCount":102},[],{"trials":1122,"activeCount":102},[],{"trials":1124,"activeCount":102},[],{"trials":1126,"activeCount":102},[],{"trials":1128,"activeCount":147,"soonestReadout":1133},[1129],{"nctId":1130,"briefTitle":1131,"status":125,"phases":1132,"primaryCompletion":1133,"completion":1134,"start":1135,"enrollment":599,"conditions":1136,"interventions":1138},"NCT05386043","Registering Genomics and Imaging of Tumors (ReGIT)",[],"2030-07-17","2032-07-17","2023-07-18",[1137],"Glioma",[1115,1139],"O-15 Radioisotope",{"intervention":1139,"totalTrials":147,"cells":1141},{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1146,"PHASE3":1148,"PHASE4":1150,"NA":1152},{"trials":1143,"activeCount":102},[],{"trials":1145,"activeCount":102},[],{"trials":1147,"activeCount":102},[],{"trials":1149,"activeCount":102},[],{"trials":1151,"activeCount":102},[],{"trials":1153,"activeCount":147,"soonestReadout":1133},[1154],{"nctId":1130,"briefTitle":1131,"status":125,"phases":1155,"primaryCompletion":1133,"completion":1134,"start":1135,"enrollment":599,"conditions":1156,"interventions":1157},[],[1137],[1115,1139],{"intervention":1159,"totalTrials":147,"cells":1160},"Cftr Modulators",{"EARLY_PHASE1":1161,"PHASE1":1163,"PHASE2":1165,"PHASE3":1167,"PHASE4":1169,"NA":1171},{"trials":1162,"activeCount":102},[],{"trials":1164,"activeCount":102},[],{"trials":1166,"activeCount":102},[],{"trials":1168,"activeCount":102},[],{"trials":1170,"activeCount":102},[],{"trials":1172,"activeCount":147,"soonestReadout":292},[1173],{"nctId":1174,"briefTitle":1175,"status":747,"phases":1176,"primaryCompletion":292,"completion":292,"start":1177,"enrollment":1178,"conditions":1179,"interventions":1183},"NCT04206436","CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis",[],"2019-12-18",63,[1180,1181,1182],"Cystic Fibrosis","Bone Loss","Muscle Loss",[1159],{"intervention":55,"totalTrials":147,"cells":1185},{"EARLY_PHASE1":1186,"PHASE1":1188,"PHASE2":1190,"PHASE3":1192,"PHASE4":1194,"NA":1196},{"trials":1187,"activeCount":102},[],{"trials":1189,"activeCount":102},[],{"trials":1191,"activeCount":102},[],{"trials":1193,"activeCount":102},[],{"trials":1195,"activeCount":102},[],{"trials":1197,"activeCount":147,"soonestReadout":54},[1198],{"nctId":52,"briefTitle":53,"status":125,"phases":1199,"primaryCompletion":54,"completion":54,"start":1200,"enrollment":1201,"conditions":1202,"interventions":1205},[],"2018-04-30",850,[1203,27,1204],"Early Onset Alzheimer Disease","Mild Cognitive Impairment",[55,1206,1207],"Florbetaben","Fluorodeoxyglucose",{"intervention":1206,"totalTrials":147,"cells":1209},{"EARLY_PHASE1":1210,"PHASE1":1212,"PHASE2":1214,"PHASE3":1216,"PHASE4":1218,"NA":1220},{"trials":1211,"activeCount":102},[],{"trials":1213,"activeCount":102},[],{"trials":1215,"activeCount":102},[],{"trials":1217,"activeCount":102},[],{"trials":1219,"activeCount":102},[],{"trials":1221,"activeCount":147,"soonestReadout":54},[1222],{"nctId":52,"briefTitle":53,"status":125,"phases":1223,"primaryCompletion":54,"completion":54,"start":1200,"enrollment":1201,"conditions":1224,"interventions":1225},[],[1203,27,1204],[55,1206,1207],{"intervention":1207,"totalTrials":147,"cells":1227},{"EARLY_PHASE1":1228,"PHASE1":1230,"PHASE2":1232,"PHASE3":1234,"PHASE4":1236,"NA":1238},{"trials":1229,"activeCount":102},[],{"trials":1231,"activeCount":102},[],{"trials":1233,"activeCount":102},[],{"trials":1235,"activeCount":102},[],{"trials":1237,"activeCount":102},[],{"trials":1239,"activeCount":147,"soonestReadout":54},[1240],{"nctId":52,"briefTitle":53,"status":125,"phases":1241,"primaryCompletion":54,"completion":54,"start":1200,"enrollment":1201,"conditions":1242,"interventions":1243},[],[1203,27,1204],[55,1206,1207],{"intervention":1245,"totalTrials":147,"cells":1246},"Buprenorphine or Methadone Treatment",{"EARLY_PHASE1":1247,"PHASE1":1249,"PHASE2":1251,"PHASE3":1253,"PHASE4":1255,"NA":1257},{"trials":1248,"activeCount":102},[],{"trials":1250,"activeCount":102},[],{"trials":1252,"activeCount":102},[],{"trials":1254,"activeCount":102},[],{"trials":1256,"activeCount":102},[],{"trials":1258,"activeCount":147,"soonestReadout":1263},[1259],{"nctId":1260,"briefTitle":1261,"status":669,"phases":1262,"primaryCompletion":1263,"completion":1264,"start":1265,"enrollment":1266,"conditions":1267,"interventions":1273},"NCT06415994","Multimodal Fetal and Placental Imaging and Biomarkers of Clinical Outcomes in Opioid Use Disorder",[],"2028-12-01","2029-12-01","2024-02-13",250,[849,1268,1269,1270,1271,1272],"Substance-Related Disorders","Pregnancy Related","Narcotic-Related Disorders","Buprenorphine Dependence","Methadone Dependence",[1245],{"intervention":1275,"totalTrials":1276,"cells":1277},"Aripiprazole",4,{"EARLY_PHASE1":1278,"PHASE1":1280,"PHASE2":1282,"PHASE3":1306,"PHASE4":1319,"NA":1331},{"trials":1279,"activeCount":102},[],{"trials":1281,"activeCount":102},[],{"trials":1283,"activeCount":102},[1284,1296],{"nctId":1285,"briefTitle":1286,"status":137,"phases":1287,"primaryCompletion":1288,"completion":1288,"start":1289,"enrollment":1290,"conditions":1291,"interventions":1294},"NCT00198055","A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.",[92],"2007-09","2005-01",25,[1292,1293],"Asperger's Disorder","Pervasive Developmental Disorder",[1295],"aripiprazole",{"nctId":1297,"briefTitle":1298,"status":137,"phases":1299,"primaryCompletion":1300,"completion":1300,"start":1301,"enrollment":1302,"conditions":1303,"interventions":1305},"NCT00420459","A Prospective Open-label Study of Aripiprazole in Fragile X Syndrome",[92],"2010-03","2007-04",12,[1304],"Fragile X Syndrome",[1275],{"trials":1307,"activeCount":102},[1308],{"nctId":1309,"briefTitle":1310,"status":137,"phases":1311,"primaryCompletion":1312,"completion":1312,"start":1313,"enrollment":1314,"conditions":1315,"interventions":1317},"NCT00198107","Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism",[93],"2011-09","2005-09",81,[1316],"Autistic Disorder",[1275,1318],"D-cycloserine",{"trials":1320,"activeCount":102},[1321],{"nctId":1322,"briefTitle":1323,"status":137,"phases":1324,"completion":1325,"start":1326,"enrollment":1327,"conditions":1328,"interventions":1330},"NCT00198198","Aripiprazole Treatment of Bipolar Depression",[94],"2006-11","2005-08",10,[1329],"Bipolar Depression",[1275],{"trials":1332,"activeCount":102},[],{"intervention":1334,"totalTrials":1276,"cells":1335},"Progesterone",{"EARLY_PHASE1":1336,"PHASE1":1338,"PHASE2":1340,"PHASE3":1353,"PHASE4":1355,"NA":1387},{"trials":1337,"activeCount":102},[],{"trials":1339,"activeCount":102},[],{"trials":1341,"activeCount":102},[1342],{"nctId":1343,"briefTitle":1344,"status":137,"phases":1345,"primaryCompletion":1346,"completion":1346,"start":1347,"enrollment":1348,"conditions":1349,"interventions":1351},"NCT01929083","Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening",[92],"2014-06","2013-04",19,[1350],"Prolonged QT Interval in EKG and Sudden Death",[1334,1352],"Ibutilide",{"trials":1354,"activeCount":102},[],{"trials":1356,"activeCount":102},[1357,1369,1378],{"nctId":1358,"briefTitle":1359,"status":137,"phases":1360,"primaryCompletion":1361,"completion":1362,"start":1363,"enrollment":1364,"conditions":1365,"interventions":1368},"NCT03834883","Reducing the Risk of Drug-Induced QT Interval Lengthening in Women",[94],"2024-05-21","2024-05-23","2019-03-26",27,[1366,1367],"Long QT Syndrome","Abnormalities, Drug-Induced",[1334,1352],{"nctId":1370,"briefTitle":1371,"status":137,"phases":1372,"primaryCompletion":1373,"completion":1373,"start":1374,"enrollment":34,"conditions":1375,"interventions":1376},"NCT02513940","Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes",[94],"2017-10-19","2016-05",[1366],[1377,1334,1352],"Testosterone",{"nctId":1379,"briefTitle":1380,"status":137,"phases":1381,"primaryCompletion":1382,"completion":1382,"start":1383,"enrollment":1384,"conditions":1385,"interventions":1386},"NCT04675788","Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening",[94],"2025-04-16","2021-09-02",73,[1366,1367],[1334,1352,1377],{"trials":1388,"activeCount":102},[],{"intervention":1352,"totalTrials":1276,"cells":1390},{"EARLY_PHASE1":1391,"PHASE1":1393,"PHASE2":1395,"PHASE3":1401,"PHASE4":1403,"NA":1417},{"trials":1392,"activeCount":102},[],{"trials":1394,"activeCount":102},[],{"trials":1396,"activeCount":102},[1397],{"nctId":1343,"briefTitle":1344,"status":137,"phases":1398,"primaryCompletion":1346,"completion":1346,"start":1347,"enrollment":1348,"conditions":1399,"interventions":1400},[92],[1350],[1334,1352],{"trials":1402,"activeCount":102},[],{"trials":1404,"activeCount":102},[1405,1409,1413],{"nctId":1358,"briefTitle":1359,"status":137,"phases":1406,"primaryCompletion":1361,"completion":1362,"start":1363,"enrollment":1364,"conditions":1407,"interventions":1408},[94],[1366,1367],[1334,1352],{"nctId":1370,"briefTitle":1371,"status":137,"phases":1410,"primaryCompletion":1373,"completion":1373,"start":1374,"enrollment":34,"conditions":1411,"interventions":1412},[94],[1366],[1377,1334,1352],{"nctId":1379,"briefTitle":1380,"status":137,"phases":1414,"primaryCompletion":1382,"completion":1382,"start":1383,"enrollment":1384,"conditions":1415,"interventions":1416},[94],[1366,1367],[1334,1352,1377],{"trials":1418,"activeCount":102},[],{"intervention":1420,"totalTrials":98,"cells":1421},"Escitalopram",{"EARLY_PHASE1":1422,"PHASE1":1424,"PHASE2":1426,"PHASE3":1428,"PHASE4":1430,"NA":1457},{"trials":1423,"activeCount":102},[],{"trials":1425,"activeCount":102},[],{"trials":1427,"activeCount":102},[],{"trials":1429,"activeCount":102},[],{"trials":1431,"activeCount":102},[1432,1441,1449],{"nctId":1433,"briefTitle":1434,"status":137,"phases":1435,"primaryCompletion":1436,"completion":1436,"start":1437,"enrollment":28,"conditions":1438,"interventions":1440},"NCT00707863","Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram",[94],"2012-12","2008-05",[1439],"Major Depression",[1420],{"nctId":1442,"briefTitle":1443,"status":114,"phases":1444,"completion":1313,"start":1445,"enrollment":599,"conditions":1446,"interventions":1447},"NCT00423969","Galantamine Augmentation of Escitalopram for Treatment of Depression",[94],"2003-11",[18],[1448,1420],"Galantamine",{"nctId":1450,"briefTitle":1451,"status":137,"phases":1452,"primaryCompletion":1453,"completion":1453,"start":1454,"enrollment":294,"conditions":1455,"interventions":1456},"NCT00456430","Serotonin Transporter Genetic Variation and Amygdalar Activation Correlates of Antidepressant Response",[94],"2007-08","2003-07",[18],[1420],{"trials":1458,"activeCount":102},[],{"intervention":1460,"totalTrials":98,"cells":1461},"Bupivacaine",{"EARLY_PHASE1":1462,"PHASE1":1464,"PHASE2":1466,"PHASE3":1478,"PHASE4":1491,"NA":1503},{"trials":1463,"activeCount":102},[],{"trials":1465,"activeCount":102},[],{"trials":1467,"activeCount":102},[1468],{"nctId":1469,"briefTitle":1470,"status":114,"phases":1471,"primaryCompletion":1472,"completion":1472,"start":1473,"enrollment":25,"conditions":1474,"interventions":1476},"NCT02343263","Effect of Bupivacaine-infused Fibrin Sealant Application on Post-tonsillectomy Pain & Hemorrhage",[92],"2017-05-31","2015-03",[144,1475],"Postoperative Hemorrhage",[1460,1477],"Fibrin Sealant",{"trials":1479,"activeCount":102},[1480],{"nctId":1481,"briefTitle":1482,"status":137,"phases":1483,"primaryCompletion":1484,"completion":1484,"start":1485,"enrollment":1486,"conditions":1487,"interventions":1490},"NCT01939314","Sphenopalatine Nerve Block for Headache Tx360",[93],"2013-12","2012-10",93,[1488,1489],"Headache","Migraine",[1460],{"trials":1492,"activeCount":102},[1493],{"nctId":1494,"briefTitle":1495,"status":137,"phases":1496,"primaryCompletion":1497,"completion":1497,"start":1498,"enrollment":1499,"conditions":1500,"interventions":1502},"NCT06120530","Intraperitoneal Bupivacaine for Pelvic Organ Prolapse",[94],"2024-03-15","2023-08-16",91,[1501],"Pelvic Organ Prolapse",[1460],{"trials":1504,"activeCount":102},[],{"intervention":1506,"totalTrials":152,"cells":1507},"Amiodarone",{"EARLY_PHASE1":1508,"PHASE1":1510,"PHASE2":1512,"PHASE3":1514,"PHASE4":1516,"NA":1535},{"trials":1509,"activeCount":102},[],{"trials":1511,"activeCount":102},[],{"trials":1513,"activeCount":102},[],{"trials":1515,"activeCount":102},[],{"trials":1517,"activeCount":102},[1518,1527],{"nctId":1519,"briefTitle":1520,"status":137,"phases":1521,"primaryCompletion":1522,"completion":1522,"start":1523,"enrollment":1524,"conditions":1525,"interventions":1526},"NCT00127712","Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery",[94],"2008-02","2004-09",130,[296],[1506],{"nctId":1528,"briefTitle":1529,"status":137,"phases":1530,"primaryCompletion":1531,"completion":1531,"start":1313,"enrollment":294,"conditions":1532,"interventions":1534},"NCT00420017","Prevention of Atrial Fibrillation Following Esophagectomy",[94],"2008-11",[296,1533],"Esophagectomy",[1506],{"trials":1536,"activeCount":102},[],{"intervention":1538,"totalTrials":152,"cells":1539},"Placebos",{"EARLY_PHASE1":1540,"PHASE1":1542,"PHASE2":1544,"PHASE3":1559,"PHASE4":1561,"NA":1575},{"trials":1541,"activeCount":102},[],{"trials":1543,"activeCount":102},[],{"trials":1545,"activeCount":102},[1546],{"nctId":1547,"briefTitle":1548,"status":137,"phases":1549,"primaryCompletion":1550,"completion":1551,"start":1552,"enrollment":1553,"conditions":1554,"interventions":1556},"NCT04072822","Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis",[92],"2022-05-24","2022-08-12","2020-07-10",147,[1555],"Alcoholic Hepatitis",[1557,1558,1538],"Anakinra and Zinc","Prednisone",{"trials":1560,"activeCount":102},[],{"trials":1562,"activeCount":102},[1563],{"nctId":1564,"briefTitle":1565,"status":114,"phases":1566,"primaryCompletion":1567,"completion":1568,"start":1569,"enrollment":1570,"conditions":1571,"interventions":1573},"NCT03040323","Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses",[94],"2018-06-30","2018-07-06","2016-12-22",83,[1572],"Liver Biopsy",[1574,1538],"Lumason 60.7Mg Powder for",{"trials":1576,"activeCount":102},[],{"intervention":1578,"totalTrials":152,"cells":1579},"Chlorthalidone",{"EARLY_PHASE1":1580,"PHASE1":1582,"PHASE2":1584,"PHASE3":1595,"PHASE4":1597,"NA":1609},{"trials":1581,"activeCount":102},[],{"trials":1583,"activeCount":102},[],{"trials":1585,"activeCount":102},[1586],{"nctId":1587,"briefTitle":1588,"status":137,"phases":1589,"primaryCompletion":1590,"completion":1590,"start":1591,"enrollment":912,"conditions":1592,"interventions":1594},"NCT02841280","Chlorthalidone in Chronic Kidney Disease",[92],"2021-04","2016-07",[1593,38],"Renal Insufficiency, Chronic",[1578],{"trials":1596,"activeCount":102},[],{"trials":1598,"activeCount":102},[1599],{"nctId":1600,"briefTitle":1601,"status":137,"phases":1602,"primaryCompletion":1603,"completion":1603,"start":1604,"enrollment":34,"conditions":1605,"interventions":1608},"NCT01750294","A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD",[94],"2013-08","2012-08",[1606,1607],"Chronic Kidney Disease","Poorly-Controlled Hypertension",[1578],{"trials":1610,"activeCount":102},[],{"intervention":1612,"totalTrials":152,"cells":1613},"naltrexone",{"EARLY_PHASE1":1614,"PHASE1":1616,"PHASE2":1618,"PHASE3":1630,"PHASE4":1632,"NA":1642},{"trials":1615,"activeCount":102},[],{"trials":1617,"activeCount":102},[],{"trials":1619,"activeCount":102},[1620],{"nctId":1621,"briefTitle":1622,"status":137,"phases":1623,"completion":1624,"start":1625,"enrollment":1626,"conditions":1627,"interventions":1629},"NCT00523133","Research on Individualized Treatment for Alcoholism",[92],"2005-07","2000-09",185,[1628],"Alcohol Dependence",[1612,1612],{"trials":1631,"activeCount":102},[],{"trials":1633,"activeCount":102},[1634],{"nctId":1635,"briefTitle":1636,"status":137,"phases":1637,"completion":1638,"start":1625,"enrollment":912,"conditions":1639,"interventions":1641},"NCT00006449","Post-Treatment Effects of Naltrexone",[94],"2006-07",[1640],"Alcoholism",[1612],{"trials":1643,"activeCount":102},[],{"intervention":1645,"totalTrials":152,"cells":1646},"Bupropion",{"EARLY_PHASE1":1647,"PHASE1":1658,"PHASE2":1660,"PHASE3":1662,"PHASE4":1664,"NA":1678},{"trials":1648,"activeCount":102},[1649],{"nctId":1650,"briefTitle":1651,"status":137,"phases":1652,"primaryCompletion":1653,"completion":1653,"start":1654,"enrollment":22,"conditions":1655,"interventions":1657},"NCT03420469","Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers",[90],"2019-05-01","2018-06-05",[1656],"Adverse Effect of Drug Therapy Metabolism Medications (Diagnosis)",[1645],{"trials":1659,"activeCount":102},[],{"trials":1661,"activeCount":102},[],{"trials":1663,"activeCount":102},[],{"trials":1665,"activeCount":102},[1666],{"nctId":1667,"briefTitle":1668,"status":137,"phases":1669,"primaryCompletion":1374,"completion":1670,"start":1671,"enrollment":1672,"conditions":1673,"interventions":1674},"NCT02401256","CYP2B6 Genetics and Drug Interactions in Healthy Volunteers",[94],"2016-05-31","2013-07",70,[754],[1675,1645,1676,1677],"Efavirenz","Rosuvastatin","Montelukast",{"trials":1679,"activeCount":102},[],{"intervention":1681,"totalTrials":152,"cells":1682},"quetiapine",{"EARLY_PHASE1":1683,"PHASE1":1685,"PHASE2":1687,"PHASE3":1699,"PHASE4":1701,"NA":1711},{"trials":1684,"activeCount":102},[],{"trials":1686,"activeCount":102},[],{"trials":1688,"activeCount":102},[1689],{"nctId":1690,"briefTitle":1691,"status":137,"phases":1692,"primaryCompletion":1693,"completion":1693,"start":1694,"enrollment":579,"conditions":1695,"interventions":1697},"NCT00550147","Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.",[92],"2005-11","2004-02",[1696],"Attention Deficit Disorder With Hyperactivity",[1698,1681],"Oros Methylphenidate",{"trials":1700,"activeCount":102},[],{"trials":1702,"activeCount":102},[1703],{"nctId":1704,"briefTitle":1705,"status":137,"phases":1706,"primaryCompletion":1707,"completion":1707,"start":1708,"enrollment":599,"conditions":1709,"interventions":1710},"NCT00982345","Brain Imaging of Quetiapine Response in Anxious Depression",[94],"2012-03","2009-03",[1439],[1681],{"trials":1712,"activeCount":102},[],{"intervention":1714,"totalTrials":152,"cells":1715},"Erythromycin",{"EARLY_PHASE1":1716,"PHASE1":1718,"PHASE2":1720,"PHASE3":1722,"PHASE4":1733,"NA":1745},{"trials":1717,"activeCount":102},[],{"trials":1719,"activeCount":102},[],{"trials":1721,"activeCount":102},[],{"trials":1723,"activeCount":102},[1724],{"nctId":1725,"briefTitle":1726,"status":861,"phases":1727,"primaryCompletion":1485,"completion":1485,"start":1728,"enrollment":102,"conditions":1729,"interventions":1731},"NCT01556334","Erythromycin Versus Azithromycin in Preterm Premature Rupture of Membranes",[93],"2010-04",[1730],"Preterm Premature Ruptured Membranes",[1732,1714],"Azithromycin",{"trials":1734,"activeCount":102},[1735],{"nctId":1736,"briefTitle":1737,"status":137,"phases":1738,"completion":1739,"start":1740,"enrollment":1741,"conditions":1742,"interventions":1743},"NCT00318201","The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers",[94],"2007-12","2006-04",7,[754],[1714,1744],"Diltiazem",{"trials":1746,"activeCount":102},[],{"intervention":1748,"totalTrials":152,"cells":1749},"Lithium",{"EARLY_PHASE1":1750,"PHASE1":1752,"PHASE2":1754,"PHASE3":1756,"PHASE4":1758,"NA":1777},{"trials":1751,"activeCount":102},[],{"trials":1753,"activeCount":102},[],{"trials":1755,"activeCount":102},[],{"trials":1757,"activeCount":102},[],{"trials":1759,"activeCount":102},[1760,1767],{"nctId":1761,"briefTitle":1762,"status":137,"phases":1763,"primaryCompletion":1764,"completion":1764,"start":1454,"enrollment":951,"conditions":1765,"interventions":1766},"NCT00457054","Functional Connectivity in Mood Regulating Circuit In Bipolar Depression and Mania",[94],"2007-03",[1329],[1748],{"nctId":1768,"briefTitle":1769,"status":137,"phases":1770,"primaryCompletion":1771,"completion":1772,"start":1453,"enrollment":1773,"conditions":1774,"interventions":1776},"NCT00596622","FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder",[94],"2012-01","2012-11",46,[1775],"Bipolar Disorder",[1748],{"trials":1778,"activeCount":102},[],{"intervention":1377,"totalTrials":152,"cells":1780},{"EARLY_PHASE1":1781,"PHASE1":1783,"PHASE2":1785,"PHASE3":1787,"PHASE4":1789,"NA":1799},{"trials":1782,"activeCount":102},[],{"trials":1784,"activeCount":102},[],{"trials":1786,"activeCount":102},[],{"trials":1788,"activeCount":102},[],{"trials":1790,"activeCount":102},[1791,1795],{"nctId":1370,"briefTitle":1371,"status":137,"phases":1792,"primaryCompletion":1373,"completion":1373,"start":1374,"enrollment":34,"conditions":1793,"interventions":1794},[94],[1366],[1377,1334,1352],{"nctId":1379,"briefTitle":1380,"status":137,"phases":1796,"primaryCompletion":1382,"completion":1382,"start":1383,"enrollment":1384,"conditions":1797,"interventions":1798},[94],[1366,1367],[1334,1352,1377],{"trials":1800,"activeCount":102},[],{"intervention":1574,"totalTrials":147,"cells":1802},{"EARLY_PHASE1":1803,"PHASE1":1805,"PHASE2":1807,"PHASE3":1809,"PHASE4":1811,"NA":1817},{"trials":1804,"activeCount":102},[],{"trials":1806,"activeCount":102},[],{"trials":1808,"activeCount":102},[],{"trials":1810,"activeCount":102},[],{"trials":1812,"activeCount":102},[1813],{"nctId":1564,"briefTitle":1565,"status":114,"phases":1814,"primaryCompletion":1567,"completion":1568,"start":1569,"enrollment":1570,"conditions":1815,"interventions":1816},[94],[1572],[1574,1538],{"trials":1818,"activeCount":102},[],{"intervention":1820,"totalTrials":147,"cells":1821},"Sodium bicarbonate",{"EARLY_PHASE1":1822,"PHASE1":1824,"PHASE2":1826,"PHASE3":1828,"PHASE4":1830,"NA":1845},{"trials":1823,"activeCount":102},[],{"trials":1825,"activeCount":102},[],{"trials":1827,"activeCount":102},[],{"trials":1829,"activeCount":102},[],{"trials":1831,"activeCount":102},[1832],{"nctId":1833,"briefTitle":1834,"status":114,"phases":1835,"primaryCompletion":1836,"completion":1836,"start":1837,"enrollment":1838,"conditions":1839,"interventions":1841},"NCT06047366","Combination of Buffered Anesthetic to Treat Mandibular Molars",[94],"2024-05-15","2023-12-05",40,[1840],"Symptomatic Irreversible Pulpitis",[1820,1842,1843,1844],"Lidocaine w\u002F epi","Articaine w\u002F epi","Mepivacaine plain",{"trials":1846,"activeCount":102},[],{"intervention":1842,"totalTrials":147,"cells":1848},{"EARLY_PHASE1":1849,"PHASE1":1851,"PHASE2":1853,"PHASE3":1855,"PHASE4":1857,"NA":1863},{"trials":1850,"activeCount":102},[],{"trials":1852,"activeCount":102},[],{"trials":1854,"activeCount":102},[],{"trials":1856,"activeCount":102},[],{"trials":1858,"activeCount":102},[1859],{"nctId":1833,"briefTitle":1834,"status":114,"phases":1860,"primaryCompletion":1836,"completion":1836,"start":1837,"enrollment":1838,"conditions":1861,"interventions":1862},[94],[1840],[1820,1842,1843,1844],{"trials":1864,"activeCount":102},[],{"intervention":1843,"totalTrials":147,"cells":1866},{"EARLY_PHASE1":1867,"PHASE1":1869,"PHASE2":1871,"PHASE3":1873,"PHASE4":1875,"NA":1881},{"trials":1868,"activeCount":102},[],{"trials":1870,"activeCount":102},[],{"trials":1872,"activeCount":102},[],{"trials":1874,"activeCount":102},[],{"trials":1876,"activeCount":102},[1877],{"nctId":1833,"briefTitle":1834,"status":114,"phases":1878,"primaryCompletion":1836,"completion":1836,"start":1837,"enrollment":1838,"conditions":1879,"interventions":1880},[94],[1840],[1820,1842,1843,1844],{"trials":1882,"activeCount":102},[],{"intervention":1844,"totalTrials":147,"cells":1884},{"EARLY_PHASE1":1885,"PHASE1":1887,"PHASE2":1889,"PHASE3":1891,"PHASE4":1893,"NA":1899},{"trials":1886,"activeCount":102},[],{"trials":1888,"activeCount":102},[],{"trials":1890,"activeCount":102},[],{"trials":1892,"activeCount":102},[],{"trials":1894,"activeCount":102},[1895],{"nctId":1833,"briefTitle":1834,"status":114,"phases":1896,"primaryCompletion":1836,"completion":1836,"start":1837,"enrollment":1838,"conditions":1897,"interventions":1898},[94],[1840],[1820,1842,1843,1844],{"trials":1900,"activeCount":102},[],{"intervention":123,"totalTrials":147,"cells":1902},{"EARLY_PHASE1":1903,"PHASE1":1905,"PHASE2":1907,"PHASE3":1909,"PHASE4":1911,"NA":1917},{"trials":1904,"activeCount":102},[],{"trials":1906,"activeCount":102},[],{"trials":1908,"activeCount":102},[],{"trials":1910,"activeCount":102},[],{"trials":1912,"activeCount":102},[1913],{"nctId":112,"briefTitle":113,"status":114,"phases":1914,"primaryCompletion":116,"completion":117,"start":118,"enrollment":119,"conditions":1915,"interventions":1916},[94],[121],[64,123],{"trials":1918,"activeCount":102},[],{"intervention":1920,"totalTrials":147,"cells":1921},"Ofloxacin 0.3%",{"EARLY_PHASE1":1922,"PHASE1":1924,"PHASE2":1926,"PHASE3":1928,"PHASE4":1930,"NA":1947},{"trials":1923,"activeCount":102},[],{"trials":1925,"activeCount":102},[],{"trials":1927,"activeCount":102},[],{"trials":1929,"activeCount":102},[],{"trials":1931,"activeCount":102},[1932],{"nctId":1933,"briefTitle":1934,"status":137,"phases":1935,"completion":1936,"start":1937,"enrollment":1938,"conditions":1939,"interventions":1941},"NCT00392275","Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs",[94],"2006-05","2002-11",48,[1940],"Cataract",[1920,1942,1943,1944,1945,1946],"Ciprofloxacin 0.3%","Levofloxacin 0.5%","Ofloxacin 400mg","Ciprofloxacin 400mg","Levofloxacin 250mg",{"trials":1948,"activeCount":102},[],{"intervention":1942,"totalTrials":147,"cells":1950},{"EARLY_PHASE1":1951,"PHASE1":1953,"PHASE2":1955,"PHASE3":1957,"PHASE4":1959,"NA":1965},{"trials":1952,"activeCount":102},[],{"trials":1954,"activeCount":102},[],{"trials":1956,"activeCount":102},[],{"trials":1958,"activeCount":102},[],{"trials":1960,"activeCount":102},[1961],{"nctId":1933,"briefTitle":1934,"status":137,"phases":1962,"completion":1936,"start":1937,"enrollment":1938,"conditions":1963,"interventions":1964},[94],[1940],[1920,1942,1943,1944,1945,1946],{"trials":1966,"activeCount":102},[],{"intervention":1943,"totalTrials":147,"cells":1968},{"EARLY_PHASE1":1969,"PHASE1":1971,"PHASE2":1973,"PHASE3":1975,"PHASE4":1977,"NA":1983},{"trials":1970,"activeCount":102},[],{"trials":1972,"activeCount":102},[],{"trials":1974,"activeCount":102},[],{"trials":1976,"activeCount":102},[],{"trials":1978,"activeCount":102},[1979],{"nctId":1933,"briefTitle":1934,"status":137,"phases":1980,"completion":1936,"start":1937,"enrollment":1938,"conditions":1981,"interventions":1982},[94],[1940],[1920,1942,1943,1944,1945,1946],{"trials":1984,"activeCount":102},[],{"intervention":1944,"totalTrials":147,"cells":1986},{"EARLY_PHASE1":1987,"PHASE1":1989,"PHASE2":1991,"PHASE3":1993,"PHASE4":1995,"NA":2001},{"trials":1988,"activeCount":102},[],{"trials":1990,"activeCount":102},[],{"trials":1992,"activeCount":102},[],{"trials":1994,"activeCount":102},[],{"trials":1996,"activeCount":102},[1997],{"nctId":1933,"briefTitle":1934,"status":137,"phases":1998,"completion":1936,"start":1937,"enrollment":1938,"conditions":1999,"interventions":2000},[94],[1940],[1920,1942,1943,1944,1945,1946],{"trials":2002,"activeCount":102},[],{"intervention":1945,"totalTrials":147,"cells":2004},{"EARLY_PHASE1":2005,"PHASE1":2007,"PHASE2":2009,"PHASE3":2011,"PHASE4":2013,"NA":2019},{"trials":2006,"activeCount":102},[],{"trials":2008,"activeCount":102},[],{"trials":2010,"activeCount":102},[],{"trials":2012,"activeCount":102},[],{"trials":2014,"activeCount":102},[2015],{"nctId":1933,"briefTitle":1934,"status":137,"phases":2016,"completion":1936,"start":1937,"enrollment":1938,"conditions":2017,"interventions":2018},[94],[1940],[1920,1942,1943,1944,1945,1946],{"trials":2020,"activeCount":102},[],{"intervention":1946,"totalTrials":147,"cells":2022},{"EARLY_PHASE1":2023,"PHASE1":2025,"PHASE2":2027,"PHASE3":2029,"PHASE4":2031,"NA":2037},{"trials":2024,"activeCount":102},[],{"trials":2026,"activeCount":102},[],{"trials":2028,"activeCount":102},[],{"trials":2030,"activeCount":102},[],{"trials":2032,"activeCount":102},[2033],{"nctId":1933,"briefTitle":1934,"status":137,"phases":2034,"completion":1936,"start":1937,"enrollment":1938,"conditions":2035,"interventions":2036},[94],[1940],[1920,1942,1943,1944,1945,1946],{"trials":2038,"activeCount":102},[],{"intervention":2040,"totalTrials":147,"cells":2041},"5-fluorouracil",{"EARLY_PHASE1":2042,"PHASE1":2044,"PHASE2":2046,"PHASE3":2048,"PHASE4":2050,"NA":2059},{"trials":2043,"activeCount":102},[],{"trials":2045,"activeCount":102},[],{"trials":2047,"activeCount":102},[],{"trials":2049,"activeCount":102},[],{"trials":2051,"activeCount":102},[2052],{"nctId":2053,"briefTitle":2054,"status":137,"phases":2055,"primaryCompletion":1453,"completion":1453,"start":1523,"enrollment":1672,"conditions":2056,"interventions":2057},"NCT00346489","Outcomes of Intraoperative 5-Fluorouracil Versus Mitomycin C",[94],[439],[2040,2058],"Mitomycin C",{"trials":2060,"activeCount":102},[],{"intervention":2058,"totalTrials":147,"cells":2062},{"EARLY_PHASE1":2063,"PHASE1":2065,"PHASE2":2067,"PHASE3":2069,"PHASE4":2071,"NA":2077},{"trials":2064,"activeCount":102},[],{"trials":2066,"activeCount":102},[],{"trials":2068,"activeCount":102},[],{"trials":2070,"activeCount":102},[],{"trials":2072,"activeCount":102},[2073],{"nctId":2053,"briefTitle":2054,"status":137,"phases":2074,"primaryCompletion":1453,"completion":1453,"start":1523,"enrollment":1672,"conditions":2075,"interventions":2076},[94],[439],[2040,2058],{"trials":2078,"activeCount":102},[],{"intervention":2080,"totalTrials":147,"cells":2081},"N-Acetyl Cysteine",{"EARLY_PHASE1":2082,"PHASE1":2084,"PHASE2":2086,"PHASE3":2088,"PHASE4":2090,"NA":2104},{"trials":2083,"activeCount":102},[],{"trials":2085,"activeCount":102},[],{"trials":2087,"activeCount":102},[],{"trials":2089,"activeCount":102},[],{"trials":2091,"activeCount":102},[2092],{"nctId":2093,"briefTitle":2094,"status":137,"phases":2095,"primaryCompletion":2096,"completion":2096,"start":2097,"enrollment":951,"conditions":2098,"interventions":2103},"NCT01339858","The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia",[94],"2015-12","2011-05",[2099,2100,2101,2102],"Schizophrenia","Psychotic Disorder NOS","Schizoaffective Disorder","Schizophreniform",[2080],{"trials":2105,"activeCount":102},[],{"intervention":2107,"totalTrials":147,"cells":2108},"IV Iron",{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2113,"PHASE3":2115,"PHASE4":2117,"NA":2129},{"trials":2110,"activeCount":102},[],{"trials":2112,"activeCount":102},[],{"trials":2114,"activeCount":102},[],{"trials":2116,"activeCount":102},[],{"trials":2118,"activeCount":102},[2119],{"nctId":2120,"briefTitle":2121,"status":114,"phases":2122,"primaryCompletion":864,"start":2123,"enrollment":2124,"conditions":2125,"interventions":2127},"NCT00830037","A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease",[94],"2008-08",136,[1606,2126],"Iron-deficiency Anemia",[2107,2128],"Ferrous Sulfate",{"trials":2130,"activeCount":102},[],{"intervention":2128,"totalTrials":147,"cells":2132},{"EARLY_PHASE1":2133,"PHASE1":2135,"PHASE2":2137,"PHASE3":2139,"PHASE4":2141,"NA":2147},{"trials":2134,"activeCount":102},[],{"trials":2136,"activeCount":102},[],{"trials":2138,"activeCount":102},[],{"trials":2140,"activeCount":102},[],{"trials":2142,"activeCount":102},[2143],{"nctId":2120,"briefTitle":2121,"status":114,"phases":2144,"primaryCompletion":864,"start":2123,"enrollment":2124,"conditions":2145,"interventions":2146},[94],[1606,2126],[2107,2128],{"trials":2148,"activeCount":102},[],{"intervention":2150,"totalTrials":147,"cells":2151},"Buspirone",{"EARLY_PHASE1":2152,"PHASE1":2154,"PHASE2":2156,"PHASE3":2158,"PHASE4":2160,"NA":2171},{"trials":2153,"activeCount":102},[],{"trials":2155,"activeCount":102},[],{"trials":2157,"activeCount":102},[],{"trials":2159,"activeCount":102},[],{"trials":2161,"activeCount":102},[2162],{"nctId":2163,"briefTitle":2164,"status":137,"phases":2165,"primaryCompletion":2166,"completion":2166,"start":2167,"enrollment":1314,"conditions":2168,"interventions":2170},"NCT01821690","Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression",[94],"2025-09-26","2013-05-15",[2169],"Traumatic Brain Injury",[2150],{"trials":2172,"activeCount":102},[],{"intervention":2174,"totalTrials":147,"cells":2175},"Eleview",{"EARLY_PHASE1":2176,"PHASE1":2178,"PHASE2":2180,"PHASE3":2182,"PHASE4":2184,"NA":2199},{"trials":2177,"activeCount":102},[],{"trials":2179,"activeCount":102},[],{"trials":2181,"activeCount":102},[],{"trials":2183,"activeCount":102},[],{"trials":2185,"activeCount":102},[2186],{"nctId":2187,"briefTitle":2188,"status":137,"phases":2189,"primaryCompletion":2190,"completion":2190,"start":2191,"enrollment":912,"conditions":2192,"interventions":2197},"NCT03350217","A Comparison of Eleview Versus Hetastarch as Injectate for EMR",[94],"2019-01-07","2017-10-09",[2193,2194,2195,2196],"Procedural Bleeding","Delayed Bleeding","Post-Polypectomy Syndrome","Post Procedural Complication",[2174,2198],"Hetastarch",{"trials":2200,"activeCount":102},[],{"intervention":2198,"totalTrials":147,"cells":2202},{"EARLY_PHASE1":2203,"PHASE1":2205,"PHASE2":2207,"PHASE3":2209,"PHASE4":2211,"NA":2217},{"trials":2204,"activeCount":102},[],{"trials":2206,"activeCount":102},[],{"trials":2208,"activeCount":102},[],{"trials":2210,"activeCount":102},[],{"trials":2212,"activeCount":102},[2213],{"nctId":2187,"briefTitle":2188,"status":137,"phases":2214,"primaryCompletion":2190,"completion":2190,"start":2191,"enrollment":912,"conditions":2215,"interventions":2216},[94],[2193,2194,2195,2196],[2174,2198],{"trials":2218,"activeCount":102},[],{"intervention":2220,"totalTrials":147,"cells":2221},"Antidepressants",{"EARLY_PHASE1":2222,"PHASE1":2224,"PHASE2":2226,"PHASE3":2228,"PHASE4":2230,"NA":2242},{"trials":2223,"activeCount":102},[],{"trials":2225,"activeCount":102},[],{"trials":2227,"activeCount":102},[],{"trials":2229,"activeCount":102},[],{"trials":2231,"activeCount":102},[2232],{"nctId":2233,"briefTitle":2234,"status":137,"phases":2235,"primaryCompletion":2236,"completion":2123,"start":1523,"enrollment":2237,"conditions":2238,"interventions":2240},"NCT00118430","Stepped Care for Depression and Musculoskeletal Pain",[94],"2008-07",500,[2239,18],"Pain",[2220,2241],"Usual Care",{"trials":2243,"activeCount":102},[],{"intervention":2241,"totalTrials":147,"cells":2245},{"EARLY_PHASE1":2246,"PHASE1":2248,"PHASE2":2250,"PHASE3":2252,"PHASE4":2254,"NA":2260},{"trials":2247,"activeCount":102},[],{"trials":2249,"activeCount":102},[],{"trials":2251,"activeCount":102},[],{"trials":2253,"activeCount":102},[],{"trials":2255,"activeCount":102},[2256],{"nctId":2233,"briefTitle":2234,"status":137,"phases":2257,"primaryCompletion":2236,"completion":2123,"start":1523,"enrollment":2237,"conditions":2258,"interventions":2259},[94],[2239,18],[2220,2241],{"trials":2261,"activeCount":102},[],{"intervention":2263,"totalTrials":147,"cells":2264},"Iron dextran",{"EARLY_PHASE1":2265,"PHASE1":2267,"PHASE2":2269,"PHASE3":2271,"PHASE4":2273,"NA":2286},{"trials":2266,"activeCount":102},[],{"trials":2268,"activeCount":102},[],{"trials":2270,"activeCount":102},[],{"trials":2272,"activeCount":102},[],{"trials":2274,"activeCount":102},[2275],{"nctId":2276,"briefTitle":2277,"status":137,"phases":2278,"primaryCompletion":2279,"completion":2279,"start":2280,"enrollment":802,"conditions":2281,"interventions":2284},"NCT03438227","Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial",[94],"2019-12-31","2018-04-15",[2282,2283],"Iron Deficiency Anemia of Pregnancy","Iron Malabsorption",[2263,2285],"Ferrous sulfate 325mg",{"trials":2287,"activeCount":102},[],{"intervention":2285,"totalTrials":147,"cells":2289},{"EARLY_PHASE1":2290,"PHASE1":2292,"PHASE2":2294,"PHASE3":2296,"PHASE4":2298,"NA":2304},{"trials":2291,"activeCount":102},[],{"trials":2293,"activeCount":102},[],{"trials":2295,"activeCount":102},[],{"trials":2297,"activeCount":102},[],{"trials":2299,"activeCount":102},[2300],{"nctId":2276,"briefTitle":2277,"status":137,"phases":2301,"primaryCompletion":2279,"completion":2279,"start":2280,"enrollment":802,"conditions":2302,"interventions":2303},[94],[2282,2283],[2263,2285],{"trials":2305,"activeCount":102},[],{"intervention":1676,"totalTrials":147,"cells":2307},{"EARLY_PHASE1":2308,"PHASE1":2310,"PHASE2":2312,"PHASE3":2314,"PHASE4":2316,"NA":2322},{"trials":2309,"activeCount":102},[],{"trials":2311,"activeCount":102},[],{"trials":2313,"activeCount":102},[],{"trials":2315,"activeCount":102},[],{"trials":2317,"activeCount":102},[2318],{"nctId":1667,"briefTitle":1668,"status":137,"phases":2319,"primaryCompletion":1374,"completion":1670,"start":1671,"enrollment":1672,"conditions":2320,"interventions":2321},[94],[754],[1675,1645,1676,1677],{"trials":2323,"activeCount":102},[],{"intervention":1677,"totalTrials":147,"cells":2325},{"EARLY_PHASE1":2326,"PHASE1":2328,"PHASE2":2330,"PHASE3":2332,"PHASE4":2334,"NA":2340},{"trials":2327,"activeCount":102},[],{"trials":2329,"activeCount":102},[],{"trials":2331,"activeCount":102},[],{"trials":2333,"activeCount":102},[],{"trials":2335,"activeCount":102},[2336],{"nctId":1667,"briefTitle":1668,"status":137,"phases":2337,"primaryCompletion":1374,"completion":1670,"start":1671,"enrollment":1672,"conditions":2338,"interventions":2339},[94],[754],[1675,1645,1676,1677],{"trials":2341,"activeCount":102},[],{"intervention":2343,"totalTrials":147,"cells":2344},"Blood and blood products for transfusion",{"EARLY_PHASE1":2345,"PHASE1":2347,"PHASE2":2349,"PHASE3":2351,"PHASE4":2353,"NA":2365},{"trials":2346,"activeCount":102},[],{"trials":2348,"activeCount":102},[],{"trials":2350,"activeCount":102},[],{"trials":2352,"activeCount":102},[],{"trials":2354,"activeCount":102},[2355],{"nctId":2356,"briefTitle":2357,"status":137,"phases":2358,"primaryCompletion":2359,"completion":2359,"start":2360,"enrollment":2361,"conditions":2362,"interventions":2364},"NCT02972593","ORthopaedic Trauma Anemia With Conservative Versus Liberal Transfusion",[94],"2022-06-24","2014-03",161,[2363],"Anemia",[2343],{"trials":2366,"activeCount":102},[],{"intervention":2368,"totalTrials":147,"cells":2369},"Tenofovir\u002Femtricitabine",{"EARLY_PHASE1":2370,"PHASE1":2372,"PHASE2":2374,"PHASE3":2376,"PHASE4":2378,"NA":2390},{"trials":2371,"activeCount":102},[],{"trials":2373,"activeCount":102},[],{"trials":2375,"activeCount":102},[],{"trials":2377,"activeCount":102},[],{"trials":2379,"activeCount":102},[2380],{"nctId":2381,"briefTitle":2382,"status":137,"phases":2383,"primaryCompletion":1485,"completion":1347,"start":2384,"enrollment":579,"conditions":2385,"interventions":2387},"NCT01270802","Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients",[94],"2011-04",[2386],"HIV",[2368,2388,2389],"Tenofovir\u002Femtricitabine\u002Fefavirenz","Raltegravir",{"trials":2391,"activeCount":102},[],{"intervention":2388,"totalTrials":147,"cells":2393},{"EARLY_PHASE1":2394,"PHASE1":2396,"PHASE2":2398,"PHASE3":2400,"PHASE4":2402,"NA":2408},{"trials":2395,"activeCount":102},[],{"trials":2397,"activeCount":102},[],{"trials":2399,"activeCount":102},[],{"trials":2401,"activeCount":102},[],{"trials":2403,"activeCount":102},[2404],{"nctId":2381,"briefTitle":2382,"status":137,"phases":2405,"primaryCompletion":1485,"completion":1347,"start":2384,"enrollment":579,"conditions":2406,"interventions":2407},[94],[2386],[2368,2388,2389],{"trials":2409,"activeCount":102},[],{"intervention":2389,"totalTrials":147,"cells":2411},{"EARLY_PHASE1":2412,"PHASE1":2414,"PHASE2":2416,"PHASE3":2418,"PHASE4":2420,"NA":2426},{"trials":2413,"activeCount":102},[],{"trials":2415,"activeCount":102},[],{"trials":2417,"activeCount":102},[],{"trials":2419,"activeCount":102},[],{"trials":2421,"activeCount":102},[2422],{"nctId":2381,"briefTitle":2382,"status":137,"phases":2423,"primaryCompletion":1485,"completion":1347,"start":2384,"enrollment":579,"conditions":2424,"interventions":2425},[94],[2386],[2368,2388,2389],{"trials":2427,"activeCount":102},[],{"intervention":2429,"totalTrials":147,"cells":2430},"dehydrated alcohol",{"EARLY_PHASE1":2431,"PHASE1":2433,"PHASE2":2435,"PHASE3":2437,"PHASE4":2439,"NA":2449},{"trials":2432,"activeCount":102},[],{"trials":2434,"activeCount":102},[],{"trials":2436,"activeCount":102},[],{"trials":2438,"activeCount":102},[],{"trials":2440,"activeCount":102},[2441],{"nctId":2442,"briefTitle":2443,"status":137,"phases":2444,"primaryCompletion":2445,"completion":2445,"start":1764,"enrollment":599,"conditions":2446,"interventions":2448},"NCT00578279","Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study",[94],"2009-06",[2447],"Pancreatic Cancer",[2429],{"trials":2450,"activeCount":102},[],{"intervention":2452,"totalTrials":147,"cells":2453},"quetiapine XR",{"EARLY_PHASE1":2454,"PHASE1":2456,"PHASE2":2458,"PHASE3":2460,"PHASE4":2462,"NA":2473},{"trials":2455,"activeCount":102},[],{"trials":2457,"activeCount":102},[],{"trials":2459,"activeCount":102},[],{"trials":2461,"activeCount":102},[],{"trials":2463,"activeCount":102},[2464],{"nctId":2465,"briefTitle":2466,"status":137,"phases":2467,"primaryCompletion":2468,"completion":2468,"start":1522,"enrollment":2469,"conditions":2470,"interventions":2472},"NCT00619892","A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients",[94],"2011-12",26,[2471],"Panic Disorder",[2452],{"trials":2474,"activeCount":102},[],{"intervention":2476,"totalTrials":147,"cells":2477},"Antiemetic",{"EARLY_PHASE1":2478,"PHASE1":2480,"PHASE2":2482,"PHASE3":2484,"PHASE4":2486,"NA":2498},{"trials":2479,"activeCount":102},[],{"trials":2481,"activeCount":102},[],{"trials":2483,"activeCount":102},[],{"trials":2485,"activeCount":102},[],{"trials":2487,"activeCount":102},[2488],{"nctId":2489,"briefTitle":2490,"status":114,"phases":2491,"primaryCompletion":2492,"completion":2492,"start":2493,"enrollment":2494,"conditions":2495,"interventions":2497},"NCT02724033","Comparative Study of Superficial Cervical Plexus Block and Nerve of Arnold Block and Incidence of PONV for Inner Ear Surgery",[94],"2018-09","2014-05",37,[2496],"Anesthesia, Pediatrics, Surgery",[2476],{"trials":2499,"activeCount":102},[],{"intervention":2501,"totalTrials":147,"cells":2502},"Bimatoprost 0.03%",{"EARLY_PHASE1":2503,"PHASE1":2505,"PHASE2":2507,"PHASE3":2509,"PHASE4":2511,"NA":2521},{"trials":2504,"activeCount":102},[],{"trials":2506,"activeCount":102},[],{"trials":2508,"activeCount":102},[],{"trials":2510,"activeCount":102},[],{"trials":2512,"activeCount":102},[2513],{"nctId":2514,"briefTitle":2515,"status":137,"phases":2516,"completion":2517,"start":2518,"enrollment":1938,"conditions":2519,"interventions":2520},"NCT00355446","Bioavailability of Bimatoprost Ophthalmic Solution in Human Aqueous.",[94],"2004-10","2001-07",[1940],[2501],{"trials":2522,"activeCount":102},[],{"intervention":2524,"totalTrials":147,"cells":2525},"Cetirizine HCl",{"EARLY_PHASE1":2526,"PHASE1":2528,"PHASE2":2530,"PHASE3":2532,"PHASE4":2534,"NA":2545},{"trials":2527,"activeCount":102},[],{"trials":2529,"activeCount":102},[],{"trials":2531,"activeCount":102},[],{"trials":2533,"activeCount":102},[],{"trials":2535,"activeCount":102},[2536],{"nctId":2537,"briefTitle":2538,"status":114,"phases":2539,"primaryCompletion":2540,"completion":2540,"start":2541,"enrollment":31,"conditions":2542,"interventions":2544},"NCT05095311","The Effect of Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers",[94],"2022-04-27","2021-05-19",[2543],"Exercise-induced Arterial Hypoxemia",[2524],{"trials":2546,"activeCount":102},[],{"intervention":2548,"totalTrials":147,"cells":2549},"JULUCA 50Mg-25Mg",{"EARLY_PHASE1":2550,"PHASE1":2552,"PHASE2":2554,"PHASE3":2556,"PHASE4":2558,"NA":2570},{"trials":2551,"activeCount":102},[],{"trials":2553,"activeCount":102},[],{"trials":2555,"activeCount":102},[],{"trials":2557,"activeCount":102},[],{"trials":2559,"activeCount":102},[2560],{"nctId":2561,"briefTitle":2562,"status":137,"phases":2563,"primaryCompletion":2564,"completion":2564,"start":2565,"enrollment":119,"conditions":2566,"interventions":2569},"NCT04431518","Pharmacokinetics of JULUCA in Hemodialysis",[94],"2023-07-31","2021-04-23",[2567,2568],"HIV\u002FAIDS","ESRD",[2548],{"trials":2571,"activeCount":102},[],{"intervention":2573,"totalTrials":147,"cells":2574},"Preoperative Gabapentin\u002FPostoperative Placebo",{"EARLY_PHASE1":2575,"PHASE1":2577,"PHASE2":2579,"PHASE3":2581,"PHASE4":2583,"NA":2597},{"trials":2576,"activeCount":102},[],{"trials":2578,"activeCount":102},[],{"trials":2580,"activeCount":102},[],{"trials":2582,"activeCount":102},[],{"trials":2584,"activeCount":102},[2585],{"nctId":2586,"briefTitle":2587,"status":137,"phases":2588,"primaryCompletion":2589,"completion":2590,"start":2591,"enrollment":2592,"conditions":2593,"interventions":2595},"NCT05494385","Effect of Perioperative Gabapentin on Postoperative Opioid Requirements",[94],"2023-06-17","2023-07-05","2021-07-27",114,[2594],"Postoperative Pain",[2573,2596],"Preoperative Gabapentin\u002FPostoperative Gabapentin",{"trials":2598,"activeCount":102},[],{"intervention":2596,"totalTrials":147,"cells":2600},{"EARLY_PHASE1":2601,"PHASE1":2603,"PHASE2":2605,"PHASE3":2607,"PHASE4":2609,"NA":2615},{"trials":2602,"activeCount":102},[],{"trials":2604,"activeCount":102},[],{"trials":2606,"activeCount":102},[],{"trials":2608,"activeCount":102},[],{"trials":2610,"activeCount":102},[2611],{"nctId":2586,"briefTitle":2587,"status":137,"phases":2612,"primaryCompletion":2589,"completion":2590,"start":2591,"enrollment":2592,"conditions":2613,"interventions":2614},[94],[2594],[2573,2596],{"trials":2616,"activeCount":102},[],{"intervention":2618,"totalTrials":147,"cells":2619},"Educational with milnacipran",{"EARLY_PHASE1":2620,"PHASE1":2622,"PHASE2":2624,"PHASE3":2626,"PHASE4":2628,"NA":2640},{"trials":2621,"activeCount":102},[],{"trials":2623,"activeCount":102},[],{"trials":2625,"activeCount":102},[],{"trials":2627,"activeCount":102},[],{"trials":2629,"activeCount":102},[2630],{"nctId":2631,"briefTitle":2632,"status":137,"phases":2633,"primaryCompletion":2634,"completion":2634,"start":2635,"enrollment":2636,"conditions":2637,"interventions":2639},"NCT01038323","Drug and Talk Therapy for Fibromyalgia",[94],"2012-09","2009-12",58,[2638],"Fibromyalgia",[2618],{"trials":2641,"activeCount":102},[],{"intervention":2643,"totalTrials":147,"cells":2644},"Acarbose",{"EARLY_PHASE1":2645,"PHASE1":2647,"PHASE2":2649,"PHASE3":2651,"PHASE4":2653,"NA":2664},{"trials":2646,"activeCount":102},[],{"trials":2648,"activeCount":102},[],{"trials":2650,"activeCount":102},[],{"trials":2652,"activeCount":102},[],{"trials":2654,"activeCount":102},[2655],{"nctId":2656,"briefTitle":2657,"status":137,"phases":2658,"primaryCompletion":1523,"completion":1523,"start":2659,"enrollment":2660,"conditions":2661,"interventions":2663},"NCT01470937","Early Diabetes Intervention Program",[94],"1998-02",219,[2662],"Type 2 Diabetes Mellitus",[2643],{"trials":2665,"activeCount":102},[],{"intervention":2667,"totalTrials":147,"cells":2668},"Octreotide",{"EARLY_PHASE1":2669,"PHASE1":2671,"PHASE2":2673,"PHASE3":2675,"PHASE4":2677,"NA":2687},{"trials":2670,"activeCount":102},[],{"trials":2672,"activeCount":102},[],{"trials":2674,"activeCount":102},[],{"trials":2676,"activeCount":102},[],{"trials":2678,"activeCount":102},[2679],{"nctId":2680,"briefTitle":2681,"status":137,"phases":2682,"primaryCompletion":1346,"completion":1346,"start":1603,"enrollment":39,"conditions":2683,"interventions":2685},"NCT01917773","Effect of Octreotide on the Colonic Motility in Pediatric Patients",[94],[2684,375],"Colonic Motility Index",[2667,2686],"Bisacodyl",{"trials":2688,"activeCount":102},[],{"intervention":2686,"totalTrials":147,"cells":2690},{"EARLY_PHASE1":2691,"PHASE1":2693,"PHASE2":2695,"PHASE3":2697,"PHASE4":2699,"NA":2705},{"trials":2692,"activeCount":102},[],{"trials":2694,"activeCount":102},[],{"trials":2696,"activeCount":102},[],{"trials":2698,"activeCount":102},[],{"trials":2700,"activeCount":102},[2701],{"nctId":2680,"briefTitle":2681,"status":137,"phases":2702,"primaryCompletion":1346,"completion":1346,"start":1603,"enrollment":39,"conditions":2703,"interventions":2704},[94],[2684,375],[2667,2686],{"trials":2706,"activeCount":102},[],{"intervention":2708,"totalTrials":147,"cells":2709},"Contrast enhanced ultrasound with Lumason",{"EARLY_PHASE1":2710,"PHASE1":2712,"PHASE2":2714,"PHASE3":2716,"PHASE4":2718,"NA":2729},{"trials":2711,"activeCount":102},[],{"trials":2713,"activeCount":102},[],{"trials":2715,"activeCount":102},[],{"trials":2717,"activeCount":102},[],{"trials":2719,"activeCount":102},[2720],{"nctId":2721,"briefTitle":2722,"status":114,"phases":2723,"primaryCompletion":2724,"completion":2724,"start":2725,"enrollment":1302,"conditions":2726,"interventions":2728},"NCT03821376","Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS)",[94],"2021-09-21","2019-07-16",[2727],"Renal Malignant Tumor",[2708],{"trials":2730,"activeCount":102},[],{"intervention":2732,"totalTrials":147,"cells":2733},"Mupirocin ointment",{"EARLY_PHASE1":2734,"PHASE1":2736,"PHASE2":2738,"PHASE3":2740,"PHASE4":2742,"NA":2753},{"trials":2735,"activeCount":102},[],{"trials":2737,"activeCount":102},[],{"trials":2739,"activeCount":102},[],{"trials":2741,"activeCount":102},[],{"trials":2743,"activeCount":102},[2744],{"nctId":2745,"briefTitle":2746,"status":114,"phases":2747,"primaryCompletion":2748,"completion":2748,"start":2749,"enrollment":34,"conditions":2750,"interventions":2752},"NCT02127658","MRSA Eradication and Decolonization in Children",[94],"2020-07-01","2016-02-18",[2751],"MRSA",[2732],{"trials":2754,"activeCount":102},[],{"intervention":146,"totalTrials":147,"cells":2756},{"EARLY_PHASE1":2757,"PHASE1":2759,"PHASE2":2761,"PHASE3":2763,"PHASE4":2765,"NA":2771},{"trials":2758,"activeCount":102},[],{"trials":2760,"activeCount":102},[],{"trials":2762,"activeCount":102},[],{"trials":2764,"activeCount":102},[],{"trials":2766,"activeCount":102},[2767],{"nctId":135,"briefTitle":136,"status":137,"phases":2768,"primaryCompletion":139,"completion":139,"start":140,"enrollment":141,"conditions":2769,"interventions":2770},[94],[143,144],[146,64],{"trials":2772,"activeCount":102},[],{"intervention":2774,"totalTrials":147,"cells":2775},"Alendronate",{"EARLY_PHASE1":2776,"PHASE1":2778,"PHASE2":2780,"PHASE3":2782,"PHASE4":2784,"NA":2797},{"trials":2777,"activeCount":102},[],{"trials":2779,"activeCount":102},[],{"trials":2781,"activeCount":102},[],{"trials":2783,"activeCount":102},[],{"trials":2785,"activeCount":102},[2786],{"nctId":2787,"briefTitle":2788,"status":137,"phases":2789,"primaryCompletion":2123,"completion":2123,"start":2790,"enrollment":25,"conditions":2791,"interventions":2795},"NCT00159419","Bisphosphonate Therapy for Osteogenesis Imperfecta",[94],"1999-08",[2792,2793,2794],"Osteogenesis Imperfecta","Osteoporosis","Paget Disease of Bone",[2774,2796],"Pamidronate",{"trials":2798,"activeCount":102},[],{"intervention":2796,"totalTrials":147,"cells":2800},{"EARLY_PHASE1":2801,"PHASE1":2803,"PHASE2":2805,"PHASE3":2807,"PHASE4":2809,"NA":2815},{"trials":2802,"activeCount":102},[],{"trials":2804,"activeCount":102},[],{"trials":2806,"activeCount":102},[],{"trials":2808,"activeCount":102},[],{"trials":2810,"activeCount":102},[2811],{"nctId":2787,"briefTitle":2788,"status":137,"phases":2812,"primaryCompletion":2123,"completion":2123,"start":2790,"enrollment":25,"conditions":2813,"interventions":2814},[94],[2792,2793,2794],[2774,2796],{"trials":2816,"activeCount":102},[],{"intervention":2818,"totalTrials":147,"cells":2819},"TAP-S",{"EARLY_PHASE1":2820,"PHASE1":2822,"PHASE2":2824,"PHASE3":2826,"PHASE4":2828,"NA":2837},{"trials":2821,"activeCount":102},[],{"trials":2823,"activeCount":102},[],{"trials":2825,"activeCount":102},[],{"trials":2827,"activeCount":102},[],{"trials":2829,"activeCount":102},[2830],{"nctId":2831,"briefTitle":2832,"status":137,"phases":2833,"primaryCompletion":2096,"completion":2096,"start":2834,"enrollment":1672,"conditions":2835,"interventions":2836},"NCT02475031","Single-shot TAP Block vs Continuous TAP Block",[94],"2012-07",[2594],[2818],{"trials":2838,"activeCount":102},[],{"intervention":2840,"totalTrials":147,"cells":2841},"Morphine PRN",{"EARLY_PHASE1":2842,"PHASE1":2844,"PHASE2":2846,"PHASE3":2848,"PHASE4":2850,"NA":2864},{"trials":2843,"activeCount":102},[],{"trials":2845,"activeCount":102},[],{"trials":2847,"activeCount":102},[],{"trials":2849,"activeCount":102},[],{"trials":2851,"activeCount":102},[2852],{"nctId":2853,"briefTitle":2854,"status":137,"phases":2855,"primaryCompletion":2856,"completion":2856,"start":2857,"enrollment":28,"conditions":2858,"interventions":2862},"NCT04298853","Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome",[94],"2021-10-01","2020-06-30",[2859,2860,2861],"Neonatal Abstinence Syndrome","Neonatal Opioid Withdrawal","Neonatal Opioid Withdrawal Syndrome",[2840,2863],"Morphine scheduled",{"trials":2865,"activeCount":102},[],{"intervention":2863,"totalTrials":147,"cells":2867},{"EARLY_PHASE1":2868,"PHASE1":2870,"PHASE2":2872,"PHASE3":2874,"PHASE4":2876,"NA":2882},{"trials":2869,"activeCount":102},[],{"trials":2871,"activeCount":102},[],{"trials":2873,"activeCount":102},[],{"trials":2875,"activeCount":102},[],{"trials":2877,"activeCount":102},[2878],{"nctId":2853,"briefTitle":2854,"status":137,"phases":2879,"primaryCompletion":2856,"completion":2856,"start":2857,"enrollment":28,"conditions":2880,"interventions":2881},[94],[2859,2860,2861],[2840,2863],{"trials":2883,"activeCount":102},[],{"intervention":2885,"totalTrials":147,"cells":2886},"Duloxetine",{"EARLY_PHASE1":2887,"PHASE1":2889,"PHASE2":2891,"PHASE3":2893,"PHASE4":2895,"NA":2904},{"trials":2888,"activeCount":102},[],{"trials":2890,"activeCount":102},[],{"trials":2892,"activeCount":102},[],{"trials":2894,"activeCount":102},[],{"trials":2896,"activeCount":102},[2897],{"nctId":2898,"briefTitle":2899,"status":137,"phases":2900,"primaryCompletion":2901,"completion":2901,"start":1288,"enrollment":1327,"conditions":2902,"interventions":2903},"NCT00532480","Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine",[94],"2009-04",[1439],[2885],{"trials":2905,"activeCount":102},[],{"intervention":2907,"totalTrials":147,"cells":2908},"Prasugrel",{"EARLY_PHASE1":2909,"PHASE1":2911,"PHASE2":2913,"PHASE3":2915,"PHASE4":2917,"NA":2931},{"trials":2910,"activeCount":102},[],{"trials":2912,"activeCount":102},[],{"trials":2914,"activeCount":102},[],{"trials":2916,"activeCount":102},[],{"trials":2918,"activeCount":102},[2919],{"nctId":2920,"briefTitle":2921,"status":114,"phases":2922,"primaryCompletion":2923,"completion":2923,"start":2924,"enrollment":2925,"conditions":2926,"interventions":2929},"NCT01612884","Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)",[94],"2017-03","2011-08",67,[2927,2928],"Thrombosis","Coronary Artery Disease",[2907,2930],"Clopidogrel",{"trials":2932,"activeCount":102},[],{"intervention":2930,"totalTrials":147,"cells":2934},{"EARLY_PHASE1":2935,"PHASE1":2937,"PHASE2":2939,"PHASE3":2941,"PHASE4":2943,"NA":2949},{"trials":2936,"activeCount":102},[],{"trials":2938,"activeCount":102},[],{"trials":2940,"activeCount":102},[],{"trials":2942,"activeCount":102},[],{"trials":2944,"activeCount":102},[2945],{"nctId":2920,"briefTitle":2921,"status":114,"phases":2946,"primaryCompletion":2923,"completion":2923,"start":2924,"enrollment":2925,"conditions":2947,"interventions":2948},[94],[2927,2928],[2907,2930],{"trials":2950,"activeCount":102},[],{"intervention":2952,"totalTrials":147,"cells":2953},"Belatacept",{"EARLY_PHASE1":2954,"PHASE1":2956,"PHASE2":2958,"PHASE3":2960,"PHASE4":2962,"NA":2972},{"trials":2955,"activeCount":102},[],{"trials":2957,"activeCount":102},[],{"trials":2959,"activeCount":102},[],{"trials":2961,"activeCount":102},[],{"trials":2963,"activeCount":102},[2964],{"nctId":2965,"briefTitle":2966,"status":137,"phases":2967,"primaryCompletion":2968,"completion":2968,"start":1346,"enrollment":776,"conditions":2969,"interventions":2971},"NCT02103855","Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients",[94],"2016-03",[2970],"Nephrotoxicity",[2952],{"trials":2973,"activeCount":102},[],{"intervention":2975,"totalTrials":147,"cells":2976},"Levetiracetam",{"EARLY_PHASE1":2977,"PHASE1":2979,"PHASE2":2981,"PHASE3":2983,"PHASE4":2985,"NA":2996},{"trials":2978,"activeCount":102},[],{"trials":2980,"activeCount":102},[],{"trials":2982,"activeCount":102},[],{"trials":2984,"activeCount":102},[],{"trials":2986,"activeCount":102},[2987],{"nctId":2988,"briefTitle":2989,"status":114,"phases":2990,"primaryCompletion":2991,"completion":2991,"start":1671,"enrollment":28,"conditions":2992,"interventions":2995},"NCT01974700","Seizure Prophylaxis in Aneurysm Repair",[94],"2016-02",[2993,2994],"Intracranial Aneurysms","Seizures",[2975],{"trials":2997,"activeCount":102},[],{"intervention":2999,"totalTrials":147,"cells":3000},"Epinephrine",{"EARLY_PHASE1":3001,"PHASE1":3003,"PHASE2":3005,"PHASE3":3007,"PHASE4":3009,"NA":3021},{"trials":3002,"activeCount":102},[],{"trials":3004,"activeCount":102},[],{"trials":3006,"activeCount":102},[],{"trials":3008,"activeCount":102},[],{"trials":3010,"activeCount":102},[3011],{"nctId":3012,"briefTitle":3013,"status":137,"phases":3014,"primaryCompletion":3015,"completion":3015,"start":3016,"enrollment":3017,"conditions":3018,"interventions":3020},"NCT04065451","Effect of Epinephrine on Post-polypectomy Pain",[94],"2021-08-17","2020-01-06",22,[3019],"Colonic Polyp",[2999],{"trials":3022,"activeCount":102},[],{"intervention":3024,"totalTrials":147,"cells":3025},"Fluorescein Sodium",{"EARLY_PHASE1":3026,"PHASE1":3028,"PHASE2":3030,"PHASE3":3032,"PHASE4":3034,"NA":3046},{"trials":3027,"activeCount":102},[],{"trials":3029,"activeCount":102},[],{"trials":3031,"activeCount":102},[],{"trials":3033,"activeCount":102},[],{"trials":3035,"activeCount":102},[3036],{"nctId":3037,"briefTitle":3038,"status":114,"phases":3039,"primaryCompletion":3040,"completion":3041,"start":1484,"enrollment":2124,"conditions":3042,"interventions":3045},"NCT02028325","Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions",[94],"2014-10","2016-10",[3043,3044],"Adult Intracranial Neoplasm","Vascular: Intracranial",[3024],{"trials":3047,"activeCount":102},[],{"intervention":3049,"totalTrials":147,"cells":3050},"Pred Forte",{"EARLY_PHASE1":3051,"PHASE1":3053,"PHASE2":3055,"PHASE3":3057,"PHASE4":3059,"NA":3070},{"trials":3052,"activeCount":102},[],{"trials":3054,"activeCount":102},[],{"trials":3056,"activeCount":102},[],{"trials":3058,"activeCount":102},[],{"trials":3060,"activeCount":102},[3061],{"nctId":3062,"briefTitle":3063,"status":137,"phases":3064,"primaryCompletion":1312,"completion":1312,"start":3065,"enrollment":951,"conditions":3066,"interventions":3067},"NCT00345046","A Comparison of Three Different Formulations of Prednisolone Acetate 1%",[94],"2002-09",[439,1940],[3049,3068,3069],"EconoPred Plus","Prednisolone Acetate",{"trials":3071,"activeCount":102},[],{"intervention":3068,"totalTrials":147,"cells":3073},{"EARLY_PHASE1":3074,"PHASE1":3076,"PHASE2":3078,"PHASE3":3080,"PHASE4":3082,"NA":3088},{"trials":3075,"activeCount":102},[],{"trials":3077,"activeCount":102},[],{"trials":3079,"activeCount":102},[],{"trials":3081,"activeCount":102},[],{"trials":3083,"activeCount":102},[3084],{"nctId":3062,"briefTitle":3063,"status":137,"phases":3085,"primaryCompletion":1312,"completion":1312,"start":3065,"enrollment":951,"conditions":3086,"interventions":3087},[94],[439,1940],[3049,3068,3069],{"trials":3089,"activeCount":102},[],{"intervention":3069,"totalTrials":147,"cells":3091},{"EARLY_PHASE1":3092,"PHASE1":3094,"PHASE2":3096,"PHASE3":3098,"PHASE4":3100,"NA":3106},{"trials":3093,"activeCount":102},[],{"trials":3095,"activeCount":102},[],{"trials":3097,"activeCount":102},[],{"trials":3099,"activeCount":102},[],{"trials":3101,"activeCount":102},[3102],{"nctId":3062,"briefTitle":3063,"status":137,"phases":3103,"primaryCompletion":1312,"completion":1312,"start":3065,"enrollment":951,"conditions":3104,"interventions":3105},[94],[439,1940],[3049,3068,3069],{"trials":3107,"activeCount":102},[],{"intervention":3109,"totalTrials":147,"cells":3110},"Wellbutrin XL",{"EARLY_PHASE1":3111,"PHASE1":3113,"PHASE2":3115,"PHASE3":3117,"PHASE4":3119,"NA":3132},{"trials":3112,"activeCount":102},[],{"trials":3114,"activeCount":102},[],{"trials":3116,"activeCount":102},[],{"trials":3118,"activeCount":102},[],{"trials":3120,"activeCount":102},[3121],{"nctId":3122,"briefTitle":3123,"status":137,"phases":3124,"completion":3125,"start":3126,"enrollment":319,"conditions":3127,"interventions":3131},"NCT00456820","Wellbutrin XL Effects on SSRIs Induced Changes",[94],"2007-11","2004-07",[18,3128,3129,3130],"Side Effects","Sexual Dysfunction","Apathy",[3109],{"trials":3133,"activeCount":102},[],{"intervention":3135,"totalTrials":147,"cells":3136},"fentanyl and Remimazolam",{"EARLY_PHASE1":3137,"PHASE1":3139,"PHASE2":3141,"PHASE3":3143,"PHASE4":3145,"NA":3156},{"trials":3138,"activeCount":102},[],{"trials":3140,"activeCount":102},[],{"trials":3142,"activeCount":102},[],{"trials":3144,"activeCount":102},[],{"trials":3146,"activeCount":102},[3147],{"nctId":3148,"briefTitle":3149,"status":861,"phases":3150,"primaryCompletion":3151,"completion":3151,"start":3152,"enrollment":102,"conditions":3153,"interventions":3155},"NCT06793358","Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction",[94],"2026-02-27","2025-07-31",[3154],"Dental Extraction",[3135],{"trials":3157,"activeCount":102},[],{"intervention":3159,"totalTrials":147,"cells":3160},"Rilpivirine",{"EARLY_PHASE1":3161,"PHASE1":3163,"PHASE2":3165,"PHASE3":3167,"PHASE4":3169,"NA":3178},{"trials":3162,"activeCount":102},[],{"trials":3164,"activeCount":102},[],{"trials":3166,"activeCount":102},[],{"trials":3168,"activeCount":102},[],{"trials":3170,"activeCount":102},[3171],{"nctId":3172,"briefTitle":3173,"status":137,"phases":3174,"primaryCompletion":2493,"completion":864,"start":2834,"enrollment":1838,"conditions":3175,"interventions":3177},"NCT01585038","Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress",[94],[3176],"Cardiovascular Disease",[1675,3159],{"trials":3179,"activeCount":102},[],{"intervention":1744,"totalTrials":147,"cells":3181},{"EARLY_PHASE1":3182,"PHASE1":3184,"PHASE2":3186,"PHASE3":3188,"PHASE4":3190,"NA":3196},{"trials":3183,"activeCount":102},[],{"trials":3185,"activeCount":102},[],{"trials":3187,"activeCount":102},[],{"trials":3189,"activeCount":102},[],{"trials":3191,"activeCount":102},[3192],{"nctId":1736,"briefTitle":1737,"status":137,"phases":3193,"completion":1739,"start":1740,"enrollment":1741,"conditions":3194,"interventions":3195},[94],[754],[1714,1744],{"trials":3197,"activeCount":102},[],{"intervention":3199,"totalTrials":147,"cells":3200},"Onset Sodium Bicarbonate Inj., 8.4%, USP Neutralizing Additive Solution",{"EARLY_PHASE1":3201,"PHASE1":3203,"PHASE2":3205,"PHASE3":3207,"PHASE4":3209,"NA":3221},{"trials":3202,"activeCount":102},[],{"trials":3204,"activeCount":102},[],{"trials":3206,"activeCount":102},[],{"trials":3208,"activeCount":102},[],{"trials":3210,"activeCount":102},[3211],{"nctId":3212,"briefTitle":3213,"status":137,"phases":3214,"primaryCompletion":3215,"completion":3216,"start":3217,"enrollment":1838,"conditions":3218,"interventions":3219},"NCT05227300","Buffered vs. Unbuffered Local Anesthesia in Mandibular Molars Diagnosed With Symptomatic Irreversible Pulpitis",[94],"2022-05-23","2022-06-30","2022-02-14",[1840],[3199,3220],"2% lidocaine with 1:100,000 epinephrine",{"trials":3222,"activeCount":102},[],{"intervention":3220,"totalTrials":147,"cells":3224},{"EARLY_PHASE1":3225,"PHASE1":3227,"PHASE2":3229,"PHASE3":3231,"PHASE4":3233,"NA":3239},{"trials":3226,"activeCount":102},[],{"trials":3228,"activeCount":102},[],{"trials":3230,"activeCount":102},[],{"trials":3232,"activeCount":102},[],{"trials":3234,"activeCount":102},[3235],{"nctId":3212,"briefTitle":3213,"status":137,"phases":3236,"primaryCompletion":3215,"completion":3216,"start":3217,"enrollment":1838,"conditions":3237,"interventions":3238},[94],[1840],[3199,3220],{"trials":3240,"activeCount":102},[],{"intervention":3242,"totalTrials":147,"cells":3243},"Riluzole",{"EARLY_PHASE1":3244,"PHASE1":3246,"PHASE2":3248,"PHASE3":3250,"PHASE4":3252,"NA":3261},{"trials":3245,"activeCount":102},[],{"trials":3247,"activeCount":102},[],{"trials":3249,"activeCount":102},[],{"trials":3251,"activeCount":102},[],{"trials":3253,"activeCount":102},[3254],{"nctId":3255,"briefTitle":3256,"status":137,"phases":3257,"primaryCompletion":3258,"completion":3258,"start":2901,"enrollment":776,"conditions":3259,"interventions":3260},"NCT00895752","Riluzole in Fragile X Syndrome",[94],"2010-07",[1304],[3242],{"trials":3262,"activeCount":102},[],{"intervention":3264,"totalTrials":147,"cells":3265},"Cetirizine",{"EARLY_PHASE1":3266,"PHASE1":3268,"PHASE2":3270,"PHASE3":3272,"PHASE4":3274,"NA":3285},{"trials":3267,"activeCount":102},[],{"trials":3269,"activeCount":102},[],{"trials":3271,"activeCount":102},[],{"trials":3273,"activeCount":102},[],{"trials":3275,"activeCount":102},[3276],{"nctId":3277,"briefTitle":3278,"status":137,"phases":3279,"primaryCompletion":3280,"completion":3280,"start":3281,"enrollment":39,"conditions":3282,"interventions":3284},"NCT03192488","Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia",[94],"2018-06-06","2017-08-31",[3283],"Hypoxia, Altitude",[3264],{"trials":3286,"activeCount":102},[],{"intervention":3288,"totalTrials":147,"cells":3289},"Sertraline and Alprazolam XR",{"EARLY_PHASE1":3290,"PHASE1":3292,"PHASE2":3294,"PHASE3":3296,"PHASE4":3298,"NA":3307},{"trials":3291,"activeCount":102},[],{"trials":3293,"activeCount":102},[],{"trials":3295,"activeCount":102},[],{"trials":3297,"activeCount":102},[],{"trials":3299,"activeCount":102},[3300],{"nctId":3301,"briefTitle":3302,"status":137,"phases":3303,"completion":1288,"start":3304,"enrollment":673,"conditions":3305,"interventions":3306},"NCT00198094","A Study of Sertraline and Early Alprazolam XR Administration Versus Sertraline Only in Panic Disorder Patients",[94],"2003-12",[2471],[3288],{"trials":3308,"activeCount":102},[],{"intervention":3310,"totalTrials":147,"cells":3311},"Glycerin Suppository",{"EARLY_PHASE1":3312,"PHASE1":3314,"PHASE2":3316,"PHASE3":3318,"PHASE4":3320,"NA":3331},{"trials":3313,"activeCount":102},[],{"trials":3315,"activeCount":102},[],{"trials":3317,"activeCount":102},[],{"trials":3319,"activeCount":102},[],{"trials":3321,"activeCount":102},[3322],{"nctId":3323,"briefTitle":3324,"status":114,"phases":3325,"primaryCompletion":3326,"completion":3326,"start":3327,"enrollment":31,"conditions":3328,"interventions":3330},"NCT03355326","Evaluation of Glycerin Suppositories to Improve Bowel Function in Gastroschisis",[94],"2020-10-01","2017-10-01",[3329],"Gastroschisis",[3310],{"trials":3332,"activeCount":102},[],{"intervention":3334,"totalTrials":147,"cells":3335},"Sodium supplementation guided by urine sodium concentration algorithm",{"EARLY_PHASE1":3336,"PHASE1":3338,"PHASE2":3340,"PHASE3":3342,"PHASE4":3344,"NA":3357},{"trials":3337,"activeCount":102},[],{"trials":3339,"activeCount":102},[],{"trials":3341,"activeCount":102},[],{"trials":3343,"activeCount":102},[],{"trials":3345,"activeCount":102},[3346],{"nctId":3347,"briefTitle":3348,"status":137,"phases":3349,"primaryCompletion":3350,"completion":3351,"start":3352,"enrollment":3353,"conditions":3354,"interventions":3356},"NCT03889197","Physiologic Approach to Sodium Supplementation in Premature Infants",[94],"2023-07-22","2023-08-15","2019-07-01",90,[3355],"Postnatal Growth Disorder",[3334],{"trials":3358,"activeCount":102},[],{"intervention":3360,"totalTrials":147,"cells":3361},"Sulfur Hexafluoride Microspheres",{"EARLY_PHASE1":3362,"PHASE1":3364,"PHASE2":3366,"PHASE3":3368,"PHASE4":3370,"NA":3381},{"trials":3363,"activeCount":102},[],{"trials":3365,"activeCount":102},[],{"trials":3367,"activeCount":102},[],{"trials":3369,"activeCount":102},[],{"trials":3371,"activeCount":102},[3372],{"nctId":3373,"briefTitle":3374,"status":137,"phases":3375,"primaryCompletion":3376,"completion":3376,"start":3377,"enrollment":14,"conditions":3378,"interventions":3380},"NCT03652636","Evaluation of the Efficacy of Contrast Enhanced Ultrasound Compared to MRI for Differentiation of Hepatic Lesions",[94],"2023-07-21","2019-08-05",[3379],"Hepatic Disease",[3360],{"trials":3382,"activeCount":102},[],{"intervention":3384,"totalTrials":147,"cells":3385},"4mg PF Dexamethasone",{"EARLY_PHASE1":3386,"PHASE1":3388,"PHASE2":3390,"PHASE3":3392,"PHASE4":3394,"NA":3406},{"trials":3387,"activeCount":102},[],{"trials":3389,"activeCount":102},[],{"trials":3391,"activeCount":102},[],{"trials":3393,"activeCount":102},[],{"trials":3395,"activeCount":102},[3396],{"nctId":3397,"briefTitle":3398,"status":114,"phases":3399,"primaryCompletion":672,"completion":3400,"start":3401,"enrollment":1021,"conditions":3402,"interventions":3404},"NCT04663269","Regional Erector Spinae Analgesic Block vs Standard of Care Undergoing Percutaneous Nephrolithotomy",[94],"2020-09-24","2020-02-24",[3403,121],"Kidney Stone",[3384,3405],"Control Test",{"trials":3407,"activeCount":102},[],{"intervention":3405,"totalTrials":147,"cells":3409},{"EARLY_PHASE1":3410,"PHASE1":3412,"PHASE2":3414,"PHASE3":3416,"PHASE4":3418,"NA":3424},{"trials":3411,"activeCount":102},[],{"trials":3413,"activeCount":102},[],{"trials":3415,"activeCount":102},[],{"trials":3417,"activeCount":102},[],{"trials":3419,"activeCount":102},[3420],{"nctId":3397,"briefTitle":3398,"status":114,"phases":3421,"primaryCompletion":672,"completion":3400,"start":3401,"enrollment":1021,"conditions":3422,"interventions":3423},[94],[3403,121],[3384,3405],{"trials":3425,"activeCount":102},[],{"intervention":3427,"totalTrials":1276,"cells":3428},"Liposomal bupivacaine",{"EARLY_PHASE1":3429,"PHASE1":3431,"PHASE2":3433,"PHASE3":3435,"PHASE4":3486,"NA":3488},{"trials":3430,"activeCount":102},[],{"trials":3432,"activeCount":102},[],{"trials":3434,"activeCount":102},[],{"trials":3436,"activeCount":102},[3437,3448,3457,3471],{"nctId":3438,"briefTitle":3439,"status":137,"phases":3440,"primaryCompletion":3441,"completion":3441,"start":3442,"enrollment":3353,"conditions":3443,"interventions":3445},"NCT03702621","Comparing Liposomal Bupivacaine Versus Standard Bupivacaine in Colorectal Surgery",[93],"2020-03-13","2018-08-30",[3444],"Colorectal Surgery",[3446,3447],"liposomal Bupivacaine","Bupivacaine Hydrochloride",{"nctId":3449,"briefTitle":3450,"status":137,"phases":3451,"primaryCompletion":3452,"completion":3452,"start":1653,"enrollment":141,"conditions":3453,"interventions":3455},"NCT04003987","ESP Block VS TAP in Laparoscopic Hysterectomy",[93],"2021-03-04",[3454],"Hysterectomy",[3427,3456],"bupivacaine, 0.125%",{"nctId":3458,"briefTitle":3459,"status":137,"phases":3460,"primaryCompletion":3461,"completion":3462,"start":3463,"enrollment":1066,"conditions":3464,"interventions":3467},"NCT03859635","Erector Spinae Block Versus Surgeon Infiltration in VATS Procedures",[93],"2022-11-06","2022-11-07","2019-02-07",[144,3465,3466],"Thoracic","Acute Pain",[3468,3469,3470],"Liposomal Bupivacaine","Bupivacaine, 0.25%","Bupivacaine, 0.5%",{"nctId":3472,"briefTitle":3473,"status":137,"phases":3474,"primaryCompletion":3475,"completion":3476,"start":3477,"enrollment":912,"conditions":3478,"interventions":3480},"NCT04300231","Thoracic Epidural Analgesia Versus Rectus Sheath Block Versus Surgeon Infiltration With Liposomal Bupivacaine or Standard Bupivacaine for Post-Operative Pain Control After Cystectomy",[93],"2021-12-23","2021-12-24","2019-10-22",[3479],"Cystectomy",[3481,3427,3482,3483,3484,3485],"epidural bupivacaine 0.05%","bupivacaine 0.125%","bupivacaine 0.5%","\u002Fhydromorphone 0.05mg\u002Fml","injectable saline",{"trials":3487,"activeCount":102},[],{"trials":3489,"activeCount":102},[],{"intervention":1318,"totalTrials":98,"cells":3491},{"EARLY_PHASE1":3492,"PHASE1":3494,"PHASE2":3496,"PHASE3":3498,"PHASE4":3520,"NA":3522},{"trials":3493,"activeCount":102},[],{"trials":3495,"activeCount":102},[],{"trials":3497,"activeCount":102},[],{"trials":3499,"activeCount":102},[3500,3507,3516],{"nctId":3501,"briefTitle":3502,"status":137,"phases":3503,"primaryCompletion":1288,"completion":3504,"start":1694,"enrollment":294,"conditions":3505,"interventions":3506},"NCT00198120","Safety and Effectiveness of D-Cycloserine in Children With Autism",[93],"2010-08",[1316],[1318],{"nctId":3508,"briefTitle":3509,"status":137,"phases":3510,"primaryCompletion":3511,"completion":3511,"start":1300,"enrollment":3512,"conditions":3513,"interventions":3515},"NCT01086475","D-Cycloserine and Social Skills Training in Autism Spectrum Disorders",[93],"2014-01",68,[1316,1292,3514],"Pervasive Developmental Disorder NOS",[1318],{"nctId":1309,"briefTitle":1310,"status":137,"phases":3517,"primaryCompletion":1312,"completion":1312,"start":1313,"enrollment":1314,"conditions":3518,"interventions":3519},[93],[1316],[1275,1318],{"trials":3521,"activeCount":102},[],{"trials":3523,"activeCount":102},[],{"intervention":3525,"totalTrials":98,"cells":3526},"Tacrolimus",{"EARLY_PHASE1":3527,"PHASE1":3529,"PHASE2":3540,"PHASE3":3542,"PHASE4":3562,"NA":3564},{"trials":3528,"activeCount":102},[],{"trials":3530,"activeCount":102},[3531],{"nctId":3532,"briefTitle":3533,"status":137,"phases":3534,"primaryCompletion":3535,"completion":3535,"start":3536,"enrollment":751,"conditions":3537,"interventions":3539},"NCT02341274","Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers",[91],"2018-01-20","2016-11-11",[3538],"Bioequivalence",[3525],{"trials":3541,"activeCount":102},[],{"trials":3543,"activeCount":102},[3544,3554],{"nctId":3545,"briefTitle":3546,"status":114,"phases":3547,"primaryCompletion":3548,"completion":3548,"start":3549,"enrollment":34,"conditions":3550,"interventions":3552},"NCT04063865","Everolimus Monotherapy as Immunosuppression After Liver Transplant",[93],"2020-07-02","2019-05-09",[3551],"Kidney Failure",[3525,3553],"Everolimus",{"nctId":3555,"briefTitle":3556,"status":114,"phases":3557,"primaryCompletion":3558,"completion":3558,"start":3559,"enrollment":1276,"conditions":3560,"interventions":3561},"NCT04258423","Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function",[93],"2020-06-27","2019-12-19",[3551],[3525,3553],{"trials":3563,"activeCount":102},[],{"trials":3565,"activeCount":102},[],{"intervention":3567,"totalTrials":152,"cells":3568},"Hydroxyurea",{"EARLY_PHASE1":3569,"PHASE1":3571,"PHASE2":3573,"PHASE3":3575,"PHASE4":3599,"NA":3601},{"trials":3570,"activeCount":102},[],{"trials":3572,"activeCount":102},[],{"trials":3574,"activeCount":102},[],{"trials":3576,"activeCount":102},[3577,3590],{"nctId":3578,"briefTitle":3579,"status":137,"phases":3580,"primaryCompletion":3581,"completion":3582,"start":3583,"enrollment":3584,"conditions":3585,"interventions":3589},"NCT03128515","Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas",[93],"2019-04-07","2020-01-28","2017-07-26",187,[3586,3587,3588],"Sickle Cell Anemia","Sickle Cell Disease","Malaria",[3567],{"nctId":3591,"briefTitle":3592,"status":137,"phases":3593,"primaryCompletion":3041,"completion":3594,"start":3595,"enrollment":3596,"conditions":3597,"interventions":3598},"NCT01976416","Novel Use Of Hydroxyurea in an African Region With Malaria",[93],"2017-11","2014-09",208,[3586,3587,3588],[3567],{"trials":3600,"activeCount":102},[],{"trials":3602,"activeCount":102},[],{"intervention":3553,"totalTrials":152,"cells":3604},{"EARLY_PHASE1":3605,"PHASE1":3607,"PHASE2":3609,"PHASE3":3611,"PHASE4":3621,"NA":3623},{"trials":3606,"activeCount":102},[],{"trials":3608,"activeCount":102},[],{"trials":3610,"activeCount":102},[],{"trials":3612,"activeCount":102},[3613,3617],{"nctId":3545,"briefTitle":3546,"status":114,"phases":3614,"primaryCompletion":3548,"completion":3548,"start":3549,"enrollment":34,"conditions":3615,"interventions":3616},[93],[3551],[3525,3553],{"nctId":3555,"briefTitle":3556,"status":114,"phases":3618,"primaryCompletion":3558,"completion":3558,"start":3559,"enrollment":1276,"conditions":3619,"interventions":3620},[93],[3551],[3525,3553],{"trials":3622,"activeCount":102},[],{"trials":3624,"activeCount":102},[],{"intervention":3626,"totalTrials":147,"cells":3627},"0 ppm F",{"EARLY_PHASE1":3628,"PHASE1":3630,"PHASE2":3632,"PHASE3":3634,"PHASE4":3648,"NA":3650},{"trials":3629,"activeCount":102},[],{"trials":3631,"activeCount":102},[],{"trials":3633,"activeCount":102},[],{"trials":3635,"activeCount":102},[3636],{"nctId":3637,"briefTitle":3638,"status":137,"phases":3639,"primaryCompletion":3640,"completion":3640,"start":3641,"enrollment":3642,"conditions":3643,"interventions":3645},"NCT06010732","In Situ Comparison of the Remineralization Potential of Optimized Fluoride Dentifrice With Control Fluoride Dentifrice",[93],"2024-02-22","2023-10-02",52,[3644],"Caries",[3626,3646,3647],"1100 ppm F as sodium fluoride","1100 ppm F as sodium fluoride Test Product",{"trials":3649,"activeCount":102},[],{"trials":3651,"activeCount":102},[],{"intervention":3646,"totalTrials":147,"cells":3653},{"EARLY_PHASE1":3654,"PHASE1":3656,"PHASE2":3658,"PHASE3":3660,"PHASE4":3666,"NA":3668},{"trials":3655,"activeCount":102},[],{"trials":3657,"activeCount":102},[],{"trials":3659,"activeCount":102},[],{"trials":3661,"activeCount":102},[3662],{"nctId":3637,"briefTitle":3638,"status":137,"phases":3663,"primaryCompletion":3640,"completion":3640,"start":3641,"enrollment":3642,"conditions":3664,"interventions":3665},[93],[3644],[3626,3646,3647],{"trials":3667,"activeCount":102},[],{"trials":3669,"activeCount":102},[],{"intervention":3647,"totalTrials":147,"cells":3671},{"EARLY_PHASE1":3672,"PHASE1":3674,"PHASE2":3676,"PHASE3":3678,"PHASE4":3684,"NA":3686},{"trials":3673,"activeCount":102},[],{"trials":3675,"activeCount":102},[],{"trials":3677,"activeCount":102},[],{"trials":3679,"activeCount":102},[3680],{"nctId":3637,"briefTitle":3638,"status":137,"phases":3681,"primaryCompletion":3640,"completion":3640,"start":3641,"enrollment":3642,"conditions":3682,"interventions":3683},[93],[3644],[3626,3646,3647],{"trials":3685,"activeCount":102},[],{"trials":3687,"activeCount":102},[],{"intervention":3689,"totalTrials":147,"cells":3690},"US Guided Single Shot Paravertebral Block",{"EARLY_PHASE1":3691,"PHASE1":3693,"PHASE2":3695,"PHASE3":3697,"PHASE4":3711,"NA":3713},{"trials":3692,"activeCount":102},[],{"trials":3694,"activeCount":102},[],{"trials":3696,"activeCount":102},[],{"trials":3698,"activeCount":102},[3699],{"nctId":3700,"briefTitle":3701,"status":137,"phases":3702,"primaryCompletion":3703,"completion":3703,"start":3704,"enrollment":1553,"conditions":3705,"interventions":3708},"NCT03151434","Comparison of Three Different Pain Blocks for Subjects Undergoing VATS (Video Assisted Thoracoscopic Surgery) Procedure.",[93],"2018-07-30","2017-02-07",[3706,144,3707],"Video Assisted Thoracoscopic Surgery","Pain, Acute",[3689,3709,3710],"US Guided Paravertebral Catheter","Thoracic Epidural",{"trials":3712,"activeCount":102},[],{"trials":3714,"activeCount":102},[],{"intervention":3709,"totalTrials":147,"cells":3716},{"EARLY_PHASE1":3717,"PHASE1":3719,"PHASE2":3721,"PHASE3":3723,"PHASE4":3729,"NA":3731},{"trials":3718,"activeCount":102},[],{"trials":3720,"activeCount":102},[],{"trials":3722,"activeCount":102},[],{"trials":3724,"activeCount":102},[3725],{"nctId":3700,"briefTitle":3701,"status":137,"phases":3726,"primaryCompletion":3703,"completion":3703,"start":3704,"enrollment":1553,"conditions":3727,"interventions":3728},[93],[3706,144,3707],[3689,3709,3710],{"trials":3730,"activeCount":102},[],{"trials":3732,"activeCount":102},[],{"intervention":3710,"totalTrials":147,"cells":3734},{"EARLY_PHASE1":3735,"PHASE1":3737,"PHASE2":3739,"PHASE3":3741,"PHASE4":3747,"NA":3749},{"trials":3736,"activeCount":102},[],{"trials":3738,"activeCount":102},[],{"trials":3740,"activeCount":102},[],{"trials":3742,"activeCount":102},[3743],{"nctId":3700,"briefTitle":3701,"status":137,"phases":3744,"primaryCompletion":3703,"completion":3703,"start":3704,"enrollment":1553,"conditions":3745,"interventions":3746},[93],[3706,144,3707],[3689,3709,3710],{"trials":3748,"activeCount":102},[],{"trials":3750,"activeCount":102},[],{"intervention":3752,"totalTrials":147,"cells":3753},"succinylcholine 1 minute after rocuronium pretreatment",{"EARLY_PHASE1":3754,"PHASE1":3756,"PHASE2":3758,"PHASE3":3760,"PHASE4":3773,"NA":3775},{"trials":3755,"activeCount":102},[],{"trials":3757,"activeCount":102},[],{"trials":3759,"activeCount":102},[],{"trials":3761,"activeCount":102},[3762],{"nctId":3763,"briefTitle":3764,"status":137,"phases":3765,"primaryCompletion":3766,"completion":3766,"start":3767,"enrollment":3768,"conditions":3769,"interventions":3771},"NCT04581395","The Effect of Pretreatment With Roc on Succinylcholine Myalgias",[93],"2023-04-25","2020-10-02",300,[3770],"Myalgia",[3752,3772],"succinylcholine 2 minutes following rocuronium pretreatment",{"trials":3774,"activeCount":102},[],{"trials":3776,"activeCount":102},[],{"intervention":3772,"totalTrials":147,"cells":3778},{"EARLY_PHASE1":3779,"PHASE1":3781,"PHASE2":3783,"PHASE3":3785,"PHASE4":3791,"NA":3793},{"trials":3780,"activeCount":102},[],{"trials":3782,"activeCount":102},[],{"trials":3784,"activeCount":102},[],{"trials":3786,"activeCount":102},[3787],{"nctId":3763,"briefTitle":3764,"status":137,"phases":3788,"primaryCompletion":3766,"completion":3766,"start":3767,"enrollment":3768,"conditions":3789,"interventions":3790},[93],[3770],[3752,3772],{"trials":3792,"activeCount":102},[],{"trials":3794,"activeCount":102},[],{"intervention":3796,"totalTrials":147,"cells":3797},"high dose indomethacin",{"EARLY_PHASE1":3798,"PHASE1":3800,"PHASE2":3802,"PHASE3":3804,"PHASE4":3817,"NA":3819},{"trials":3799,"activeCount":102},[],{"trials":3801,"activeCount":102},[],{"trials":3803,"activeCount":102},[],{"trials":3805,"activeCount":102},[3806],{"nctId":3807,"briefTitle":3808,"status":137,"phases":3809,"primaryCompletion":3810,"completion":3811,"start":1671,"enrollment":3812,"conditions":3813,"interventions":3815},"NCT01912716","Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis",[92,93],"2018-04","2018-10",1037,[3814],"Post-ERCP Pancreatitis",[3796,3816],"standard dose indomethacin",{"trials":3818,"activeCount":102},[],{"trials":3820,"activeCount":102},[],{"intervention":3816,"totalTrials":147,"cells":3822},{"EARLY_PHASE1":3823,"PHASE1":3825,"PHASE2":3827,"PHASE3":3829,"PHASE4":3835,"NA":3837},{"trials":3824,"activeCount":102},[],{"trials":3826,"activeCount":102},[],{"trials":3828,"activeCount":102},[],{"trials":3830,"activeCount":102},[3831],{"nctId":3807,"briefTitle":3808,"status":137,"phases":3832,"primaryCompletion":3810,"completion":3811,"start":1671,"enrollment":3812,"conditions":3833,"interventions":3834},[92,93],[3814],[3796,3816],{"trials":3836,"activeCount":102},[],{"trials":3838,"activeCount":102},[],{"intervention":3447,"totalTrials":147,"cells":3840},{"EARLY_PHASE1":3841,"PHASE1":3843,"PHASE2":3845,"PHASE3":3847,"PHASE4":3853,"NA":3855},{"trials":3842,"activeCount":102},[],{"trials":3844,"activeCount":102},[],{"trials":3846,"activeCount":102},[],{"trials":3848,"activeCount":102},[3849],{"nctId":3438,"briefTitle":3439,"status":137,"phases":3850,"primaryCompletion":3441,"completion":3441,"start":3442,"enrollment":3353,"conditions":3851,"interventions":3852},[93],[3444],[3446,3447],{"trials":3854,"activeCount":102},[],{"trials":3856,"activeCount":102},[],{"intervention":3858,"totalTrials":147,"cells":3859},"zinc sulfate",{"EARLY_PHASE1":3860,"PHASE1":3862,"PHASE2":3864,"PHASE3":3866,"PHASE4":3876,"NA":3878},{"trials":3861,"activeCount":102},[],{"trials":3863,"activeCount":102},[],{"trials":3865,"activeCount":102},[],{"trials":3867,"activeCount":102},[3868],{"nctId":3869,"briefTitle":3870,"status":137,"phases":3871,"primaryCompletion":3872,"completion":3872,"start":3873,"enrollment":344,"conditions":3874,"interventions":3875},"NCT06561061","Zinc for Infection Prevention in Sickle Cell Anemia-2 (ZIPS-2)",[92,93],"2025-11-07","2025-02-10",[3587],[3858],{"trials":3877,"activeCount":102},[],{"trials":3879,"activeCount":102},[],{"intervention":1732,"totalTrials":147,"cells":3881},{"EARLY_PHASE1":3882,"PHASE1":3884,"PHASE2":3886,"PHASE3":3888,"PHASE4":3894,"NA":3896},{"trials":3883,"activeCount":102},[],{"trials":3885,"activeCount":102},[],{"trials":3887,"activeCount":102},[],{"trials":3889,"activeCount":102},[3890],{"nctId":1725,"briefTitle":1726,"status":861,"phases":3891,"primaryCompletion":1485,"completion":1485,"start":1728,"enrollment":102,"conditions":3892,"interventions":3893},[93],[1730],[1732,1714],{"trials":3895,"activeCount":102},[],{"trials":3897,"activeCount":102},[],{"intervention":3899,"totalTrials":147,"cells":3900},"misoprostol\u002Fplacebo",{"EARLY_PHASE1":3901,"PHASE1":3903,"PHASE2":3905,"PHASE3":3907,"PHASE4":3917,"NA":3919},{"trials":3902,"activeCount":102},[],{"trials":3904,"activeCount":102},[],{"trials":3906,"activeCount":102},[],{"trials":3908,"activeCount":102},[3909],{"nctId":3910,"briefTitle":3911,"status":137,"phases":3912,"primaryCompletion":3594,"completion":3913,"start":3914,"enrollment":3768,"conditions":3915,"interventions":3916},"NCT02408315","Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium (IMPROVE)",[93],"2021-12","2015-09",[530],[3899],{"trials":3918,"activeCount":102},[],{"trials":3920,"activeCount":102},[],{"intervention":3922,"totalTrials":147,"cells":3923},"Ketotifen",{"EARLY_PHASE1":3924,"PHASE1":3926,"PHASE2":3928,"PHASE3":3930,"PHASE4":3939,"NA":3941},{"trials":3925,"activeCount":102},[],{"trials":3927,"activeCount":102},[],{"trials":3929,"activeCount":102},[],{"trials":3931,"activeCount":102},[3932],{"nctId":3933,"briefTitle":3934,"status":137,"phases":3935,"primaryCompletion":1436,"completion":1436,"start":1707,"enrollment":3936,"conditions":3937,"interventions":3938},"NCT01553318","Novel Use of (Oral) Ketotifen for the Treatment of Fibromyalgia: A Pilot Study",[93],51,[2638],[3922],{"trials":3940,"activeCount":102},[],{"trials":3942,"activeCount":102},[],{"intervention":3944,"totalTrials":147,"cells":3945},"Lisinopril",{"EARLY_PHASE1":3946,"PHASE1":3948,"PHASE2":3950,"PHASE3":3952,"PHASE4":3964,"NA":3966},{"trials":3947,"activeCount":102},[],{"trials":3949,"activeCount":102},[],{"trials":3951,"activeCount":102},[],{"trials":3953,"activeCount":102},[3954],{"nctId":3955,"briefTitle":3956,"status":114,"phases":3957,"primaryCompletion":3958,"completion":3958,"start":1326,"enrollment":699,"conditions":3959,"interventions":3962},"NCT00582114","Hypertension in Hemodialysis Patients (Aim 3)",[93],"2013-09",[3960,38,3961],"Hemodialysis","Left Ventricular Hypertrophy",[3944,3963],"Atenolol",{"trials":3965,"activeCount":102},[],{"trials":3967,"activeCount":102},[],{"intervention":3963,"totalTrials":147,"cells":3969},{"EARLY_PHASE1":3970,"PHASE1":3972,"PHASE2":3974,"PHASE3":3976,"PHASE4":3982,"NA":3984},{"trials":3971,"activeCount":102},[],{"trials":3973,"activeCount":102},[],{"trials":3975,"activeCount":102},[],{"trials":3977,"activeCount":102},[3978],{"nctId":3955,"briefTitle":3956,"status":114,"phases":3979,"primaryCompletion":3958,"completion":3958,"start":1326,"enrollment":699,"conditions":3980,"interventions":3981},[93],[3960,38,3961],[3944,3963],{"trials":3983,"activeCount":102},[],{"trials":3985,"activeCount":102},[],{"intervention":3987,"totalTrials":147,"cells":3988},"Doxycycline",{"EARLY_PHASE1":3989,"PHASE1":3991,"PHASE2":3993,"PHASE3":3995,"PHASE4":4005,"NA":4007},{"trials":3990,"activeCount":102},[],{"trials":3992,"activeCount":102},[],{"trials":3994,"activeCount":102},[],{"trials":3996,"activeCount":102},[3997],{"nctId":3998,"briefTitle":3999,"status":137,"phases":4000,"completion":2518,"start":4001,"enrollment":4002,"conditions":4003,"interventions":4004},"NCT00000403","Doxycycline and OA Progression",[93],"1996-09",432,[866],[3987],{"trials":4006,"activeCount":102},[],{"trials":4008,"activeCount":102},[],{"intervention":4010,"totalTrials":147,"cells":4011},"GLP-1 Low Dose",{"EARLY_PHASE1":4012,"PHASE1":4014,"PHASE2":4016,"PHASE3":4018,"PHASE4":4031,"NA":4033},{"trials":4013,"activeCount":102},[],{"trials":4015,"activeCount":102},[],{"trials":4017,"activeCount":102},[],{"trials":4019,"activeCount":102},[4020],{"nctId":4021,"briefTitle":4022,"status":137,"phases":4023,"primaryCompletion":1436,"completion":1436,"start":4024,"enrollment":4025,"conditions":4026,"interventions":4027},"NCT01607450","Modulation of Human Myocardial Metabolism by GLP-1 Dose Response",[92,93],"2010-05",33,[2662,754],[4010,4028,4029,4030],"GLP-1 Mid-Range Dose","GLP-1 High Dose","Saline",{"trials":4032,"activeCount":102},[],{"trials":4034,"activeCount":102},[],{"intervention":4028,"totalTrials":147,"cells":4036},{"EARLY_PHASE1":4037,"PHASE1":4039,"PHASE2":4041,"PHASE3":4043,"PHASE4":4049,"NA":4051},{"trials":4038,"activeCount":102},[],{"trials":4040,"activeCount":102},[],{"trials":4042,"activeCount":102},[],{"trials":4044,"activeCount":102},[4045],{"nctId":4021,"briefTitle":4022,"status":137,"phases":4046,"primaryCompletion":1436,"completion":1436,"start":4024,"enrollment":4025,"conditions":4047,"interventions":4048},[92,93],[2662,754],[4010,4028,4029,4030],{"trials":4050,"activeCount":102},[],{"trials":4052,"activeCount":102},[],{"intervention":4029,"totalTrials":147,"cells":4054},{"EARLY_PHASE1":4055,"PHASE1":4057,"PHASE2":4059,"PHASE3":4061,"PHASE4":4067,"NA":4069},{"trials":4056,"activeCount":102},[],{"trials":4058,"activeCount":102},[],{"trials":4060,"activeCount":102},[],{"trials":4062,"activeCount":102},[4063],{"nctId":4021,"briefTitle":4022,"status":137,"phases":4064,"primaryCompletion":1436,"completion":1436,"start":4024,"enrollment":4025,"conditions":4065,"interventions":4066},[92,93],[2662,754],[4010,4028,4029,4030],{"trials":4068,"activeCount":102},[],{"trials":4070,"activeCount":102},[],{"intervention":4072,"totalTrials":147,"cells":4073},"Smoflipid 20% Lipid Emulsion for",{"EARLY_PHASE1":4074,"PHASE1":4076,"PHASE2":4078,"PHASE3":4080,"PHASE4":4093,"NA":4095},{"trials":4075,"activeCount":102},[],{"trials":4077,"activeCount":102},[],{"trials":4079,"activeCount":102},[],{"trials":4081,"activeCount":102},[4082],{"nctId":4083,"briefTitle":4084,"status":137,"phases":4085,"primaryCompletion":4086,"completion":4087,"start":4088,"enrollment":751,"conditions":4089,"interventions":4091},"NCT03387579","Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates",[93],"2021-03-28","2024-03-19","2018-11-30",[4090],"Cholestasis of Parenteral Nutrition",[4072,4092,4092],"Intralipid, 20% Intravenous Emulsion",{"trials":4094,"activeCount":102},[],{"trials":4096,"activeCount":102},[],{"intervention":4092,"totalTrials":147,"cells":4098},{"EARLY_PHASE1":4099,"PHASE1":4101,"PHASE2":4103,"PHASE3":4105,"PHASE4":4111,"NA":4113},{"trials":4100,"activeCount":102},[],{"trials":4102,"activeCount":102},[],{"trials":4104,"activeCount":102},[],{"trials":4106,"activeCount":102},[4107],{"nctId":4083,"briefTitle":4084,"status":137,"phases":4108,"primaryCompletion":4086,"completion":4087,"start":4088,"enrollment":751,"conditions":4109,"interventions":4110},[93],[4090],[4072,4092,4092],{"trials":4112,"activeCount":102},[],{"trials":4114,"activeCount":102},[],{"intervention":4116,"totalTrials":147,"cells":4117},"Paliperidone ER",{"EARLY_PHASE1":4118,"PHASE1":4120,"PHASE2":4122,"PHASE3":4124,"PHASE4":4134,"NA":4136},{"trials":4119,"activeCount":102},[],{"trials":4121,"activeCount":102},[],{"trials":4123,"activeCount":102},[],{"trials":4125,"activeCount":102},[4126],{"nctId":4127,"briefTitle":4128,"status":137,"phases":4129,"primaryCompletion":4130,"completion":4130,"start":3125,"enrollment":1290,"conditions":4131,"interventions":4133},"NCT00549562","Study of Paliperidone ER in Adolescents and Young Adults With Autism",[93],"2010-09",[4132],"Autism",[4116],{"trials":4135,"activeCount":102},[],{"trials":4137,"activeCount":102},[],{"intervention":4139,"totalTrials":147,"cells":4140},"Secnidazole 2 GM Oral Granules",{"EARLY_PHASE1":4141,"PHASE1":4143,"PHASE2":4145,"PHASE3":4147,"PHASE4":4158,"NA":4160},{"trials":4142,"activeCount":102},[],{"trials":4144,"activeCount":102},[],{"trials":4146,"activeCount":102},[],{"trials":4148,"activeCount":102},[4149],{"nctId":4150,"briefTitle":4151,"status":137,"phases":4152,"primaryCompletion":4153,"completion":4153,"start":4154,"enrollment":751,"conditions":4155,"interventions":4157},"NCT05033743","Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study",[92,93],"2022-10-07","2021-07-09",[4156],"Recurrent Bacterial Vaginosis",[4139],{"trials":4159,"activeCount":102},[],{"trials":4161,"activeCount":102},[],{"intervention":4163,"totalTrials":147,"cells":4164},"Aripiprazole oral product",{"EARLY_PHASE1":4165,"PHASE1":4167,"PHASE2":4169,"PHASE3":4171,"PHASE4":4181,"NA":4183},{"trials":4166,"activeCount":102},[],{"trials":4168,"activeCount":102},[],{"trials":4170,"activeCount":102},[],{"trials":4172,"activeCount":102},[4173],{"nctId":4174,"briefTitle":4175,"status":137,"phases":4176,"primaryCompletion":1473,"completion":4177,"start":4178,"enrollment":4025,"conditions":4179,"interventions":4180},"NCT00870727","Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders",[93],"2015-05","2009-02",[1293],[4163],{"trials":4182,"activeCount":102},[],{"trials":4184,"activeCount":102},[],{"intervention":4186,"totalTrials":147,"cells":4187},"Exenatide",{"EARLY_PHASE1":4188,"PHASE1":4190,"PHASE2":4192,"PHASE3":4194,"PHASE4":4204,"NA":4206},{"trials":4189,"activeCount":102},[],{"trials":4191,"activeCount":102},[],{"trials":4193,"activeCount":102},[],{"trials":4195,"activeCount":102},[4196],{"nctId":4197,"briefTitle":4198,"status":137,"phases":4199,"primaryCompletion":3504,"completion":3504,"start":4200,"enrollment":119,"conditions":4201,"interventions":4203},"NCT00650546","Role of Exenatide in NASH-a Pilot Study",[92,93],"2006-08",[4202],"Nonalcoholic Fatty Liver Disease",[4186],{"trials":4205,"activeCount":102},[],{"trials":4207,"activeCount":102},[],{"intervention":3456,"totalTrials":147,"cells":4209},{"EARLY_PHASE1":4210,"PHASE1":4212,"PHASE2":4214,"PHASE3":4216,"PHASE4":4222,"NA":4224},{"trials":4211,"activeCount":102},[],{"trials":4213,"activeCount":102},[],{"trials":4215,"activeCount":102},[],{"trials":4217,"activeCount":102},[4218],{"nctId":3449,"briefTitle":3450,"status":137,"phases":4219,"primaryCompletion":3452,"completion":3452,"start":1653,"enrollment":141,"conditions":4220,"interventions":4221},[93],[3454],[3427,3456],{"trials":4223,"activeCount":102},[],{"trials":4225,"activeCount":102},[],{"intervention":4227,"totalTrials":147,"cells":4228},"Clozapine augmented with atomoxetine up to 40 mg or placebo",{"EARLY_PHASE1":4229,"PHASE1":4231,"PHASE2":4233,"PHASE3":4235,"PHASE4":4246,"NA":4248},{"trials":4230,"activeCount":102},[],{"trials":4232,"activeCount":102},[],{"trials":4234,"activeCount":102},[],{"trials":4236,"activeCount":102},[4237],{"nctId":4238,"briefTitle":4239,"status":114,"phases":4240,"primaryCompletion":4241,"completion":4242,"start":1313,"enrollment":4243,"conditions":4244,"interventions":4245},"NCT00216281","Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia",[93],"2006-10","2008-09",126,[2099],[4227],{"trials":4247,"activeCount":102},[],{"trials":4249,"activeCount":102},[],{"intervention":3469,"totalTrials":147,"cells":4251},{"EARLY_PHASE1":4252,"PHASE1":4254,"PHASE2":4256,"PHASE3":4258,"PHASE4":4264,"NA":4266},{"trials":4253,"activeCount":102},[],{"trials":4255,"activeCount":102},[],{"trials":4257,"activeCount":102},[],{"trials":4259,"activeCount":102},[4260],{"nctId":3458,"briefTitle":3459,"status":137,"phases":4261,"primaryCompletion":3461,"completion":3462,"start":3463,"enrollment":1066,"conditions":4262,"interventions":4263},[93],[144,3465,3466],[3468,3469,3470],{"trials":4265,"activeCount":102},[],{"trials":4267,"activeCount":102},[],{"intervention":3470,"totalTrials":147,"cells":4269},{"EARLY_PHASE1":4270,"PHASE1":4272,"PHASE2":4274,"PHASE3":4276,"PHASE4":4282,"NA":4284},{"trials":4271,"activeCount":102},[],{"trials":4273,"activeCount":102},[],{"trials":4275,"activeCount":102},[],{"trials":4277,"activeCount":102},[4278],{"nctId":3458,"briefTitle":3459,"status":137,"phases":4279,"primaryCompletion":3461,"completion":3462,"start":3463,"enrollment":1066,"conditions":4280,"interventions":4281},[93],[144,3465,3466],[3468,3469,3470],{"trials":4283,"activeCount":102},[],{"trials":4285,"activeCount":102},[],{"intervention":3481,"totalTrials":147,"cells":4287},{"EARLY_PHASE1":4288,"PHASE1":4290,"PHASE2":4292,"PHASE3":4294,"PHASE4":4300,"NA":4302},{"trials":4289,"activeCount":102},[],{"trials":4291,"activeCount":102},[],{"trials":4293,"activeCount":102},[],{"trials":4295,"activeCount":102},[4296],{"nctId":3472,"briefTitle":3473,"status":137,"phases":4297,"primaryCompletion":3475,"completion":3476,"start":3477,"enrollment":912,"conditions":4298,"interventions":4299},[93],[3479],[3481,3427,3482,3483,3484,3485],{"trials":4301,"activeCount":102},[],{"trials":4303,"activeCount":102},[],{"intervention":3482,"totalTrials":147,"cells":4305},{"EARLY_PHASE1":4306,"PHASE1":4308,"PHASE2":4310,"PHASE3":4312,"PHASE4":4318,"NA":4320},{"trials":4307,"activeCount":102},[],{"trials":4309,"activeCount":102},[],{"trials":4311,"activeCount":102},[],{"trials":4313,"activeCount":102},[4314],{"nctId":3472,"briefTitle":3473,"status":137,"phases":4315,"primaryCompletion":3475,"completion":3476,"start":3477,"enrollment":912,"conditions":4316,"interventions":4317},[93],[3479],[3481,3427,3482,3483,3484,3485],{"trials":4319,"activeCount":102},[],{"trials":4321,"activeCount":102},[],{"intervention":3483,"totalTrials":147,"cells":4323},{"EARLY_PHASE1":4324,"PHASE1":4326,"PHASE2":4328,"PHASE3":4330,"PHASE4":4336,"NA":4338},{"trials":4325,"activeCount":102},[],{"trials":4327,"activeCount":102},[],{"trials":4329,"activeCount":102},[],{"trials":4331,"activeCount":102},[4332],{"nctId":3472,"briefTitle":3473,"status":137,"phases":4333,"primaryCompletion":3475,"completion":3476,"start":3477,"enrollment":912,"conditions":4334,"interventions":4335},[93],[3479],[3481,3427,3482,3483,3484,3485],{"trials":4337,"activeCount":102},[],{"trials":4339,"activeCount":102},[],{"intervention":3484,"totalTrials":147,"cells":4341},{"EARLY_PHASE1":4342,"PHASE1":4344,"PHASE2":4346,"PHASE3":4348,"PHASE4":4354,"NA":4356},{"trials":4343,"activeCount":102},[],{"trials":4345,"activeCount":102},[],{"trials":4347,"activeCount":102},[],{"trials":4349,"activeCount":102},[4350],{"nctId":3472,"briefTitle":3473,"status":137,"phases":4351,"primaryCompletion":3475,"completion":3476,"start":3477,"enrollment":912,"conditions":4352,"interventions":4353},[93],[3479],[3481,3427,3482,3483,3484,3485],{"trials":4355,"activeCount":102},[],{"trials":4357,"activeCount":102},[],{"intervention":3485,"totalTrials":147,"cells":4359},{"EARLY_PHASE1":4360,"PHASE1":4362,"PHASE2":4364,"PHASE3":4366,"PHASE4":4372,"NA":4374},{"trials":4361,"activeCount":102},[],{"trials":4363,"activeCount":102},[],{"trials":4365,"activeCount":102},[],{"trials":4367,"activeCount":102},[4368],{"nctId":3472,"briefTitle":3473,"status":137,"phases":4369,"primaryCompletion":3475,"completion":3476,"start":3477,"enrollment":912,"conditions":4370,"interventions":4371},[93],[3479],[3481,3427,3482,3483,3484,3485],{"trials":4373,"activeCount":102},[],{"trials":4375,"activeCount":102},[],{"intervention":4377,"totalTrials":98,"cells":4378},"Pentoxifylline",{"EARLY_PHASE1":4379,"PHASE1":4381,"PHASE2":4383,"PHASE3":4417,"PHASE4":4419,"NA":4421},{"trials":4380,"activeCount":102},[],{"trials":4382,"activeCount":102},[],{"trials":4384,"activeCount":102},[4385,4395,4404],{"nctId":4386,"briefTitle":4387,"status":137,"phases":4388,"primaryCompletion":4389,"completion":4389,"start":4390,"enrollment":2469,"conditions":4391,"interventions":4394},"NCT00796822","Evaluating the Effectiveness of Pentoxifylline at Improving Blood Vessel Function in HIV-infected People Not Receiving Antiretroviral Medications",[92],"2011-10","2009-01",[2386,4392,4393],"Cardiovascular Diseases","Atherosclerosis",[4377],{"nctId":4396,"briefTitle":4397,"status":137,"phases":4398,"primaryCompletion":1436,"completion":1436,"start":1708,"enrollment":1348,"conditions":4399,"interventions":4402},"NCT00864916","Pentoxifylline and Combination Antiretroviral Therapy to Improve Blood Vessel Function in HIV-Infected People",[92],[2386,4400,4392,4393,4401],"Vascular Diseases","HIV Infections",[4403,4377],"Combination antiretroviral therapy",{"nctId":4405,"briefTitle":4406,"status":137,"phases":4407,"primaryCompletion":2493,"completion":2493,"start":4408,"enrollment":4409,"conditions":4410,"interventions":4416},"NCT01625845","Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED)",[92],"2012-06",36,[4411,18,4412,4413,4414,4415],"Major Depressive Disorder","Depressive Symptoms","Cardiovascular Disease (CVD)","Coronary Artery Disease (CAD)","Heart Disease",[4377],{"trials":4418,"activeCount":102},[],{"trials":4420,"activeCount":102},[],{"trials":4422,"activeCount":102},[],{"intervention":4424,"totalTrials":98,"cells":4425},"Gleevec",{"EARLY_PHASE1":4426,"PHASE1":4428,"PHASE2":4439,"PHASE3":4456,"PHASE4":4458,"NA":4460},{"trials":4427,"activeCount":102},[],{"trials":4429,"activeCount":102},[4430],{"nctId":4431,"briefTitle":4432,"status":137,"phases":4433,"primaryCompletion":4434,"completion":4434,"start":1740,"enrollment":4435,"conditions":4436,"interventions":4438},"NCT00314873","Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma",[91],"2011-03",11,[4437],"Thymic Carcinoma",[4424],{"trials":4440,"activeCount":102},[4441,4449],{"nctId":4442,"briefTitle":4443,"status":114,"phases":4444,"primaryCompletion":1603,"completion":1484,"start":4445,"enrollment":147,"conditions":4446,"interventions":4448},"NCT00583115","Safety Study of Gleevec® in Children With Pulmonary Hypertension",[92],"2007-10",[4447],"Pulmonary Hypertension",[4424],{"nctId":4450,"briefTitle":4451,"status":137,"phases":4452,"primaryCompletion":2468,"completion":1604,"start":1936,"enrollment":4409,"conditions":4453,"interventions":4455},"NCT01673009","Phase II Study of Gleevec\u002FImatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas",[92],[4454],"Neurofibromatosis",[4424],{"trials":4457,"activeCount":102},[],{"trials":4459,"activeCount":102},[],{"trials":4461,"activeCount":102},[],{"intervention":4463,"totalTrials":152,"cells":4464},"Erlotinib",{"EARLY_PHASE1":4465,"PHASE1":4467,"PHASE2":4469,"PHASE3":4487,"PHASE4":4489,"NA":4491},{"trials":4466,"activeCount":102},[],{"trials":4468,"activeCount":102},[],{"trials":4470,"activeCount":102},[4471,4478],{"nctId":4472,"briefTitle":4473,"status":137,"phases":4474,"primaryCompletion":1707,"completion":1707,"start":3258,"enrollment":4435,"conditions":4475,"interventions":4477},"NCT01174043","Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia",[92],[4476],"Leukemia, Myelomonocytic, Acute",[4463],{"nctId":4479,"briefTitle":4480,"status":137,"phases":4481,"primaryCompletion":1288,"completion":1288,"start":4200,"enrollment":25,"conditions":4482,"interventions":4485},"NCT00369889","A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer",[92],[4483,4484],"Thymic Cancer","Thymoma",[4486,4463],"bevacizumab",{"trials":4488,"activeCount":102},[],{"trials":4490,"activeCount":102},[],{"trials":4492,"activeCount":102},[],{"intervention":4494,"totalTrials":152,"cells":4495},"FOLFIRINOX",{"EARLY_PHASE1":4496,"PHASE1":4498,"PHASE2":4500,"PHASE3":4521,"PHASE4":4523,"NA":4525},{"trials":4497,"activeCount":102},[],{"trials":4499,"activeCount":102},[],{"trials":4501,"activeCount":102},[4502,4511],{"nctId":4503,"briefTitle":4504,"status":861,"phases":4505,"primaryCompletion":4506,"completion":4507,"start":3352,"enrollment":102,"conditions":4508,"interventions":4510},"NCT04130399","Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer",[92],"2022-01-01","2023-01-01",[2447,4509],"Pancreatic Adenocarcinoma",[4494],{"nctId":4512,"briefTitle":4513,"status":137,"phases":4514,"primaryCompletion":4515,"completion":4516,"start":4517,"enrollment":1938,"conditions":4518,"interventions":4520},"NCT02178709","A Phase II Study of Neoadjuvant FOLFIRINOX",[92],"2018-02-14","2019-10-28","2014-06-03",[4519],"Resectable Pancreatic Ductal Adenocarcinoma",[4494],{"trials":4522,"activeCount":102},[],{"trials":4524,"activeCount":102},[],{"trials":4526,"activeCount":102},[],{"intervention":4486,"totalTrials":152,"cells":4528},{"EARLY_PHASE1":4529,"PHASE1":4531,"PHASE2":4542,"PHASE3":4548,"PHASE4":4550,"NA":4552},{"trials":4530,"activeCount":102},[],{"trials":4532,"activeCount":102},[4533],{"nctId":4534,"briefTitle":4535,"status":137,"phases":4536,"primaryCompletion":4537,"completion":4538,"start":1301,"enrollment":4435,"conditions":4539,"interventions":4541},"NCT00393497","A Pilot Study of VEGF Inhibition in Patients With Lymphedema Following Breast Cancer Treatment",[91],"2009-10","2011-01",[24,4540],"Lymphedema",[4486],{"trials":4543,"activeCount":102},[4544],{"nctId":4479,"briefTitle":4480,"status":137,"phases":4545,"primaryCompletion":1288,"completion":1288,"start":4200,"enrollment":25,"conditions":4546,"interventions":4547},[92],[4483,4484],[4486,4463],{"trials":4549,"activeCount":102},[],{"trials":4551,"activeCount":102},[],{"trials":4553,"activeCount":102},[],{"intervention":4555,"totalTrials":152,"cells":4556},"Imatinib Mesylate",{"EARLY_PHASE1":4557,"PHASE1":4559,"PHASE2":4561,"PHASE3":4581,"PHASE4":4583,"NA":4585},{"trials":4558,"activeCount":102},[],{"trials":4560,"activeCount":102},[],{"trials":4562,"activeCount":102},[4563,4571],{"nctId":4564,"briefTitle":4565,"status":114,"phases":4566,"primaryCompletion":4567,"completion":4567,"start":4568,"enrollment":1741,"conditions":4569,"interventions":4570},"NCT03997903","Imatinib for Pain in Sickle Cell Anemia",[91,92],"2024-08-06","2020-02-26",[3587],[4555],{"nctId":4572,"briefTitle":4573,"status":861,"phases":4574,"primaryCompletion":4575,"completion":4576,"start":4577,"enrollment":102,"conditions":4578,"interventions":4580},"NCT03688568","Study of Imatinib in Children With Neurofibromatosis and Airway Tumors",[92],"2020-09-01","2021-09-01","2018-09-01",[4579],"Neurofibroma, Plexiform",[4555],{"trials":4582,"activeCount":102},[],{"trials":4584,"activeCount":102},[],{"trials":4586,"activeCount":102},[],{"intervention":4588,"totalTrials":152,"cells":4589},"Antidepressant Medications",{"EARLY_PHASE1":4590,"PHASE1":4592,"PHASE2":4594,"PHASE3":4620,"PHASE4":4622,"NA":4624},{"trials":4591,"activeCount":102},[],{"trials":4593,"activeCount":102},[],{"trials":4595,"activeCount":102},[4596,4609],{"nctId":4597,"briefTitle":4598,"status":137,"phases":4599,"primaryCompletion":4600,"completion":4601,"start":4602,"enrollment":4603,"conditions":4604,"interventions":4608},"NCT02458690","eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients",[92],"2019-08","2021-03","2015-07",216,[18,4411,4605,4412,4392,4606,2928,4607],"Dysthymic Disorder","Heart Diseases","Stroke",[4588],{"nctId":4610,"briefTitle":4611,"status":137,"phases":4612,"primaryCompletion":4613,"completion":4613,"start":4614,"enrollment":1773,"conditions":4615,"interventions":4619},"NCT04437485","eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk",[92],"2022-08-29","2020-10-14",[18,4411,4605,4412,4616,4617,4618],"Type 2 Diabetes","PreDiabetes","Insulin Resistance",[4588],{"trials":4621,"activeCount":102},[],{"trials":4623,"activeCount":102},[],{"trials":4625,"activeCount":102},[],{"intervention":4627,"totalTrials":152,"cells":4628},"Mirabegron",{"EARLY_PHASE1":4629,"PHASE1":4631,"PHASE2":4633,"PHASE3":4654,"PHASE4":4656,"NA":4658},{"trials":4630,"activeCount":102},[],{"trials":4632,"activeCount":102},[],{"trials":4634,"activeCount":102},[4635,4646],{"nctId":4636,"briefTitle":4637,"status":137,"phases":4638,"primaryCompletion":4639,"completion":4639,"start":4640,"enrollment":579,"conditions":4641,"interventions":4645},"NCT04766021","Mirabegron and Physiological Function in Cold Environments",[91,92],"2023-04-27","2021-11-30",[4642,4643,4644],"Resting Energy Expenditure","Thermogenesis","Brown Adipose Tissue",[4627],{"nctId":4647,"briefTitle":4648,"status":137,"phases":4649,"primaryCompletion":4650,"completion":4650,"start":4651,"enrollment":28,"conditions":4652,"interventions":4653},"NCT05990387","MIrabegron and Physiological Function in Cold Environments",[91,92],"2024-04-23","2023-07-19",[4642,4643,4644],[4627],{"trials":4655,"activeCount":102},[],{"trials":4657,"activeCount":102},[],{"trials":4659,"activeCount":102},[],{"intervention":4661,"totalTrials":152,"cells":4662},"Sitagliptin",{"EARLY_PHASE1":4663,"PHASE1":4665,"PHASE2":4667,"PHASE3":4696,"PHASE4":4698,"NA":4700},{"trials":4664,"activeCount":102},[],{"trials":4666,"activeCount":102},[],{"trials":4668,"activeCount":102},[4669,4681],{"nctId":4670,"briefTitle":4671,"status":137,"phases":4672,"primaryCompletion":1772,"completion":118,"start":1708,"enrollment":4673,"conditions":4674,"interventions":4680},"NCT00862719","Sitagliptin Umbilical Cord Blood Transplant Study",[92],29,[4675,4676,4677,4678,4679],"Leukemia, Myeloid, Acute","Acute Lymphoblastic Leukemia","Myelodysplasia","Leukemia, Myelogenous, Chronic","Lymphoma, Non-Hodgkin",[4661],{"nctId":4682,"briefTitle":4683,"status":861,"phases":4684,"primaryCompletion":4685,"completion":4685,"start":4686,"enrollment":102,"conditions":4687,"interventions":4693},"NCT05895201","High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD",[91,92],"2025-12","2023-11",[4688,4689,4690,4691,4692],"Bone Marrow Transplant Complications","Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia, Adult","Myelodysplastic Syndromes","Chronic Myelomonocytic Leukemia",[4661,4694,4695],"Bortezomib","Cyclophosphamide",{"trials":4697,"activeCount":102},[],{"trials":4699,"activeCount":102},[],{"trials":4701,"activeCount":102},[],{"intervention":4703,"totalTrials":147,"cells":4704},"Vitamin E",{"EARLY_PHASE1":4705,"PHASE1":4707,"PHASE2":4709,"PHASE3":4721,"PHASE4":4723,"NA":4725},{"trials":4706,"activeCount":102},[],{"trials":4708,"activeCount":102},[],{"trials":4710,"activeCount":102},[4711],{"nctId":4712,"briefTitle":4713,"status":114,"phases":4714,"primaryCompletion":4715,"completion":4715,"start":4716,"enrollment":98,"conditions":4717,"interventions":4720},"NCT03669133","Vitamin E for NASH Treatment in HIV Infected Individuals",[92],"2021-03-08","2019-10-01",[4718,4719,4401],"NAFLD","NASH - Nonalcoholic Steatohepatitis",[4703],{"trials":4722,"activeCount":102},[],{"trials":4724,"activeCount":102},[],{"trials":4726,"activeCount":102},[],{"intervention":4728,"totalTrials":147,"cells":4729},"Zenapax",{"EARLY_PHASE1":4730,"PHASE1":4732,"PHASE2":4734,"PHASE3":4745,"PHASE4":4747,"NA":4749},{"trials":4731,"activeCount":102},[],{"trials":4733,"activeCount":102},[],{"trials":4735,"activeCount":102},[4736],{"nctId":4737,"briefTitle":4738,"status":137,"phases":4739,"primaryCompletion":4740,"completion":4740,"start":4741,"enrollment":1838,"conditions":4742,"interventions":4744},"NCT00198146","Prevention of Diabetes Progression Trial (PDPT)",[92],"2007-02-23","2000-07",[4743],"Newly Diagnosed With Type 1 Diabetes",[4728],{"trials":4746,"activeCount":102},[],{"trials":4748,"activeCount":102},[],{"trials":4750,"activeCount":102},[],{"intervention":1477,"totalTrials":147,"cells":4752},{"EARLY_PHASE1":4753,"PHASE1":4755,"PHASE2":4757,"PHASE3":4763,"PHASE4":4765,"NA":4767},{"trials":4754,"activeCount":102},[],{"trials":4756,"activeCount":102},[],{"trials":4758,"activeCount":102},[4759],{"nctId":1469,"briefTitle":1470,"status":114,"phases":4760,"primaryCompletion":1472,"completion":1472,"start":1473,"enrollment":25,"conditions":4761,"interventions":4762},[92],[144,1475],[1460,1477],{"trials":4764,"activeCount":102},[],{"trials":4766,"activeCount":102},[],{"trials":4768,"activeCount":102},[],{"intervention":4770,"totalTrials":147,"cells":4771},"ZD1839 Iressa",{"EARLY_PHASE1":4772,"PHASE1":4774,"PHASE2":4776,"PHASE3":4788,"PHASE4":4790,"NA":4792},{"trials":4773,"activeCount":102},[],{"trials":4775,"activeCount":102},[],{"trials":4777,"activeCount":102},[4778],{"nctId":4779,"briefTitle":4780,"status":114,"phases":4781,"primaryCompletion":4782,"completion":4783,"start":3065,"enrollment":4784,"conditions":4785,"interventions":4787},"NCT00198159","A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR",[92],"2006-02","2006-03",21,[4786],"Refractory Germ Cell Tumors Expressing EGRF",[4770],{"trials":4789,"activeCount":102},[],{"trials":4791,"activeCount":102},[],{"trials":4793,"activeCount":102},[],{"intervention":4795,"totalTrials":147,"cells":4796},"perillyl alcohol",{"EARLY_PHASE1":4797,"PHASE1":4799,"PHASE2":4801,"PHASE3":4810,"PHASE4":4812,"NA":4814},{"trials":4798,"activeCount":102},[],{"trials":4800,"activeCount":102},[],{"trials":4802,"activeCount":102},[4803],{"nctId":4804,"briefTitle":4805,"status":137,"phases":4806,"primaryCompletion":2518,"completion":2518,"start":4807,"conditions":4808,"interventions":4809},"NCT00003769","Perillyl Alcohol Followed by Surgery in Treating Patients With Stage II or Stage III Pancreatic Cancer",[92],"1999-02",[2447],[4795],{"trials":4811,"activeCount":102},[],{"trials":4813,"activeCount":102},[],{"trials":4815,"activeCount":102},[],{"intervention":4817,"totalTrials":147,"cells":4818},"Iron dextran 1000 mg IV",{"EARLY_PHASE1":4819,"PHASE1":4821,"PHASE2":4823,"PHASE3":4833,"PHASE4":4835,"NA":4837},{"trials":4820,"activeCount":102},[],{"trials":4822,"activeCount":102},[],{"trials":4824,"activeCount":102},[4825],{"nctId":4826,"briefTitle":4827,"status":861,"phases":4828,"primaryCompletion":527,"completion":527,"start":4829,"enrollment":102,"conditions":4830,"interventions":4832},"NCT06508827","Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma",[92],"2025-05",[4831,998],"Anemia, Iron Deficiency",[4817],{"trials":4834,"activeCount":102},[],{"trials":4836,"activeCount":102},[],{"trials":4838,"activeCount":102},[],{"intervention":4840,"totalTrials":147,"cells":4841},"Acetylcarnitine",{"EARLY_PHASE1":4842,"PHASE1":4844,"PHASE2":4846,"PHASE3":4858,"PHASE4":4860,"NA":4862},{"trials":4843,"activeCount":102},[],{"trials":4845,"activeCount":102},[],{"trials":4847,"activeCount":102},[4848],{"nctId":4849,"briefTitle":4850,"status":114,"phases":4851,"primaryCompletion":4852,"completion":4853,"start":4854,"enrollment":119,"conditions":4855,"interventions":4857},"NCT02598622","A Pilot Study Investigating the Effects of Acetyl-L-Carnitine and Vincristine-Induced Neuropathy in Pediatric Patients With ALL",[92],"2012-05","2016-01","2009-09",[4856],"Vincristine Induced Neuropathy",[4840],{"trials":4859,"activeCount":102},[],{"trials":4861,"activeCount":102},[],{"trials":4863,"activeCount":102},[],{"intervention":4865,"totalTrials":147,"cells":4866},"Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments",{"EARLY_PHASE1":4867,"PHASE1":4869,"PHASE2":4871,"PHASE3":4882,"PHASE4":4884,"NA":4886},{"trials":4868,"activeCount":102},[],{"trials":4870,"activeCount":102},[],{"trials":4872,"activeCount":102},[4873],{"nctId":4874,"briefTitle":4875,"status":137,"phases":4876,"primaryCompletion":4877,"completion":4877,"start":4878,"enrollment":579,"conditions":4879,"interventions":4881},"NCT04884763","Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder",[92],"2024-01-04","2021-11-15",[4880],"Temporomandibular Disorder",[4865],{"trials":4883,"activeCount":102},[],{"trials":4885,"activeCount":102},[],{"trials":4887,"activeCount":102},[],{"intervention":4889,"totalTrials":147,"cells":4890},"docetaxel & capecitabine",{"EARLY_PHASE1":4891,"PHASE1":4893,"PHASE2":4895,"PHASE3":4905,"PHASE4":4907,"NA":4909},{"trials":4892,"activeCount":102},[],{"trials":4894,"activeCount":102},[],{"trials":4896,"activeCount":102},[4897],{"nctId":4898,"briefTitle":4899,"status":137,"phases":4900,"completion":4901,"start":4902,"enrollment":1838,"conditions":4903,"interventions":4904},"NCT00198237","Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer",[92],"2005-12","2003-03",[24],[4889],{"trials":4906,"activeCount":102},[],{"trials":4908,"activeCount":102},[],{"trials":4910,"activeCount":102},[],{"intervention":4912,"totalTrials":147,"cells":4913},"Essential oils",{"EARLY_PHASE1":4914,"PHASE1":4916,"PHASE2":4918,"PHASE3":4930,"PHASE4":4932,"NA":4934},{"trials":4915,"activeCount":102},[],{"trials":4917,"activeCount":102},[],{"trials":4919,"activeCount":102},[4920],{"nctId":4921,"briefTitle":4922,"status":137,"phases":4923,"primaryCompletion":4924,"completion":4924,"start":4925,"enrollment":4926,"conditions":4927,"interventions":4929},"NCT05251337","Use of Aromatherapy to Reduce Symptom Burden",[92],"2023-06-22","2022-03-07",92,[21,4928],"Chemotherapy-induced Nausea and Vomiting",[4912],{"trials":4931,"activeCount":102},[],{"trials":4933,"activeCount":102},[],{"trials":4935,"activeCount":102},[],{"intervention":4937,"totalTrials":147,"cells":4938},"Subcutaneous Secretin",{"EARLY_PHASE1":4939,"PHASE1":4941,"PHASE2":4943,"PHASE3":4951,"PHASE4":4953,"NA":4955},{"trials":4940,"activeCount":102},[],{"trials":4942,"activeCount":102},[],{"trials":4944,"activeCount":102},[4945],{"nctId":4946,"briefTitle":4947,"status":137,"phases":4948,"completion":4200,"start":1693,"enrollment":579,"conditions":4949,"interventions":4950},"NCT00235274","Effects of RG1068 (Secretin) on Information Processing in Schizophrenia",[92],[2099],[4937],{"trials":4952,"activeCount":102},[],{"trials":4954,"activeCount":102},[],{"trials":4956,"activeCount":102},[],{"intervention":4958,"totalTrials":147,"cells":4959},"Sutent®\u002FSunitinib",{"EARLY_PHASE1":4960,"PHASE1":4962,"PHASE2":4964,"PHASE3":4975,"PHASE4":4977,"NA":4979},{"trials":4961,"activeCount":102},[],{"trials":4963,"activeCount":102},[],{"trials":4965,"activeCount":102},[4966],{"nctId":4967,"briefTitle":4968,"status":114,"phases":4969,"primaryCompletion":4970,"completion":4515,"start":1707,"enrollment":1348,"conditions":4971,"interventions":4974},"NCT01402817","Study of Sutent®\u002FSunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas",[92],"2015-10",[4454,4972,4973],"NF1","Plexiform Neurofibromas",[4958],{"trials":4976,"activeCount":102},[],{"trials":4978,"activeCount":102},[],{"trials":4980,"activeCount":102},[],{"intervention":4982,"totalTrials":147,"cells":4983},"N-acetylcysteine",{"EARLY_PHASE1":4984,"PHASE1":4986,"PHASE2":4988,"PHASE3":5001,"PHASE4":5003,"NA":5005},{"trials":4985,"activeCount":102},[],{"trials":4987,"activeCount":102},[],{"trials":4989,"activeCount":102},[4990],{"nctId":4991,"briefTitle":4992,"status":137,"phases":4993,"primaryCompletion":4994,"completion":4995,"start":1764,"enrollment":4996,"conditions":4997,"interventions":5000},"NCT00453180","A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders",[92],"2009-08","2009-11",31,[1316,4998,4999],"Asperger Syndrome","Child Development Disorders, Pervasive",[4982],{"trials":5002,"activeCount":102},[],{"trials":5004,"activeCount":102},[],{"trials":5006,"activeCount":102},[],{"intervention":5008,"totalTrials":147,"cells":5009},"Pioglitazone",{"EARLY_PHASE1":5010,"PHASE1":5012,"PHASE2":5014,"PHASE3":5026,"PHASE4":5028,"NA":5030},{"trials":5011,"activeCount":102},[],{"trials":5013,"activeCount":102},[],{"trials":5015,"activeCount":102},[5016],{"nctId":5017,"briefTitle":5018,"status":137,"phases":5019,"primaryCompletion":5020,"completion":5021,"start":5022,"enrollment":25,"conditions":5023,"interventions":5025},"NCT02697617","Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease",[92],"2019-10","2020-01","2016-01-26",[5024],"Polycystic Kidney Disease",[5008],{"trials":5027,"activeCount":102},[],{"trials":5029,"activeCount":102},[],{"trials":5031,"activeCount":102},[],{"intervention":5033,"totalTrials":147,"cells":5034},"Cisplatin plus Epirubicin",{"EARLY_PHASE1":5035,"PHASE1":5037,"PHASE2":5039,"PHASE3":5048,"PHASE4":5050,"NA":5052},{"trials":5036,"activeCount":102},[],{"trials":5038,"activeCount":102},[],{"trials":5040,"activeCount":102},[5041],{"nctId":5042,"briefTitle":5043,"status":114,"phases":5044,"completion":1764,"start":5045,"enrollment":2494,"conditions":5046,"interventions":5047},"NCT00198172","Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors",[92],"2000-10",[804],[5033],{"trials":5049,"activeCount":102},[],{"trials":5051,"activeCount":102},[],{"trials":5053,"activeCount":102},[],{"intervention":5055,"totalTrials":147,"cells":5056},"COX-2 Inhibitor 6-8 weeks prior to surgery",{"EARLY_PHASE1":5057,"PHASE1":5059,"PHASE2":5061,"PHASE3":5072,"PHASE4":5074,"NA":5076},{"trials":5058,"activeCount":102},[],{"trials":5060,"activeCount":102},[],{"trials":5062,"activeCount":102},[5063],{"nctId":5064,"briefTitle":5065,"status":114,"phases":5066,"primaryCompletion":5067,"completion":5067,"start":1313,"enrollment":119,"conditions":5068,"interventions":5070},"NCT00198081","Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)",[92],"2012-04",[5069],"Pancreas Neoplasms",[5055,5071],"COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP",{"trials":5073,"activeCount":102},[],{"trials":5075,"activeCount":102},[],{"trials":5077,"activeCount":102},[],{"intervention":5071,"totalTrials":147,"cells":5079},{"EARLY_PHASE1":5080,"PHASE1":5082,"PHASE2":5084,"PHASE3":5090,"PHASE4":5092,"NA":5094},{"trials":5081,"activeCount":102},[],{"trials":5083,"activeCount":102},[],{"trials":5085,"activeCount":102},[5086],{"nctId":5064,"briefTitle":5065,"status":114,"phases":5087,"primaryCompletion":5067,"completion":5067,"start":1313,"enrollment":119,"conditions":5088,"interventions":5089},[92],[5069],[5055,5071],{"trials":5091,"activeCount":102},[],{"trials":5093,"activeCount":102},[],{"trials":5095,"activeCount":102},[],{"intervention":5097,"totalTrials":147,"cells":5098},"venlafaxine",{"EARLY_PHASE1":5099,"PHASE1":5101,"PHASE2":5103,"PHASE3":5113,"PHASE4":5115,"NA":5117},{"trials":5100,"activeCount":102},[],{"trials":5102,"activeCount":102},[],{"trials":5104,"activeCount":102},[5105],{"nctId":5106,"briefTitle":5107,"status":137,"phases":5108,"primaryCompletion":1693,"completion":1693,"start":5109,"enrollment":5110,"conditions":5111,"interventions":5112},"NCT00198250","Venlafaxine for Hot Flashes After Breast Cancer",[92],"2000-05",75,[24],[5097],{"trials":5114,"activeCount":102},[],{"trials":5116,"activeCount":102},[],{"trials":5118,"activeCount":102},[],{"intervention":5120,"totalTrials":147,"cells":5121},"denosumab",{"EARLY_PHASE1":5122,"PHASE1":5124,"PHASE2":5126,"PHASE3":5142,"PHASE4":5144,"NA":5146},{"trials":5123,"activeCount":102},[],{"trials":5125,"activeCount":102},[],{"trials":5127,"activeCount":102},[5128],{"nctId":5129,"briefTitle":5130,"status":861,"phases":5131,"primaryCompletion":5132,"completion":5132,"start":5133,"enrollment":102,"conditions":5134,"interventions":5141},"NCT02418273","Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders",[91,92],"2021-06","2019-08-01",[2793,5135,5136,5137,5138,5139,5140],"Juvenile Rheumatoid Arthritis","Dermatomyositis","Polyarthritis","Systemic Lupus Erythematosis","Vasculitis","Glucocorticoid-induced Osteoporosis",[5120],{"trials":5143,"activeCount":102},[],{"trials":5145,"activeCount":102},[],{"trials":5147,"activeCount":102},[],{"intervention":5149,"totalTrials":147,"cells":5150},"Inhaled Nitric Oxide",{"EARLY_PHASE1":5151,"PHASE1":5153,"PHASE2":5155,"PHASE3":5166,"PHASE4":5168,"NA":5170},{"trials":5152,"activeCount":102},[],{"trials":5154,"activeCount":102},[],{"trials":5156,"activeCount":102},[5157],{"nctId":5158,"briefTitle":5159,"status":137,"phases":5160,"primaryCompletion":5161,"completion":5161,"start":5162,"enrollment":141,"conditions":5163,"interventions":5165},"NCT01939301","Nitric Oxide to Treat Pulmonary Embolism",[92],"2016-10-31","2013-10",[5164],"Pulmonary Embolism",[5149],{"trials":5167,"activeCount":102},[],{"trials":5169,"activeCount":102},[],{"trials":5171,"activeCount":102},[],{"intervention":4403,"totalTrials":147,"cells":5173},{"EARLY_PHASE1":5174,"PHASE1":5176,"PHASE2":5178,"PHASE3":5184,"PHASE4":5186,"NA":5188},{"trials":5175,"activeCount":102},[],{"trials":5177,"activeCount":102},[],{"trials":5179,"activeCount":102},[5180],{"nctId":4396,"briefTitle":4397,"status":137,"phases":5181,"primaryCompletion":1436,"completion":1436,"start":1708,"enrollment":1348,"conditions":5182,"interventions":5183},[92],[2386,4400,4392,4393,4401],[4403,4377],{"trials":5185,"activeCount":102},[],{"trials":5187,"activeCount":102},[],{"trials":5189,"activeCount":102},[],{"intervention":5191,"totalTrials":147,"cells":5192},"Intranasal oxytocin",{"EARLY_PHASE1":5193,"PHASE1":5195,"PHASE2":5197,"PHASE3":5208,"PHASE4":5210,"NA":5212},{"trials":5194,"activeCount":102},[],{"trials":5196,"activeCount":102},[],{"trials":5198,"activeCount":102},[5199],{"nctId":5200,"briefTitle":5201,"status":114,"phases":5202,"primaryCompletion":5203,"completion":5203,"start":5204,"enrollment":776,"conditions":5205,"interventions":5206},"NCT05312008","Does Oxytocin Alter Tolerance to or Motivation for Alcohol",[92],"2023-12-21","2022-01-16",[701],[5191,5207],"Intranasal placebo",{"trials":5209,"activeCount":102},[],{"trials":5211,"activeCount":102},[],{"trials":5213,"activeCount":102},[],{"intervention":5207,"totalTrials":147,"cells":5215},{"EARLY_PHASE1":5216,"PHASE1":5218,"PHASE2":5220,"PHASE3":5226,"PHASE4":5228,"NA":5230},{"trials":5217,"activeCount":102},[],{"trials":5219,"activeCount":102},[],{"trials":5221,"activeCount":102},[5222],{"nctId":5200,"briefTitle":5201,"status":114,"phases":5223,"primaryCompletion":5203,"completion":5203,"start":5204,"enrollment":776,"conditions":5224,"interventions":5225},[92],[701],[5191,5207],{"trials":5227,"activeCount":102},[],{"trials":5229,"activeCount":102},[],{"trials":5231,"activeCount":102},[],{"intervention":5233,"totalTrials":147,"cells":5234},"ACTIMMUNE",{"EARLY_PHASE1":5235,"PHASE1":5237,"PHASE2":5239,"PHASE3":5250,"PHASE4":5252,"NA":5254},{"trials":5236,"activeCount":102},[],{"trials":5238,"activeCount":102},[],{"trials":5240,"activeCount":102},[5241],{"nctId":5242,"briefTitle":5243,"status":137,"phases":5244,"primaryCompletion":5245,"completion":5245,"start":5246,"enrollment":1302,"conditions":5247,"interventions":5249},"NCT02584608","Use of ACTIMMUNE in Patients With ADO2",[92],"2019-11-12","2016-01-01",[5248],"Autosomal Dominant Osteopetrosis Type 2",[5233],{"trials":5251,"activeCount":102},[],{"trials":5253,"activeCount":102},[],{"trials":5255,"activeCount":102},[],{"intervention":5257,"totalTrials":147,"cells":5258},"Milrinone",{"EARLY_PHASE1":5259,"PHASE1":5261,"PHASE2":5263,"PHASE3":5275,"PHASE4":5277,"NA":5279},{"trials":5260,"activeCount":102},[],{"trials":5262,"activeCount":102},[],{"trials":5264,"activeCount":102},[5265],{"nctId":5266,"briefTitle":5267,"status":114,"phases":5268,"primaryCompletion":5269,"completion":5270,"start":5271,"enrollment":1276,"conditions":5272,"interventions":5274},"NCT02712788","Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage",[92],"2017-10-24","2018-05-03","2016-04-18",[5273],"Cerebral Vasospasm",[5257],{"trials":5276,"activeCount":102},[],{"trials":5278,"activeCount":102},[],{"trials":5280,"activeCount":102},[],{"intervention":5282,"totalTrials":147,"cells":5283},"Furosemide",{"EARLY_PHASE1":5284,"PHASE1":5286,"PHASE2":5288,"PHASE3":5299,"PHASE4":5301,"NA":5303},{"trials":5285,"activeCount":102},[],{"trials":5287,"activeCount":102},[],{"trials":5289,"activeCount":102},[5290],{"nctId":5291,"briefTitle":5292,"status":861,"phases":5293,"primaryCompletion":5294,"completion":5294,"start":5295,"enrollment":102,"conditions":5296,"interventions":5297},"NCT02450773","Prevention of Severe Postpartum Hypertension",[92],"2022-05","2015-08",[38],[5282,5298],"Potassium chloride",{"trials":5300,"activeCount":102},[],{"trials":5302,"activeCount":102},[],{"trials":5304,"activeCount":102},[],{"intervention":5298,"totalTrials":147,"cells":5306},{"EARLY_PHASE1":5307,"PHASE1":5309,"PHASE2":5311,"PHASE3":5317,"PHASE4":5319,"NA":5321},{"trials":5308,"activeCount":102},[],{"trials":5310,"activeCount":102},[],{"trials":5312,"activeCount":102},[5313],{"nctId":5291,"briefTitle":5292,"status":861,"phases":5314,"primaryCompletion":5294,"completion":5294,"start":5295,"enrollment":102,"conditions":5315,"interventions":5316},[92],[38],[5282,5298],{"trials":5318,"activeCount":102},[],{"trials":5320,"activeCount":102},[],{"trials":5322,"activeCount":102},[],{"intervention":5324,"totalTrials":147,"cells":5325},"Cabozantinib",{"EARLY_PHASE1":5326,"PHASE1":5328,"PHASE2":5330,"PHASE3":5344,"PHASE4":5346,"NA":5348},{"trials":5327,"activeCount":102},[],{"trials":5329,"activeCount":102},[],{"trials":5331,"activeCount":102},[5332],{"nctId":5333,"briefTitle":5334,"status":114,"phases":5335,"primaryCompletion":5336,"completion":5336,"start":5337,"enrollment":1276,"conditions":5338,"interventions":5343},"NCT02885324","Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children",[92],"2020-08-25","2017-05-18",[5339,5340,5341,5342],"Glioblastoma Multiforme","Anaplastic Astrocytoma","Malignant Brain Tumor","High Grade Glioma",[5324],{"trials":5345,"activeCount":102},[],{"trials":5347,"activeCount":102},[],{"trials":5349,"activeCount":102},[],{"intervention":5351,"totalTrials":147,"cells":5352},"Granisetron",{"EARLY_PHASE1":5353,"PHASE1":5355,"PHASE2":5357,"PHASE3":5368,"PHASE4":5370,"NA":5372},{"trials":5354,"activeCount":102},[],{"trials":5356,"activeCount":102},[],{"trials":5358,"activeCount":102},[5359],{"nctId":5360,"briefTitle":5361,"status":861,"phases":5362,"primaryCompletion":5363,"completion":5364,"start":5365,"enrollment":102,"conditions":5366,"interventions":5367},"NCT04501211","Open Label Transdermal Granisetron to Relieve Chronic Nausea and Emesis",[92],"2020-12-31","2021-12-31","2019-01-01",[36],[5351],{"trials":5369,"activeCount":102},[],{"trials":5371,"activeCount":102},[],{"trials":5373,"activeCount":102},[],{"intervention":5375,"totalTrials":147,"cells":5376},"Acamprosate",{"EARLY_PHASE1":5377,"PHASE1":5379,"PHASE2":5381,"PHASE3":5390,"PHASE4":5392,"NA":5394},{"trials":5378,"activeCount":102},[],{"trials":5380,"activeCount":102},[],{"trials":5382,"activeCount":102},[5383],{"nctId":5384,"briefTitle":5385,"status":137,"phases":5386,"primaryCompletion":1312,"completion":1312,"start":3504,"enrollment":34,"conditions":5387,"interventions":5389},"NCT01300923","Acamprosate in Youth With Fragile X Syndrome",[92],[1304,5388],"Autism Spectrum Disorders",[5375],{"trials":5391,"activeCount":102},[],{"trials":5393,"activeCount":102},[],{"trials":5395,"activeCount":102},[],{"intervention":5397,"totalTrials":147,"cells":5398},"IT",{"EARLY_PHASE1":5399,"PHASE1":5401,"PHASE2":5403,"PHASE3":5416,"PHASE4":5418,"NA":5420},{"trials":5400,"activeCount":102},[],{"trials":5402,"activeCount":102},[],{"trials":5404,"activeCount":102},[5405],{"nctId":5406,"briefTitle":5407,"status":114,"phases":5408,"primaryCompletion":5409,"completion":5410,"start":5411,"enrollment":5412,"conditions":5413,"interventions":5414},"NCT05257941","ESP Block VS Intrathecal Opioid After Laparoscopic Colorectal Surgery",[91,92],"2024-08-26","2024-08-29","2022-01-27",116,[121],[5397,5415],"ESP Block",{"trials":5417,"activeCount":102},[],{"trials":5419,"activeCount":102},[],{"trials":5421,"activeCount":102},[],{"intervention":5415,"totalTrials":147,"cells":5423},{"EARLY_PHASE1":5424,"PHASE1":5426,"PHASE2":5428,"PHASE3":5434,"PHASE4":5436,"NA":5438},{"trials":5425,"activeCount":102},[],{"trials":5427,"activeCount":102},[],{"trials":5429,"activeCount":102},[5430],{"nctId":5406,"briefTitle":5407,"status":114,"phases":5431,"primaryCompletion":5409,"completion":5410,"start":5411,"enrollment":5412,"conditions":5432,"interventions":5433},[91,92],[121],[5397,5415],{"trials":5435,"activeCount":102},[],{"trials":5437,"activeCount":102},[],{"trials":5439,"activeCount":102},[],{"intervention":5441,"totalTrials":147,"cells":5442},"mifepristone",{"EARLY_PHASE1":5443,"PHASE1":5445,"PHASE2":5447,"PHASE3":5457,"PHASE4":5459,"NA":5461},{"trials":5444,"activeCount":102},[],{"trials":5446,"activeCount":102},[],{"trials":5448,"activeCount":102},[5449],{"nctId":5450,"briefTitle":5451,"status":114,"phases":5452,"primaryCompletion":5453,"completion":5453,"start":4130,"enrollment":3017,"conditions":5454,"interventions":5456},"NCT01212588","Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)",[92],"2016-09",[5455],"Borderline Personality Disorder",[5441],{"trials":5458,"activeCount":102},[],{"trials":5460,"activeCount":102},[],{"trials":5462,"activeCount":102},[],{"intervention":5464,"totalTrials":147,"cells":5465},"Medroxyprogesterone progesterone acetate",{"EARLY_PHASE1":5466,"PHASE1":5468,"PHASE2":5470,"PHASE3":5484,"PHASE4":5486,"NA":5488},{"trials":5467,"activeCount":102},[],{"trials":5469,"activeCount":102},[],{"trials":5471,"activeCount":102},[5472],{"nctId":5473,"briefTitle":5474,"status":137,"phases":5475,"primaryCompletion":2468,"completion":2468,"start":5476,"enrollment":579,"conditions":5477,"interventions":5482},"NCT00577122","Medroxyprogesterone +\u002F- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent\u002FMetastatic Breast Cancer",[92],"2007-07",[5478,5479,5480,5481],"Estrogen Receptor-negative Breast Cancer","Progesterone Receptor-negative Breast Cancer","Recurrent Breast Cancer","Stage IV Breast Cancer",[5464,5483],"Medroxyprogesterone with Cyclophosphamide + Methotrexate",{"trials":5485,"activeCount":102},[],{"trials":5487,"activeCount":102},[],{"trials":5489,"activeCount":102},[],{"intervention":5483,"totalTrials":147,"cells":5491},{"EARLY_PHASE1":5492,"PHASE1":5494,"PHASE2":5496,"PHASE3":5502,"PHASE4":5504,"NA":5506},{"trials":5493,"activeCount":102},[],{"trials":5495,"activeCount":102},[],{"trials":5497,"activeCount":102},[5498],{"nctId":5473,"briefTitle":5474,"status":137,"phases":5499,"primaryCompletion":2468,"completion":2468,"start":5476,"enrollment":579,"conditions":5500,"interventions":5501},[92],[5478,5479,5480,5481],[5464,5483],{"trials":5503,"activeCount":102},[],{"trials":5505,"activeCount":102},[],{"trials":5507,"activeCount":102},[],{"intervention":5509,"totalTrials":147,"cells":5510},"decitabine",{"EARLY_PHASE1":5511,"PHASE1":5513,"PHASE2":5515,"PHASE3":5524,"PHASE4":5526,"NA":5528},{"trials":5512,"activeCount":102},[],{"trials":5514,"activeCount":102},[],{"trials":5516,"activeCount":102},[5517],{"nctId":5518,"briefTitle":5519,"status":137,"phases":5520,"primaryCompletion":2097,"completion":3958,"start":5476,"enrollment":22,"conditions":5521,"interventions":5523},"NCT00477386","Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer",[91,92],[5522],"Ovarian Cancer",[5509],{"trials":5525,"activeCount":102},[],{"trials":5527,"activeCount":102},[],{"trials":5529,"activeCount":102},[],{"intervention":5531,"totalTrials":147,"cells":5532},"Olanzapine",{"EARLY_PHASE1":5533,"PHASE1":5535,"PHASE2":5537,"PHASE3":5548,"PHASE4":5550,"NA":5552},{"trials":5534,"activeCount":102},[],{"trials":5536,"activeCount":102},[],{"trials":5538,"activeCount":102},[5539],{"nctId":5540,"briefTitle":5541,"status":137,"phases":5542,"primaryCompletion":118,"completion":1473,"start":5543,"enrollment":319,"conditions":5544,"interventions":5546},"NCT02097823","Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy",[92],"2014-02",[5545],"Chemotherapy Induced Nausea and Vomiting",[5531,5547],"Aprepitant",{"trials":5549,"activeCount":102},[],{"trials":5551,"activeCount":102},[],{"trials":5553,"activeCount":102},[],{"intervention":5547,"totalTrials":147,"cells":5555},{"EARLY_PHASE1":5556,"PHASE1":5558,"PHASE2":5560,"PHASE3":5566,"PHASE4":5568,"NA":5570},{"trials":5557,"activeCount":102},[],{"trials":5559,"activeCount":102},[],{"trials":5561,"activeCount":102},[5562],{"nctId":5540,"briefTitle":5541,"status":137,"phases":5563,"primaryCompletion":118,"completion":1473,"start":5543,"enrollment":319,"conditions":5564,"interventions":5565},[92],[5545],[5531,5547],{"trials":5567,"activeCount":102},[],{"trials":5569,"activeCount":102},[],{"trials":5571,"activeCount":102},[],{"intervention":5573,"totalTrials":147,"cells":5574},"Cytalux™ (pafolacianine) for fluorescent imaging",{"EARLY_PHASE1":5575,"PHASE1":5577,"PHASE2":5579,"PHASE3":5591,"PHASE4":5593,"NA":5595},{"trials":5576,"activeCount":102},[],{"trials":5578,"activeCount":102},[],{"trials":5580,"activeCount":102},[5581],{"nctId":5582,"briefTitle":5583,"status":137,"phases":5584,"primaryCompletion":5585,"completion":5585,"start":5586,"enrollment":5587,"conditions":5588,"interventions":5590},"NCT06434909","CYTALUX™for the Intraoperative Imaging of Prostate Cancer",[92],"2025-09-04","2024-09-19",9,[5589],"Prostate Cancer",[5573],{"trials":5592,"activeCount":102},[],{"trials":5594,"activeCount":102},[],{"trials":5596,"activeCount":102},[],{"intervention":4694,"totalTrials":147,"cells":5598},{"EARLY_PHASE1":5599,"PHASE1":5601,"PHASE2":5603,"PHASE3":5609,"PHASE4":5611,"NA":5613},{"trials":5600,"activeCount":102},[],{"trials":5602,"activeCount":102},[],{"trials":5604,"activeCount":102},[5605],{"nctId":4682,"briefTitle":4683,"status":861,"phases":5606,"primaryCompletion":4685,"completion":4685,"start":4686,"enrollment":102,"conditions":5607,"interventions":5608},[91,92],[4688,4689,4690,4691,4692],[4661,4694,4695],{"trials":5610,"activeCount":102},[],{"trials":5612,"activeCount":102},[],{"trials":5614,"activeCount":102},[],{"intervention":5616,"totalTrials":147,"cells":5617},"Gabapentin 600mg",{"EARLY_PHASE1":5618,"PHASE1":5620,"PHASE2":5622,"PHASE3":5633,"PHASE4":5635,"NA":5637},{"trials":5619,"activeCount":102},[],{"trials":5621,"activeCount":102},[],{"trials":5623,"activeCount":102},[5624],{"nctId":5625,"briefTitle":5626,"status":861,"phases":5627,"primaryCompletion":5628,"completion":5629,"start":5630,"enrollment":102,"conditions":5631,"interventions":5632},"NCT03750773","Gabapentin for Relief of Immediate Postoperative Pain",[91,92],"2020-03","2020-04","2019-07-02",[2594],[5616],{"trials":5634,"activeCount":102},[],{"trials":5636,"activeCount":102},[],{"trials":5638,"activeCount":102},[],{"intervention":5640,"totalTrials":147,"cells":5641},"Fingolimod",{"EARLY_PHASE1":5642,"PHASE1":5644,"PHASE2":5646,"PHASE3":5655,"PHASE4":5657,"NA":5659},{"trials":5643,"activeCount":102},[],{"trials":5645,"activeCount":102},[],{"trials":5647,"activeCount":102},[5648],{"nctId":5649,"briefTitle":5650,"status":137,"phases":5651,"primaryCompletion":863,"completion":863,"start":5652,"enrollment":1838,"conditions":5653,"interventions":5654},"NCT01779700","Fingolimod in Schizophrenia Patients",[92],"2013-01",[2099],[5640],{"trials":5656,"activeCount":102},[],{"trials":5658,"activeCount":102},[],{"trials":5660,"activeCount":102},[],{"intervention":5662,"totalTrials":147,"cells":5663},"Durvalumab",{"EARLY_PHASE1":5664,"PHASE1":5666,"PHASE2":5668,"PHASE3":5679,"PHASE4":5681,"NA":5683},{"trials":5665,"activeCount":102},[],{"trials":5667,"activeCount":102},[],{"trials":5669,"activeCount":102},[5670],{"nctId":5671,"briefTitle":5672,"status":861,"phases":5673,"primaryCompletion":5674,"completion":5674,"start":5675,"enrollment":102,"conditions":5676,"interventions":5678},"NCT05757843","Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab",[92],"2025-12-31","2024-09-13",[5677],"NSCLC, Stage III",[5662],{"trials":5680,"activeCount":102},[],{"trials":5682,"activeCount":102},[],{"trials":5684,"activeCount":102},[],{"intervention":5686,"totalTrials":147,"cells":5687},"LY500307 150mg",{"EARLY_PHASE1":5688,"PHASE1":5690,"PHASE2":5692,"PHASE3":5704,"PHASE4":5706,"NA":5708},{"trials":5689,"activeCount":102},[],{"trials":5691,"activeCount":102},[],{"trials":5693,"activeCount":102},[5694],{"nctId":5695,"briefTitle":5696,"status":114,"phases":5697,"primaryCompletion":117,"completion":117,"start":5698,"enrollment":5699,"conditions":5700,"interventions":5701},"NCT01874756","The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia",[92],"2013-06",95,[2099],[5686,5702,5703],"LY500307 75mg","LY500307 25mg",{"trials":5705,"activeCount":102},[],{"trials":5707,"activeCount":102},[],{"trials":5709,"activeCount":102},[],{"intervention":5702,"totalTrials":147,"cells":5711},{"EARLY_PHASE1":5712,"PHASE1":5714,"PHASE2":5716,"PHASE3":5722,"PHASE4":5724,"NA":5726},{"trials":5713,"activeCount":102},[],{"trials":5715,"activeCount":102},[],{"trials":5717,"activeCount":102},[5718],{"nctId":5695,"briefTitle":5696,"status":114,"phases":5719,"primaryCompletion":117,"completion":117,"start":5698,"enrollment":5699,"conditions":5720,"interventions":5721},[92],[2099],[5686,5702,5703],{"trials":5723,"activeCount":102},[],{"trials":5725,"activeCount":102},[],{"trials":5727,"activeCount":102},[],{"intervention":5703,"totalTrials":147,"cells":5729},{"EARLY_PHASE1":5730,"PHASE1":5732,"PHASE2":5734,"PHASE3":5740,"PHASE4":5742,"NA":5744},{"trials":5731,"activeCount":102},[],{"trials":5733,"activeCount":102},[],{"trials":5735,"activeCount":102},[5736],{"nctId":5695,"briefTitle":5696,"status":114,"phases":5737,"primaryCompletion":117,"completion":117,"start":5698,"enrollment":5699,"conditions":5738,"interventions":5739},[92],[2099],[5686,5702,5703],{"trials":5741,"activeCount":102},[],{"trials":5743,"activeCount":102},[],{"trials":5745,"activeCount":102},[],{"intervention":5747,"totalTrials":147,"cells":5748},"Valacyclovir HCI 500 mg",{"EARLY_PHASE1":5749,"PHASE1":5751,"PHASE2":5753,"PHASE3":5764,"PHASE4":5766,"NA":5768},{"trials":5750,"activeCount":102},[],{"trials":5752,"activeCount":102},[],{"trials":5754,"activeCount":102},[5755],{"nctId":5756,"briefTitle":5757,"status":137,"phases":5758,"primaryCompletion":5759,"completion":5759,"start":5760,"enrollment":5761,"conditions":5762,"interventions":5763},"NCT02008773","A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia",[92],"2017-06-20","2014-03-26",170,[2099],[5747],{"trials":5765,"activeCount":102},[],{"trials":5767,"activeCount":102},[],{"trials":5769,"activeCount":102},[],{"intervention":5771,"totalTrials":147,"cells":5772},"Lactulose",{"EARLY_PHASE1":5773,"PHASE1":5775,"PHASE2":5777,"PHASE3":5787,"PHASE4":5789,"NA":5791},{"trials":5774,"activeCount":102},[],{"trials":5776,"activeCount":102},[],{"trials":5778,"activeCount":102},[5779],{"nctId":5780,"briefTitle":5781,"status":114,"phases":5782,"primaryCompletion":5783,"completion":5783,"start":4390,"enrollment":31,"conditions":5784,"interventions":5786},"NCT00811434","Study of Lactulose in Children With Chronic Liver Disease",[92],"2010-11",[5785],"Minimal Hepatic Encephalopathy",[5771],{"trials":5788,"activeCount":102},[],{"trials":5790,"activeCount":102},[],{"trials":5792,"activeCount":102},[],{"intervention":1557,"totalTrials":147,"cells":5794},{"EARLY_PHASE1":5795,"PHASE1":5797,"PHASE2":5799,"PHASE3":5805,"PHASE4":5807,"NA":5809},{"trials":5796,"activeCount":102},[],{"trials":5798,"activeCount":102},[],{"trials":5800,"activeCount":102},[5801],{"nctId":1547,"briefTitle":1548,"status":137,"phases":5802,"primaryCompletion":1550,"completion":1551,"start":1552,"enrollment":1553,"conditions":5803,"interventions":5804},[92],[1555],[1557,1558,1538],{"trials":5806,"activeCount":102},[],{"trials":5808,"activeCount":102},[],{"trials":5810,"activeCount":102},[],{"intervention":1558,"totalTrials":147,"cells":5812},{"EARLY_PHASE1":5813,"PHASE1":5815,"PHASE2":5817,"PHASE3":5823,"PHASE4":5825,"NA":5827},{"trials":5814,"activeCount":102},[],{"trials":5816,"activeCount":102},[],{"trials":5818,"activeCount":102},[5819],{"nctId":1547,"briefTitle":1548,"status":137,"phases":5820,"primaryCompletion":1550,"completion":1551,"start":1552,"enrollment":1553,"conditions":5821,"interventions":5822},[92],[1555],[1557,1558,1538],{"trials":5824,"activeCount":102},[],{"trials":5826,"activeCount":102},[],{"trials":5828,"activeCount":102},[],{"intervention":5830,"totalTrials":147,"cells":5831},"Bromelain",{"EARLY_PHASE1":5832,"PHASE1":5834,"PHASE2":5836,"PHASE3":5849,"PHASE4":5851,"NA":5853},{"trials":5833,"activeCount":102},[],{"trials":5835,"activeCount":102},[],{"trials":5837,"activeCount":102},[5838],{"nctId":5839,"briefTitle":5840,"status":137,"phases":5841,"primaryCompletion":5842,"completion":5843,"start":5844,"enrollment":1773,"conditions":5845,"interventions":5848},"NCT04512482","Evaluation of Oral Plaque Removal Utilizing an Adjunct Enzyme Pre-rinse",[92],"2018-07-24","2019-03-04","2018-06-14",[5846,5847],"Dental Plaque","Dental Caries",[5830],{"trials":5850,"activeCount":102},[],{"trials":5852,"activeCount":102},[],{"trials":5854,"activeCount":102},[],{"intervention":5856,"totalTrials":147,"cells":5857},"RG1068",{"EARLY_PHASE1":5858,"PHASE1":5860,"PHASE2":5862,"PHASE3":5872,"PHASE4":5874,"NA":5876},{"trials":5859,"activeCount":102},[],{"trials":5861,"activeCount":102},[],{"trials":5863,"activeCount":102},[5864],{"nctId":5865,"briefTitle":5866,"status":137,"phases":5867,"primaryCompletion":1740,"completion":1740,"start":5868,"enrollment":1302,"conditions":5869,"interventions":5871},"NCT00216294","Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder",[92],"2005-02",[5870],"Obsessive Compulsive Disorder (OCD)",[5856],{"trials":5873,"activeCount":102},[],{"trials":5875,"activeCount":102},[],{"trials":5877,"activeCount":102},[],{"intervention":5879,"totalTrials":147,"cells":5880},"Intravenous Loop Diuretic",{"EARLY_PHASE1":5881,"PHASE1":5883,"PHASE2":5885,"PHASE3":5901,"PHASE4":5903,"NA":5905},{"trials":5882,"activeCount":102},[],{"trials":5884,"activeCount":102},[],{"trials":5886,"activeCount":102},[5887],{"nctId":5888,"briefTitle":5889,"status":137,"phases":5890,"primaryCompletion":5891,"completion":5892,"start":5893,"enrollment":1524,"conditions":5894,"interventions":5899},"NCT03136198","B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial",[92],"2019-03-20","2019-06-20","2017-07-10",[5895,5896,5897,5898],"Heart Failure","Heart Failure Acute","Acute Cardiac Pulmonary Edema","Acute Cardiac Failure",[5879,5900],"Vasodilator",{"trials":5902,"activeCount":102},[],{"trials":5904,"activeCount":102},[],{"trials":5906,"activeCount":102},[],{"intervention":5900,"totalTrials":147,"cells":5908},{"EARLY_PHASE1":5909,"PHASE1":5911,"PHASE2":5913,"PHASE3":5919,"PHASE4":5921,"NA":5923},{"trials":5910,"activeCount":102},[],{"trials":5912,"activeCount":102},[],{"trials":5914,"activeCount":102},[5915],{"nctId":5888,"briefTitle":5889,"status":137,"phases":5916,"primaryCompletion":5891,"completion":5892,"start":5893,"enrollment":1524,"conditions":5917,"interventions":5918},[92],[5895,5896,5897,5898],[5879,5900],{"trials":5920,"activeCount":102},[],{"trials":5922,"activeCount":102},[],{"trials":5924,"activeCount":102},[],{"intervention":5926,"totalTrials":147,"cells":5927},"Nitrates",{"EARLY_PHASE1":5928,"PHASE1":5930,"PHASE2":5932,"PHASE3":5942,"PHASE4":5944,"NA":5946},{"trials":5929,"activeCount":102},[],{"trials":5931,"activeCount":102},[],{"trials":5933,"activeCount":102},[5934],{"nctId":5935,"briefTitle":5936,"status":114,"phases":5937,"primaryCompletion":5364,"completion":5364,"start":5938,"enrollment":3642,"conditions":5939,"interventions":5940},"NCT03259165","Nitroglycerin vs. Furosemide Using Lung Ultrasound Pilot Trial",[92],"2017-12-14",[5895,5896,5898,5897],[5926,5941],"Loop Diuretics",{"trials":5943,"activeCount":102},[],{"trials":5945,"activeCount":102},[],{"trials":5947,"activeCount":102},[],{"intervention":5941,"totalTrials":147,"cells":5949},{"EARLY_PHASE1":5950,"PHASE1":5952,"PHASE2":5954,"PHASE3":5960,"PHASE4":5962,"NA":5964},{"trials":5951,"activeCount":102},[],{"trials":5953,"activeCount":102},[],{"trials":5955,"activeCount":102},[5956],{"nctId":5935,"briefTitle":5936,"status":114,"phases":5957,"primaryCompletion":5364,"completion":5364,"start":5938,"enrollment":3642,"conditions":5958,"interventions":5959},[92],[5895,5896,5898,5897],[5926,5941],{"trials":5961,"activeCount":102},[],{"trials":5963,"activeCount":102},[],{"trials":5965,"activeCount":102},[],{"intervention":5967,"totalTrials":147,"cells":5968},"palifosfamide",{"EARLY_PHASE1":5969,"PHASE1":5971,"PHASE2":5973,"PHASE3":5992,"PHASE4":5994,"NA":5996},{"trials":5970,"activeCount":102},[],{"trials":5972,"activeCount":102},[],{"trials":5974,"activeCount":102},[5975],{"nctId":5976,"briefTitle":5977,"status":114,"phases":5978,"primaryCompletion":864,"completion":864,"start":5979,"enrollment":1021,"conditions":5980,"interventions":5991},"NCT01808534","Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors",[92],"2013-02",[5981,5982,5983,5984,5985,5986,5987,5988,5989,5990],"Adult Central Nervous System Germ Cell Tumor","Adult Teratoma","Malignant Extragonadal Germ Cell Tumor","Malignant Extragonadal Non-Seminomatous Germ Cell Tumor","Extragonadal Seminoma","Recurrent Malignant Testicular Germ Cell Tumor","Recurrent Ovarian Germ Cell Tumor","Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor","Stage IV Extragonadal Seminoma","Stage IV Ovarian Germ Cell Tumor",[5967],{"trials":5993,"activeCount":102},[],{"trials":5995,"activeCount":102},[],{"trials":5997,"activeCount":102},[],{"intervention":1698,"totalTrials":147,"cells":5999},{"EARLY_PHASE1":6000,"PHASE1":6002,"PHASE2":6004,"PHASE3":6010,"PHASE4":6012,"NA":6014},{"trials":6001,"activeCount":102},[],{"trials":6003,"activeCount":102},[],{"trials":6005,"activeCount":102},[6006],{"nctId":1690,"briefTitle":1691,"status":137,"phases":6007,"primaryCompletion":1693,"completion":1693,"start":1694,"enrollment":579,"conditions":6008,"interventions":6009},[92],[1696],[1698,1681],{"trials":6011,"activeCount":102},[],{"trials":6013,"activeCount":102},[],{"trials":6015,"activeCount":102},[],{"intervention":6017,"totalTrials":147,"cells":6018},"Bevacizumab and Oxaliplatin",{"EARLY_PHASE1":6019,"PHASE1":6021,"PHASE2":6023,"PHASE3":6032,"PHASE4":6034,"NA":6036},{"trials":6020,"activeCount":102},[],{"trials":6022,"activeCount":102},[],{"trials":6024,"activeCount":102},[6025],{"nctId":6026,"briefTitle":6027,"status":137,"phases":6028,"primaryCompletion":1485,"completion":864,"start":4241,"enrollment":4673,"conditions":6029,"interventions":6031},"NCT00393861","Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients",[92],[6030],"Neoplasms, Germ Cell and Embryonal",[6017],{"trials":6033,"activeCount":102},[],{"trials":6035,"activeCount":102},[],{"trials":6037,"activeCount":102},[],{"intervention":6039,"totalTrials":152,"cells":6040},"Sorafenib",{"EARLY_PHASE1":6041,"PHASE1":6043,"PHASE2":6061,"PHASE3":6063,"PHASE4":6065,"NA":6067},{"trials":6042,"activeCount":102},[],{"trials":6044,"activeCount":102},[6045,6053],{"nctId":6046,"briefTitle":6047,"status":114,"phases":6048,"primaryCompletion":1436,"completion":2360,"start":2097,"enrollment":1021,"conditions":6049,"interventions":6051},"NCT01348503","Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma",[91],[6050],"Hepatocellular Carcinoma",[6052,6039],"Lenalidomide",{"nctId":6054,"briefTitle":6055,"status":861,"phases":6056,"primaryCompletion":6057,"completion":3040,"start":6058,"enrollment":102,"conditions":6059,"interventions":6060},"NCT01801163","A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)",[91],"2014-08","2012-02",[6050],[6039],{"trials":6062,"activeCount":102},[],{"trials":6064,"activeCount":102},[],{"trials":6066,"activeCount":102},[],{"trials":6068,"activeCount":102},[],{"intervention":6070,"totalTrials":152,"cells":6071},"clofarabine",{"EARLY_PHASE1":6072,"PHASE1":6074,"PHASE2":6091,"PHASE3":6093,"PHASE4":6095,"NA":6097},{"trials":6073,"activeCount":102},[],{"trials":6075,"activeCount":102},[6076,6084],{"nctId":6077,"briefTitle":6078,"status":137,"phases":6079,"primaryCompletion":5783,"completion":5783,"start":6080,"enrollment":25,"conditions":6081,"interventions":6083},"NCT00477945","Phase I Trial of Clofarabine in Combo w\u002F HD Etoposide & Cyclophosphamide and APBSCT for Pts w\u002F High-Risk or Refractory NHL",[91],"2007-05",[6082],"Non Hodgkin's Lymphoma",[6070],{"nctId":6085,"briefTitle":6086,"status":137,"phases":6087,"primaryCompletion":5783,"completion":5783,"start":6080,"enrollment":25,"conditions":6088,"interventions":6090},"NCT00477542","A Phase I Trial of Myeloablative Conditioning w\u002F Clofarabine and HD Busulfan for Pts w\u002F Refractory Heme Malignancies Undergoing Allo PBSCT",[91],[6089],"Hematologic Malignancies",[6070],{"trials":6092,"activeCount":102},[],{"trials":6094,"activeCount":102},[],{"trials":6096,"activeCount":102},[],{"trials":6098,"activeCount":102},[],{"intervention":6052,"totalTrials":147,"cells":6100},{"EARLY_PHASE1":6101,"PHASE1":6103,"PHASE2":6109,"PHASE3":6111,"PHASE4":6113,"NA":6115},{"trials":6102,"activeCount":102},[],{"trials":6104,"activeCount":102},[6105],{"nctId":6046,"briefTitle":6047,"status":114,"phases":6106,"primaryCompletion":1436,"completion":2360,"start":2097,"enrollment":1021,"conditions":6107,"interventions":6108},[91],[6050],[6052,6039],{"trials":6110,"activeCount":102},[],{"trials":6112,"activeCount":102},[],{"trials":6114,"activeCount":102},[],{"trials":6116,"activeCount":102},[],{"intervention":6118,"totalTrials":147,"cells":6119},"Gemcitabine, Sorafenib",{"EARLY_PHASE1":6120,"PHASE1":6122,"PHASE2":6132,"PHASE3":6134,"PHASE4":6136,"NA":6138},{"trials":6121,"activeCount":102},[],{"trials":6123,"activeCount":102},[6124],{"nctId":6125,"briefTitle":6126,"status":137,"phases":6127,"primaryCompletion":5783,"completion":864,"start":6128,"enrollment":1364,"conditions":6129,"interventions":6131},"NCT00375310","Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer",[91],"2006-09",[2447,6130],"Adenocarcinoma of the Pancreas",[6118],{"trials":6133,"activeCount":102},[],{"trials":6135,"activeCount":102},[],{"trials":6137,"activeCount":102},[],{"trials":6139,"activeCount":102},[],{"intervention":6141,"totalTrials":147,"cells":6142},"gene therapy",{"EARLY_PHASE1":6143,"PHASE1":6145,"PHASE2":6161,"PHASE3":6163,"PHASE4":6165,"NA":6167},{"trials":6144,"activeCount":102},[],{"trials":6146,"activeCount":102},[6147],{"nctId":6148,"briefTitle":6149,"status":137,"phases":6150,"primaryCompletion":6151,"completion":2468,"start":6152,"enrollment":1327,"conditions":6153,"interventions":6157},"NCT00005796","Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors",[91],"2003-06","2000-02",[6154,6155,6156],"Bone Marrow Suppression","Brain and Central Nervous System Tumors","Drug\u002FAgent Toxicity by Tissue\u002FOrgan",[6141,6158,6159,6160],"lomustine","procarbazine hydrochloride","vincristine sulfate",{"trials":6162,"activeCount":102},[],{"trials":6164,"activeCount":102},[],{"trials":6166,"activeCount":102},[],{"trials":6168,"activeCount":102},[],{"intervention":6158,"totalTrials":147,"cells":6170},{"EARLY_PHASE1":6171,"PHASE1":6173,"PHASE2":6179,"PHASE3":6181,"PHASE4":6183,"NA":6185},{"trials":6172,"activeCount":102},[],{"trials":6174,"activeCount":102},[6175],{"nctId":6148,"briefTitle":6149,"status":137,"phases":6176,"primaryCompletion":6151,"completion":2468,"start":6152,"enrollment":1327,"conditions":6177,"interventions":6178},[91],[6154,6155,6156],[6141,6158,6159,6160],{"trials":6180,"activeCount":102},[],{"trials":6182,"activeCount":102},[],{"trials":6184,"activeCount":102},[],{"trials":6186,"activeCount":102},[],{"intervention":6159,"totalTrials":147,"cells":6188},{"EARLY_PHASE1":6189,"PHASE1":6191,"PHASE2":6197,"PHASE3":6199,"PHASE4":6201,"NA":6203},{"trials":6190,"activeCount":102},[],{"trials":6192,"activeCount":102},[6193],{"nctId":6148,"briefTitle":6149,"status":137,"phases":6194,"primaryCompletion":6151,"completion":2468,"start":6152,"enrollment":1327,"conditions":6195,"interventions":6196},[91],[6154,6155,6156],[6141,6158,6159,6160],{"trials":6198,"activeCount":102},[],{"trials":6200,"activeCount":102},[],{"trials":6202,"activeCount":102},[],{"trials":6204,"activeCount":102},[],{"intervention":6160,"totalTrials":147,"cells":6206},{"EARLY_PHASE1":6207,"PHASE1":6209,"PHASE2":6215,"PHASE3":6217,"PHASE4":6219,"NA":6221},{"trials":6208,"activeCount":102},[],{"trials":6210,"activeCount":102},[6211],{"nctId":6148,"briefTitle":6149,"status":137,"phases":6212,"primaryCompletion":6151,"completion":2468,"start":6152,"enrollment":1327,"conditions":6213,"interventions":6214},[91],[6154,6155,6156],[6141,6158,6159,6160],{"trials":6216,"activeCount":102},[],{"trials":6218,"activeCount":102},[],{"trials":6220,"activeCount":102},[],{"trials":6222,"activeCount":102},[],{"intervention":6224,"totalTrials":147,"cells":6225},"Omeprazole 20mg",{"EARLY_PHASE1":6226,"PHASE1":6228,"PHASE2":6238,"PHASE3":6240,"PHASE4":6242,"NA":6244},{"trials":6227,"activeCount":102},[],{"trials":6229,"activeCount":102},[6230],{"nctId":6231,"briefTitle":6232,"status":137,"phases":6233,"primaryCompletion":6234,"completion":6234,"start":2856,"enrollment":4435,"conditions":6235,"interventions":6237},"NCT04199624","Assessment of Gastric pH Changes Induced by Ascorbic Acid Tablets",[91],"2023-06-07",[6236],"Hypochlorhydria",[6224],{"trials":6239,"activeCount":102},[],{"trials":6241,"activeCount":102},[],{"trials":6243,"activeCount":102},[],{"trials":6245,"activeCount":102},[],{"intervention":6247,"totalTrials":147,"cells":6248},"Sorafenib-Vorinostat",{"EARLY_PHASE1":6249,"PHASE1":6251,"PHASE2":6260,"PHASE3":6262,"PHASE4":6264,"NA":6266},{"trials":6250,"activeCount":102},[],{"trials":6252,"activeCount":102},[6253],{"nctId":6254,"briefTitle":6255,"status":137,"phases":6256,"primaryCompletion":4024,"completion":5162,"start":2901,"enrollment":319,"conditions":6257,"interventions":6259},"NCT00875745","Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)",[91],[4675,6258,4691],"Leukemia, Promyelocytic, Acute",[6247],{"trials":6261,"activeCount":102},[],{"trials":6263,"activeCount":102},[],{"trials":6265,"activeCount":102},[],{"trials":6267,"activeCount":102},[],{"intervention":6269,"totalTrials":147,"cells":6270},"Difluoromethylornithine",{"EARLY_PHASE1":6271,"PHASE1":6273,"PHASE2":6285,"PHASE3":6287,"PHASE4":6289,"NA":6291},{"trials":6272,"activeCount":102},[],{"trials":6274,"activeCount":102},[6275],{"nctId":6276,"briefTitle":6277,"status":137,"phases":6278,"primaryCompletion":6279,"completion":3016,"start":6280,"enrollment":6281,"conditions":6282,"interventions":6284},"NCT02384889","DFMO in Children With Type 1 Diabetes",[91],"2019-10-07","2015-04",41,[6283],"Type 1 Diabetes",[6269],{"trials":6286,"activeCount":102},[],{"trials":6288,"activeCount":102},[],{"trials":6290,"activeCount":102},[],{"trials":6292,"activeCount":102},[],{"intervention":6294,"totalTrials":147,"cells":6295},"GRN163L in combination with trastuzumab",{"EARLY_PHASE1":6296,"PHASE1":6298,"PHASE2":6307,"PHASE3":6309,"PHASE4":6311,"NA":6313},{"trials":6297,"activeCount":102},[],{"trials":6299,"activeCount":102},[6300],{"nctId":6301,"briefTitle":6302,"status":137,"phases":6303,"primaryCompletion":1604,"completion":4970,"start":4538,"enrollment":1327,"conditions":6304,"interventions":6306},"NCT01265927","A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer",[91],[6305],"Breast Neoplasms",[6294],{"trials":6308,"activeCount":102},[],{"trials":6310,"activeCount":102},[],{"trials":6312,"activeCount":102},[],{"trials":6314,"activeCount":102},[],{"intervention":6316,"totalTrials":147,"cells":6317},"Tarceva",{"EARLY_PHASE1":6318,"PHASE1":6320,"PHASE2":6328,"PHASE3":6330,"PHASE4":6332,"NA":6334},{"trials":6319,"activeCount":102},[],{"trials":6321,"activeCount":102},[6322],{"nctId":6323,"briefTitle":6324,"status":137,"phases":6325,"primaryCompletion":3504,"completion":4389,"start":1693,"enrollment":119,"conditions":6326,"interventions":6327},"NCT00243854","Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer",[91],[2447],[6316],{"trials":6329,"activeCount":102},[],{"trials":6331,"activeCount":102},[],{"trials":6333,"activeCount":102},[],{"trials":6335,"activeCount":102},[],{"intervention":6337,"totalTrials":147,"cells":6338},"fondaparinux",{"EARLY_PHASE1":6339,"PHASE1":6341,"PHASE2":6351,"PHASE3":6353,"PHASE4":6355,"NA":6357},{"trials":6340,"activeCount":102},[],{"trials":6342,"activeCount":102},[6343],{"nctId":6344,"briefTitle":6345,"status":861,"phases":6346,"primaryCompletion":6347,"completion":4390,"start":4200,"enrollment":102,"conditions":6348,"interventions":6350},"NCT00346879","Study to Determine Effective Dosing of Fondaparinux in Obese Persons",[91],"2008-12",[6349],"Morbid Obesity",[6337],{"trials":6352,"activeCount":102},[],{"trials":6354,"activeCount":102},[],{"trials":6356,"activeCount":102},[],{"trials":6358,"activeCount":102},[],{"intervention":6360,"totalTrials":147,"cells":6361},"Paclitaxel plus PTK787",{"EARLY_PHASE1":6362,"PHASE1":6364,"PHASE2":6375,"PHASE3":6377,"PHASE4":6379,"NA":6381},{"trials":6363,"activeCount":102},[],{"trials":6365,"activeCount":102},[6366],{"nctId":6367,"briefTitle":6368,"status":137,"phases":6369,"primaryCompletion":4242,"completion":3504,"start":6370,"enrollment":22,"conditions":6371,"interventions":6374},"NCT00731861","Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors",[91],"2005-05",[6372,6373],"Neoplasm Metastasis","Carcinoma",[6360],{"trials":6376,"activeCount":102},[],{"trials":6378,"activeCount":102},[],{"trials":6380,"activeCount":102},[],{"trials":6382,"activeCount":102},[],{"intervention":6384,"totalTrials":147,"cells":6385},"Chronic salsalate",{"EARLY_PHASE1":6386,"PHASE1":6388,"PHASE2":6400,"PHASE3":6402,"PHASE4":6404,"NA":6406},{"trials":6387,"activeCount":102},[],{"trials":6389,"activeCount":102},[6390],{"nctId":6391,"briefTitle":6392,"status":114,"phases":6393,"primaryCompletion":6394,"completion":3504,"start":1708,"enrollment":31,"conditions":6395,"interventions":6398},"NCT00837590","Vascular Function, Endothelin, and Inflammation in Pre-diabetic Obesity Versus Lean Healthy Controls",[91],"2010-06",[6396,6397],"Pre-diabetes","Obesity",[6384,6399],"Acute Salsalate",{"trials":6401,"activeCount":102},[],{"trials":6403,"activeCount":102},[],{"trials":6405,"activeCount":102},[],{"trials":6407,"activeCount":102},[],{"intervention":6399,"totalTrials":147,"cells":6409},{"EARLY_PHASE1":6410,"PHASE1":6412,"PHASE2":6418,"PHASE3":6420,"PHASE4":6422,"NA":6424},{"trials":6411,"activeCount":102},[],{"trials":6413,"activeCount":102},[6414],{"nctId":6391,"briefTitle":6392,"status":114,"phases":6415,"primaryCompletion":6394,"completion":3504,"start":1708,"enrollment":31,"conditions":6416,"interventions":6417},[91],[6396,6397],[6384,6399],{"trials":6419,"activeCount":102},[],{"trials":6421,"activeCount":102},[],{"trials":6423,"activeCount":102},[],{"trials":6425,"activeCount":102},[],{"intervention":6427,"totalTrials":147,"cells":6428},"Allogeneic bone marrow derived mesenchymal stem cells",{"EARLY_PHASE1":6429,"PHASE1":6431,"PHASE2":6450,"PHASE3":6452,"PHASE4":6454,"NA":6456},{"trials":6430,"activeCount":102},[],{"trials":6432,"activeCount":102},[6433],{"nctId":6434,"briefTitle":6435,"status":137,"phases":6436,"primaryCompletion":6437,"completion":6437,"start":6438,"enrollment":1314,"conditions":6439,"interventions":6449},"NCT02685098","A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation",[91],"2023-10-03","2017-01-23",[6440,6441,6442,6443,6444,6445,4393,3176,6446,6447,6448],"Ischemia","Peripheral Arterial Disease","Peripheral Vascular Disease","Vascular Disease","Arterial Occlusive Disease","Arteriosclerosis","Pathologic Processes","Orthopedic Procedures","Amputation",[6427],{"trials":6451,"activeCount":102},[],{"trials":6453,"activeCount":102},[],{"trials":6455,"activeCount":102},[],{"trials":6457,"activeCount":102},[],{"intervention":6459,"totalTrials":147,"cells":6460},"recombinant interleukin-12",{"EARLY_PHASE1":6461,"PHASE1":6463,"PHASE2":6480,"PHASE3":6482,"PHASE4":6484,"NA":6486},{"trials":6462,"activeCount":102},[],{"trials":6464,"activeCount":102},[6465],{"nctId":6466,"briefTitle":6467,"status":137,"phases":6468,"start":6469,"conditions":6470,"interventions":6479},"NCT00003107","Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors",[91],"1997-10",[24,6471,6472,6473,6474,6475,6476,4691,6477,5522,6478],"Chronic Myeloproliferative Disorders","Gestational Trophoblastic Tumor","Kidney Cancer","Leukemia","Lymphoma","Multiple Myeloma and Plasma Cell Neoplasm","Neuroblastoma","Testicular Germ Cell Tumor",[6459],{"trials":6481,"activeCount":102},[],{"trials":6483,"activeCount":102},[],{"trials":6485,"activeCount":102},[],{"trials":6487,"activeCount":102},[],{"intervention":6489,"totalTrials":147,"cells":6490},"Etravirine",{"EARLY_PHASE1":6491,"PHASE1":6493,"PHASE2":6504,"PHASE3":6506,"PHASE4":6508,"NA":6510},{"trials":6492,"activeCount":102},[],{"trials":6494,"activeCount":102},[6495],{"nctId":6496,"briefTitle":6497,"status":137,"phases":6498,"primaryCompletion":1300,"completion":3258,"start":2901,"enrollment":22,"conditions":6499,"interventions":6503},"NCT00871234","Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study",[91],[6500,6501,4618,6502,4401],"Endothelial Function","Lipids","Inflammation",[6489],{"trials":6505,"activeCount":102},[],{"trials":6507,"activeCount":102},[],{"trials":6509,"activeCount":102},[],{"trials":6511,"activeCount":102},[],{"intervention":6513,"totalTrials":147,"cells":6514},"Tacrolimus single dose",{"EARLY_PHASE1":6515,"PHASE1":6517,"PHASE2":6533,"PHASE3":6535,"PHASE4":6537,"NA":6539},{"trials":6516,"activeCount":102},[],{"trials":6518,"activeCount":102},[6519],{"nctId":6520,"briefTitle":6521,"status":137,"phases":6522,"primaryCompletion":6523,"completion":6523,"start":6524,"enrollment":6525,"conditions":6526,"interventions":6530},"NCT05490511","Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus",[91],"2025-08-31","2022-10-31",57,[6527,6528,6529],"CBD","Transplant Complication","Kidney Disease, Chronic",[6513,6531,6532],"Epidiolex single dose","Epidiolex steady-state and tacrolimus single dose",{"trials":6534,"activeCount":102},[],{"trials":6536,"activeCount":102},[],{"trials":6538,"activeCount":102},[],{"trials":6540,"activeCount":102},[],{"intervention":6531,"totalTrials":147,"cells":6542},{"EARLY_PHASE1":6543,"PHASE1":6545,"PHASE2":6551,"PHASE3":6553,"PHASE4":6555,"NA":6557},{"trials":6544,"activeCount":102},[],{"trials":6546,"activeCount":102},[6547],{"nctId":6520,"briefTitle":6521,"status":137,"phases":6548,"primaryCompletion":6523,"completion":6523,"start":6524,"enrollment":6525,"conditions":6549,"interventions":6550},[91],[6527,6528,6529],[6513,6531,6532],{"trials":6552,"activeCount":102},[],{"trials":6554,"activeCount":102},[],{"trials":6556,"activeCount":102},[],{"trials":6558,"activeCount":102},[],{"intervention":6532,"totalTrials":147,"cells":6560},{"EARLY_PHASE1":6561,"PHASE1":6563,"PHASE2":6569,"PHASE3":6571,"PHASE4":6573,"NA":6575},{"trials":6562,"activeCount":102},[],{"trials":6564,"activeCount":102},[6565],{"nctId":6520,"briefTitle":6521,"status":137,"phases":6566,"primaryCompletion":6523,"completion":6523,"start":6524,"enrollment":6525,"conditions":6567,"interventions":6568},[91],[6527,6528,6529],[6513,6531,6532],{"trials":6570,"activeCount":102},[],{"trials":6572,"activeCount":102},[],{"trials":6574,"activeCount":102},[],{"trials":6576,"activeCount":102},[],{"intervention":6578,"totalTrials":147,"cells":6579},"Bortezomib administration",{"EARLY_PHASE1":6580,"PHASE1":6582,"PHASE2":6594,"PHASE3":6596,"PHASE4":6598,"NA":6600},{"trials":6581,"activeCount":102},[],{"trials":6583,"activeCount":102},[6584],{"nctId":6585,"briefTitle":6586,"status":137,"phases":6587,"primaryCompletion":6588,"completion":6589,"start":6590,"enrollment":319,"conditions":6591,"interventions":6593},"NCT01926899","A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients",[91],"2018-02-01","2018-03-15","2013-08-01",[6592],"Hematopoetic Stem Cell Transplant",[6578],{"trials":6595,"activeCount":102},[],{"trials":6597,"activeCount":102},[],{"trials":6599,"activeCount":102},[],{"trials":6601,"activeCount":102},[],{"intervention":6603,"totalTrials":147,"cells":6604},"Salsalate",{"EARLY_PHASE1":6605,"PHASE1":6607,"PHASE2":6617,"PHASE3":6619,"PHASE4":6621,"NA":6623},{"trials":6606,"activeCount":102},[],{"trials":6608,"activeCount":102},[6609],{"nctId":6610,"briefTitle":6611,"status":114,"phases":6612,"primaryCompletion":6613,"completion":6613,"start":6058,"enrollment":14,"conditions":6614,"interventions":6616},"NCT01489319","Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS)",[91],"2015-06",[6615],"Polycystic Ovary Syndrome",[6603,6603],{"trials":6618,"activeCount":102},[],{"trials":6620,"activeCount":102},[],{"trials":6622,"activeCount":102},[],{"trials":6624,"activeCount":102},[],{"intervention":6626,"totalTrials":147,"cells":6627},"Stable isotope infusions",{"EARLY_PHASE1":6628,"PHASE1":6630,"PHASE2":6641,"PHASE3":6643,"PHASE4":6645,"NA":6647},{"trials":6629,"activeCount":102},[],{"trials":6631,"activeCount":102},[6632],{"nctId":6633,"briefTitle":6634,"status":137,"phases":6635,"primaryCompletion":6347,"completion":6347,"start":4782,"enrollment":319,"conditions":6636,"interventions":6640},"NCT00583232","Protein and Energy Metabolism in Pediatric Crohn's Disease",[91],[6637,6638,6639],"Crohn's Disease","Protein Metabolism","Energy Metabolism",[6626],{"trials":6642,"activeCount":102},[],{"trials":6644,"activeCount":102},[],{"trials":6646,"activeCount":102},[],{"trials":6648,"activeCount":102},[],{"intervention":6650,"totalTrials":147,"cells":6651},"Chondroitin sulfate",{"EARLY_PHASE1":6652,"PHASE1":6654,"PHASE2":6667,"PHASE3":6669,"PHASE4":6671,"NA":6673},{"trials":6653,"activeCount":102},[],{"trials":6655,"activeCount":102},[6656],{"nctId":6657,"briefTitle":6658,"status":861,"phases":6659,"primaryCompletion":6660,"completion":6661,"start":6662,"enrollment":102,"conditions":6663,"interventions":6666},"NCT06547424","Phase I Clinical Study of Chondroitin Sulfate for Treatment of NEC",[91],"2028-12","2029-03","2025-01",[6664,6665],"Necrotizing Enterocolitis","Intestinal Ischemia",[6650],{"trials":6668,"activeCount":102},[],{"trials":6670,"activeCount":102},[],{"trials":6672,"activeCount":102},[],{"trials":6674,"activeCount":102},[],{"intervention":6676,"totalTrials":147,"cells":6677},"cilengitide",{"EARLY_PHASE1":6678,"PHASE1":6680,"PHASE2":6694,"PHASE3":6696,"PHASE4":6698,"NA":6700},{"trials":6679,"activeCount":102},[],{"trials":6681,"activeCount":102},[6682],{"nctId":6683,"briefTitle":6684,"status":137,"phases":6685,"primaryCompletion":6686,"completion":6687,"start":6688,"enrollment":1838,"conditions":6689,"interventions":6693},"NCT00004258","EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer",[91],"2001-08","2001-09","1999-12",[6471,6474,6475,6476,4691,6690,6691,6692],"Precancerous\u002FNonmalignant Condition","Small Intestine Cancer","Unspecified Adult Solid Tumor, Protocol Specific",[6676],{"trials":6695,"activeCount":102},[],{"trials":6697,"activeCount":102},[],{"trials":6699,"activeCount":102},[],{"trials":6701,"activeCount":102},[],{"intervention":6703,"totalTrials":147,"cells":6704},"Acetylated and Butyrylated High Amylose Maize Starch",{"EARLY_PHASE1":6705,"PHASE1":6707,"PHASE2":6717,"PHASE3":6719,"PHASE4":6721,"NA":6723},{"trials":6706,"activeCount":102},[],{"trials":6708,"activeCount":102},[6709],{"nctId":6710,"briefTitle":6711,"status":137,"phases":6712,"primaryCompletion":6713,"completion":6713,"start":6714,"enrollment":1302,"conditions":6715,"interventions":6716},"NCT04114357","Effect of Prebiotics on the Gut Microbiome Profile and Beta Cell Function",[91],"2023-06-09","2020-06-22",[6283],[6703],{"trials":6718,"activeCount":102},[],{"trials":6720,"activeCount":102},[],{"trials":6722,"activeCount":102},[],{"trials":6724,"activeCount":102},[],{"intervention":6726,"totalTrials":147,"cells":6727},"Probenecid Oral",{"EARLY_PHASE1":6728,"PHASE1":6739,"PHASE2":6741,"PHASE3":6743,"PHASE4":6745,"NA":6747},{"trials":6729,"activeCount":102},[6730],{"nctId":6731,"briefTitle":6732,"status":137,"phases":6733,"primaryCompletion":6734,"completion":6734,"start":116,"enrollment":319,"conditions":6735,"interventions":6737},"NCT03202511","Assessment of a New \"Boosting\" Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers",[90],"2018-07-02",[6736],"Pre-Exposure Prophylaxis",[6726,6738],"Tenofovir disoproxil fumarate\u002FEmtricitabine",{"trials":6740,"activeCount":102},[],{"trials":6742,"activeCount":102},[],{"trials":6744,"activeCount":102},[],{"trials":6746,"activeCount":102},[],{"trials":6748,"activeCount":102},[],{"intervention":6738,"totalTrials":147,"cells":6750},{"EARLY_PHASE1":6751,"PHASE1":6757,"PHASE2":6759,"PHASE3":6761,"PHASE4":6763,"NA":6765},{"trials":6752,"activeCount":102},[6753],{"nctId":6731,"briefTitle":6732,"status":137,"phases":6754,"primaryCompletion":6734,"completion":6734,"start":116,"enrollment":319,"conditions":6755,"interventions":6756},[90],[6736],[6726,6738],{"trials":6758,"activeCount":102},[],{"trials":6760,"activeCount":102},[],{"trials":6762,"activeCount":102},[],{"trials":6764,"activeCount":102},[],{"trials":6766,"activeCount":102},[],{"intervention":6768,"totalTrials":147,"cells":6769},"Tasigna",{"EARLY_PHASE1":6770,"PHASE1":6779,"PHASE2":6781,"PHASE3":6783,"PHASE4":6785,"NA":6787},{"trials":6771,"activeCount":102},[6772],{"nctId":6773,"briefTitle":6774,"status":137,"phases":6775,"primaryCompletion":1591,"completion":3041,"start":4538,"enrollment":776,"conditions":6776,"interventions":6778},"NCT01275586","Study of Tasigna®\u002FNilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas",[90],[4454,4972,6777],"Neurofibromas",[6768],{"trials":6780,"activeCount":102},[],{"trials":6782,"activeCount":102},[],{"trials":6784,"activeCount":102},[],{"trials":6786,"activeCount":102},[],{"trials":6788,"activeCount":102},[],{"intervention":6790,"totalTrials":147,"cells":6791},"boceprevir",{"EARLY_PHASE1":6792,"PHASE1":6802,"PHASE2":6804,"PHASE3":6806,"PHASE4":6808,"NA":6810},{"trials":6793,"activeCount":102},[6794],{"nctId":6795,"briefTitle":6796,"status":137,"phases":6797,"primaryCompletion":6798,"completion":6798,"start":5698,"enrollment":147,"conditions":6799,"interventions":6801},"NCT01909401","Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation",[90],"2014-07",[6800],"Liver Transplantation",[6790],{"trials":6803,"activeCount":102},[],{"trials":6805,"activeCount":102},[],{"trials":6807,"activeCount":102},[],{"trials":6809,"activeCount":102},[],{"trials":6811,"activeCount":102},[],{"intervention":1675,"totalTrials":1276,"cells":6813},{"EARLY_PHASE1":6814,"PHASE1":6816,"PHASE2":6818,"PHASE3":6820,"PHASE4":6822,"NA":6832},{"trials":6815,"activeCount":102},[],{"trials":6817,"activeCount":102},[],{"trials":6819,"activeCount":102},[],{"trials":6821,"activeCount":102},[],{"trials":6823,"activeCount":102},[6824,6828],{"nctId":1667,"briefTitle":1668,"status":137,"phases":6825,"primaryCompletion":1374,"completion":1670,"start":1671,"enrollment":1672,"conditions":6826,"interventions":6827},[94],[754],[1675,1645,1676,1677],{"nctId":3172,"briefTitle":3173,"status":137,"phases":6829,"primaryCompletion":2493,"completion":864,"start":2834,"enrollment":1838,"conditions":6830,"interventions":6831},[94],[3176],[1675,3159],{"trials":6833,"activeCount":102},[6834,6840],{"nctId":6835,"briefTitle":6836,"status":137,"phases":6837,"primaryCompletion":1728,"completion":1728,"start":6080,"enrollment":1384,"conditions":6838,"interventions":6839},"NCT00668395","Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics",[95],[2386],[1675],{"nctId":6841,"briefTitle":6842,"status":137,"phases":6843,"primaryCompletion":2384,"completion":1347,"start":1300,"enrollment":6844,"conditions":6845,"interventions":6847},"NCT01104376","Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers",[95],61,[6846],"Efavirenz, Metabolism and Pharmacokinetics Changes",[1675,6848],"voriconazole",{"intervention":6850,"totalTrials":98,"cells":6851},"Gabapentin",{"EARLY_PHASE1":6852,"PHASE1":6854,"PHASE2":6865,"PHASE3":6867,"PHASE4":6879,"NA":6881},{"trials":6853,"activeCount":102},[],{"trials":6855,"activeCount":102},[6856],{"nctId":6857,"briefTitle":6858,"status":137,"phases":6859,"primaryCompletion":6860,"completion":6860,"start":4970,"enrollment":39,"conditions":6861,"interventions":6863},"NCT02490345","Gabapentin as Adjunctive Treatment for Postoperative Pain Control",[91],"2017-06-29",[6862],"Drug Usage",[6864],"gabapentin",{"trials":6866,"activeCount":102},[],{"trials":6868,"activeCount":102},[6869],{"nctId":6870,"briefTitle":6871,"status":114,"phases":6872,"primaryCompletion":6873,"completion":6874,"start":6875,"enrollment":599,"conditions":6876,"interventions":6878},"NCT05172570","Gabapentin Dosages for Postoperative Analgesia Following Open Thoracotomy",[93],"2022-02-25","2022-03-02","2021-04-06",[6877,144],"Thoracotomy",[6850],{"trials":6880,"activeCount":102},[],{"trials":6882,"activeCount":102},[6883],{"nctId":6884,"briefTitle":6885,"status":137,"phases":6886,"primaryCompletion":2468,"completion":2468,"start":1728,"enrollment":6887,"conditions":6888,"interventions":6890},"NCT01143766","Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP)",[95],56,[6889],"Conscious Sedation",[6850],{"intervention":6892,"totalTrials":152,"cells":6893},"Memantine",{"EARLY_PHASE1":6894,"PHASE1":6896,"PHASE2":6898,"PHASE3":6900,"PHASE4":6902,"NA":6911},{"trials":6895,"activeCount":102},[],{"trials":6897,"activeCount":102},[],{"trials":6899,"activeCount":102},[],{"trials":6901,"activeCount":102},[],{"trials":6903,"activeCount":102},[6904],{"nctId":6905,"briefTitle":6906,"status":137,"phases":6907,"primaryCompletion":6908,"completion":2468,"start":1326,"enrollment":4673,"conditions":6909,"interventions":6910},"NCT00305578","Memantine Augmentation of Lamotrigine Incomplete-Response in Bipolar Depression",[94],"2010-12",[1329],[6892],{"trials":6912,"activeCount":102},[6913],{"nctId":6914,"briefTitle":6915,"status":137,"phases":6916,"primaryCompletion":6917,"completion":6917,"start":6918,"enrollment":4435,"conditions":6919,"interventions":6920},"NCT02240589","Memantine for Neuroprotection and Cognitive Enhancement Following Traumatic Brain Injury",[95],"2016-04","2014-12",[2169],[6892],{"intervention":4695,"totalTrials":152,"cells":6922},{"EARLY_PHASE1":6923,"PHASE1":6925,"PHASE2":6927,"PHASE3":6933,"PHASE4":6935,"NA":6937},{"trials":6924,"activeCount":102},[],{"trials":6926,"activeCount":102},[],{"trials":6928,"activeCount":102},[6929],{"nctId":4682,"briefTitle":4683,"status":861,"phases":6930,"primaryCompletion":4685,"completion":4685,"start":4686,"enrollment":102,"conditions":6931,"interventions":6932},[91,92],[4688,4689,4690,4691,4692],[4661,4694,4695],{"trials":6934,"activeCount":102},[],{"trials":6936,"activeCount":102},[],{"trials":6938,"activeCount":102},[6939],{"nctId":6940,"briefTitle":6941,"status":114,"phases":6942,"primaryCompletion":6943,"start":4445,"enrollment":1327,"conditions":6944,"interventions":6954},"NCT00594308","In-Vivo Activated T-Cell Depletion to Prevent GVHD",[95],"2008-10",[6945,6946,6947,6948,4677,6949,6950,6951,6952,6953],"Acute Myelogenous Leukemia","Acute Lymphocytic Leukemia","Chronic Myelogenous Leukemia","Chronic Lymphocytic Leukemia","Lymphoma, Non-Hodgkin's","Mantle-Cell Lymphoma","Hodgkin's Disease","Multiple Myeloma","Myelofibrosis",[4695,6955,6956,6957,6958],"Fludarabine","Cyclosporine","Mycophenolate mofetil","Basiliximab",{"intervention":6958,"totalTrials":152,"cells":6960},{"EARLY_PHASE1":6961,"PHASE1":6963,"PHASE2":6965,"PHASE3":6977,"PHASE4":6979,"NA":6981},{"trials":6962,"activeCount":102},[],{"trials":6964,"activeCount":102},[],{"trials":6966,"activeCount":102},[6967],{"nctId":6968,"briefTitle":6969,"status":137,"phases":6970,"primaryCompletion":1485,"completion":6971,"start":4854,"enrollment":28,"conditions":6972,"interventions":6976},"NCT00975975","Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer",[92],"2013-11",[6945,6946,6947,6948,4677,6973,6951,6952,6953,6974,6975],"Non-Hodgkin's Lymphoma","Anemia, Aplastic","Hemoglobinuria, Paroxysmal",[6958],{"trials":6978,"activeCount":102},[],{"trials":6980,"activeCount":102},[],{"trials":6982,"activeCount":102},[6983],{"nctId":6940,"briefTitle":6941,"status":114,"phases":6984,"primaryCompletion":6943,"start":4445,"enrollment":1327,"conditions":6985,"interventions":6986},[95],[6945,6946,6947,6948,4677,6949,6950,6951,6952,6953],[4695,6955,6956,6957,6958],{"intervention":6988,"totalTrials":152,"cells":6989},"Paricalcitol",{"EARLY_PHASE1":6990,"PHASE1":6992,"PHASE2":6994,"PHASE3":6996,"PHASE4":6998,"NA":7007},{"trials":6991,"activeCount":102},[],{"trials":6993,"activeCount":102},[],{"trials":6995,"activeCount":102},[],{"trials":6997,"activeCount":102},[],{"trials":6999,"activeCount":102},[7000],{"nctId":7001,"briefTitle":7002,"status":137,"phases":7003,"primaryCompletion":4434,"completion":7004,"start":3504,"enrollment":31,"conditions":7005,"interventions":7006},"NCT01163162","The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate",[94],"2011-06",[1606],[6988],{"trials":7008,"activeCount":102},[7009],{"nctId":7010,"briefTitle":7011,"status":137,"phases":7012,"primaryCompletion":5476,"completion":5476,"start":1325,"enrollment":751,"conditions":7013,"interventions":7015},"NCT00428246","Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation",[95],[1606,7014,6502,38],"Endothelial Dysfunction",[7016],"paricalcitol",{"intervention":7018,"totalTrials":152,"cells":7019},"Spironolactone",{"EARLY_PHASE1":7020,"PHASE1":7022,"PHASE2":7024,"PHASE3":7035,"PHASE4":7037,"NA":7039},{"trials":7021,"activeCount":102},[],{"trials":7023,"activeCount":102},[],{"trials":7025,"activeCount":102},[7026],{"nctId":7027,"briefTitle":7028,"status":861,"phases":7029,"primaryCompletion":7030,"completion":7031,"start":4177,"enrollment":102,"conditions":7032,"interventions":7034},"NCT02299726","Early Aldosterone Blockade in Acute Heart Failure: An Exploratory Safety Study",[92],"2018-05","2018-11",[7033],"Acute Heart Failure",[7018],{"trials":7036,"activeCount":102},[],{"trials":7038,"activeCount":102},[],{"trials":7040,"activeCount":102},[7041],{"nctId":7042,"briefTitle":7043,"status":137,"phases":7044,"completion":7045,"start":7046,"enrollment":1327,"conditions":7047,"interventions":7050},"NCT00276289","Spironolactone to Decrease Potassium Wasting in Hypercalciurics on Thiazides Diuretics",[95],"2006-06","2006-01",[7048,7049],"Idiopathic Hypercalciuria","Hypokalemia Caused by Thiazide Diuretics",[7018],{"intervention":7052,"totalTrials":152,"cells":7053},"Apixaban",{"EARLY_PHASE1":7054,"PHASE1":7056,"PHASE2":7058,"PHASE3":7060,"PHASE4":7072,"NA":7074},{"trials":7055,"activeCount":102},[],{"trials":7057,"activeCount":102},[],{"trials":7059,"activeCount":102},[],{"trials":7061,"activeCount":102},[7062],{"nctId":7063,"briefTitle":7064,"status":137,"phases":7065,"primaryCompletion":7066,"completion":7066,"start":5453,"enrollment":1348,"conditions":7067,"interventions":7070},"NCT02829957","RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding",[92,93],"2020-02-13",[7068,7069],"Venous Thromboembolism","Menstruation",[7052,7071],"Rivaroxaban",{"trials":7073,"activeCount":102},[],{"trials":7075,"activeCount":102},[7076],{"nctId":7077,"briefTitle":7078,"status":137,"phases":7079,"primaryCompletion":7080,"completion":7080,"start":7081,"enrollment":7082,"conditions":7083,"interventions":7084},"NCT03404635","Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism",[],"2020-05-08","2017-08-04",1300,[7068],[7052,7071],{"intervention":7071,"totalTrials":152,"cells":7086},{"EARLY_PHASE1":7087,"PHASE1":7089,"PHASE2":7091,"PHASE3":7093,"PHASE4":7099,"NA":7101},{"trials":7088,"activeCount":102},[],{"trials":7090,"activeCount":102},[],{"trials":7092,"activeCount":102},[],{"trials":7094,"activeCount":102},[7095],{"nctId":7063,"briefTitle":7064,"status":137,"phases":7096,"primaryCompletion":7066,"completion":7066,"start":5453,"enrollment":1348,"conditions":7097,"interventions":7098},[92,93],[7068,7069],[7052,7071],{"trials":7100,"activeCount":102},[],{"trials":7102,"activeCount":102},[7103],{"nctId":7077,"briefTitle":7078,"status":137,"phases":7104,"primaryCompletion":7080,"completion":7080,"start":7081,"enrollment":7082,"conditions":7105,"interventions":7106},[],[7068],[7052,7071],{"intervention":4030,"totalTrials":152,"cells":7108},{"EARLY_PHASE1":7109,"PHASE1":7111,"PHASE2":7113,"PHASE3":7115,"PHASE4":7121,"NA":7123},{"trials":7110,"activeCount":102},[],{"trials":7112,"activeCount":102},[],{"trials":7114,"activeCount":102},[],{"trials":7116,"activeCount":102},[7117],{"nctId":4021,"briefTitle":4022,"status":137,"phases":7118,"primaryCompletion":1436,"completion":1436,"start":4024,"enrollment":4025,"conditions":7119,"interventions":7120},[92,93],[2662,754],[4010,4028,4029,4030],{"trials":7122,"activeCount":102},[],{"trials":7124,"activeCount":102},[7125],{"nctId":7126,"briefTitle":7127,"status":137,"phases":7128,"primaryCompletion":2445,"completion":2445,"start":7129,"enrollment":25,"conditions":7130,"interventions":7131},"NCT02563834","A Novel Positron Emission Tomography (PET) Approach to Measuring Myocardial Metabolism",[95],"2007-01",[2662],[7132,4030,7133],"thiapalmitate tracer","Insulin",{"intervention":7135,"totalTrials":152,"cells":7136},"Donepezil",{"EARLY_PHASE1":7137,"PHASE1":7139,"PHASE2":7141,"PHASE3":7143,"PHASE4":7145,"NA":7155},{"trials":7138,"activeCount":102},[],{"trials":7140,"activeCount":102},[],{"trials":7142,"activeCount":102},[],{"trials":7144,"activeCount":102},[],{"trials":7146,"activeCount":102},[7147],{"nctId":7148,"briefTitle":7149,"status":137,"phases":7150,"primaryCompletion":1301,"completion":1301,"start":3126,"enrollment":579,"conditions":7151,"interventions":7154},"NCT00182884","Donepezil in Preventing Delirium in Hospitalized Elderly",[94],[7152,7153],"Postoperative Complications","Delirium",[7135],{"trials":7156,"activeCount":102},[7157],{"nctId":7158,"briefTitle":7159,"status":114,"phases":7160,"primaryCompletion":4970,"completion":4970,"start":2384,"enrollment":699,"conditions":7161,"interventions":7163},"NCT01362686","Comparative Research of Alzheimer's Disease Drugs",[95],[33,7162],"Alzheimer's Disease",[7135,1448,7164],"Rivastigmine",{"intervention":1448,"totalTrials":152,"cells":7166},{"EARLY_PHASE1":7167,"PHASE1":7169,"PHASE2":7171,"PHASE3":7173,"PHASE4":7175,"NA":7181},{"trials":7168,"activeCount":102},[],{"trials":7170,"activeCount":102},[],{"trials":7172,"activeCount":102},[],{"trials":7174,"activeCount":102},[],{"trials":7176,"activeCount":102},[7177],{"nctId":1442,"briefTitle":1443,"status":114,"phases":7178,"completion":1313,"start":1445,"enrollment":599,"conditions":7179,"interventions":7180},[94],[18],[1448,1420],{"trials":7182,"activeCount":102},[7183],{"nctId":7158,"briefTitle":7159,"status":114,"phases":7184,"primaryCompletion":4970,"completion":4970,"start":2384,"enrollment":699,"conditions":7185,"interventions":7186},[95],[33,7162],[7135,1448,7164],{"intervention":7188,"totalTrials":152,"cells":7189},"Haloperidol",{"EARLY_PHASE1":7190,"PHASE1":7192,"PHASE2":7194,"PHASE3":7196,"PHASE4":7198,"NA":7209},{"trials":7191,"activeCount":102},[],{"trials":7193,"activeCount":102},[],{"trials":7195,"activeCount":102},[],{"trials":7197,"activeCount":102},[],{"trials":7199,"activeCount":102},[7200],{"nctId":7201,"briefTitle":7202,"status":137,"phases":7203,"primaryCompletion":2096,"completion":2096,"start":3958,"enrollment":7204,"conditions":7205,"interventions":7208},"NCT02213900","Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy",[94],135,[7153,7206,7207,18,21],"Cognitive Impairment","Post-traumatic Stress Disorder",[7188],{"trials":7210,"activeCount":102},[7211],{"nctId":7212,"briefTitle":7213,"status":137,"phases":7214,"primaryCompletion":4602,"completion":4602,"start":4178,"enrollment":7215,"conditions":7216,"interventions":7217},"NCT00842608","Pharmacological Management of Delirium",[95],551,[7153,7206],[7188],{"intervention":7219,"totalTrials":147,"cells":7220},"itraconazole",{"EARLY_PHASE1":7221,"PHASE1":7223,"PHASE2":7225,"PHASE3":7227,"PHASE4":7229,"NA":7231},{"trials":7222,"activeCount":102},[],{"trials":7224,"activeCount":102},[],{"trials":7226,"activeCount":102},[],{"trials":7228,"activeCount":102},[],{"trials":7230,"activeCount":102},[],{"trials":7232,"activeCount":102},[7233],{"nctId":7234,"briefTitle":7235,"status":137,"phases":7236,"primaryCompletion":6058,"completion":1707,"start":1531,"enrollment":39,"conditions":7237,"interventions":7238},"NCT00798135","A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer",[95],[6305,6372],[7219],{"intervention":7240,"totalTrials":147,"cells":7241},"Mannitol",{"EARLY_PHASE1":7242,"PHASE1":7244,"PHASE2":7246,"PHASE3":7248,"PHASE4":7250,"NA":7252},{"trials":7243,"activeCount":102},[],{"trials":7245,"activeCount":102},[],{"trials":7247,"activeCount":102},[],{"trials":7249,"activeCount":102},[],{"trials":7251,"activeCount":102},[],{"trials":7253,"activeCount":102},[7254],{"nctId":7255,"briefTitle":7256,"status":861,"phases":7257,"primaryCompletion":7258,"completion":7258,"start":7259,"enrollment":102,"conditions":7260,"interventions":7261},"NCT01215019","Osmotic Therapy for Treatment of Intracranial Hypertension for Traumatic Brain Injury",[95],"2020-10","2010-10",[2169],[7240,7262],"NaCl",{"intervention":7262,"totalTrials":147,"cells":7264},{"EARLY_PHASE1":7265,"PHASE1":7267,"PHASE2":7269,"PHASE3":7271,"PHASE4":7273,"NA":7275},{"trials":7266,"activeCount":102},[],{"trials":7268,"activeCount":102},[],{"trials":7270,"activeCount":102},[],{"trials":7272,"activeCount":102},[],{"trials":7274,"activeCount":102},[],{"trials":7276,"activeCount":102},[7277],{"nctId":7255,"briefTitle":7256,"status":861,"phases":7278,"primaryCompletion":7258,"completion":7258,"start":7259,"enrollment":102,"conditions":7279,"interventions":7280},[95],[2169],[7240,7262],{"intervention":7282,"totalTrials":147,"cells":7283},"sunitinib alone",{"EARLY_PHASE1":7284,"PHASE1":7286,"PHASE2":7288,"PHASE3":7290,"PHASE4":7292,"NA":7294},{"trials":7285,"activeCount":102},[],{"trials":7287,"activeCount":102},[],{"trials":7289,"activeCount":102},[],{"trials":7291,"activeCount":102},[],{"trials":7293,"activeCount":102},[],{"trials":7295,"activeCount":102},[7296],{"nctId":7297,"briefTitle":7298,"status":137,"phases":7299,"primaryCompletion":4130,"completion":4130,"start":7300,"enrollment":7301,"conditions":7302,"interventions":7303},"NCT00656669","Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer",[95],"2008-04",23,[24],[7282,7304,7305],"sunitinib plus paclitaxel","doxorubicin and cyclophosphamide",{"intervention":7304,"totalTrials":147,"cells":7307},{"EARLY_PHASE1":7308,"PHASE1":7310,"PHASE2":7312,"PHASE3":7314,"PHASE4":7316,"NA":7318},{"trials":7309,"activeCount":102},[],{"trials":7311,"activeCount":102},[],{"trials":7313,"activeCount":102},[],{"trials":7315,"activeCount":102},[],{"trials":7317,"activeCount":102},[],{"trials":7319,"activeCount":102},[7320],{"nctId":7297,"briefTitle":7298,"status":137,"phases":7321,"primaryCompletion":4130,"completion":4130,"start":7300,"enrollment":7301,"conditions":7322,"interventions":7323},[95],[24],[7282,7304,7305],{"intervention":7305,"totalTrials":147,"cells":7325},{"EARLY_PHASE1":7326,"PHASE1":7328,"PHASE2":7330,"PHASE3":7332,"PHASE4":7334,"NA":7336},{"trials":7327,"activeCount":102},[],{"trials":7329,"activeCount":102},[],{"trials":7331,"activeCount":102},[],{"trials":7333,"activeCount":102},[],{"trials":7335,"activeCount":102},[],{"trials":7337,"activeCount":102},[7338],{"nctId":7297,"briefTitle":7298,"status":137,"phases":7339,"primaryCompletion":4130,"completion":4130,"start":7300,"enrollment":7301,"conditions":7340,"interventions":7341},[95],[24],[7282,7304,7305],{"intervention":7343,"totalTrials":147,"cells":7344},"150-Water",{"EARLY_PHASE1":7345,"PHASE1":7347,"PHASE2":7349,"PHASE3":7351,"PHASE4":7353,"NA":7355},{"trials":7346,"activeCount":102},[],{"trials":7348,"activeCount":102},[],{"trials":7350,"activeCount":102},[],{"trials":7352,"activeCount":102},[],{"trials":7354,"activeCount":102},[],{"trials":7356,"activeCount":102},[7357],{"nctId":7358,"briefTitle":7359,"status":114,"phases":7360,"primaryCompletion":5543,"completion":5543,"start":4389,"enrollment":34,"conditions":7361,"interventions":7363},"NCT01502228","PET\u002FCT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma",[95],[7362],"Renal Cell Carcinoma",[7343,7364,7365],"62Cu-ethylglyoxal bis","Sunitinib",{"intervention":7364,"totalTrials":147,"cells":7367},{"EARLY_PHASE1":7368,"PHASE1":7370,"PHASE2":7372,"PHASE3":7374,"PHASE4":7376,"NA":7378},{"trials":7369,"activeCount":102},[],{"trials":7371,"activeCount":102},[],{"trials":7373,"activeCount":102},[],{"trials":7375,"activeCount":102},[],{"trials":7377,"activeCount":102},[],{"trials":7379,"activeCount":102},[7380],{"nctId":7358,"briefTitle":7359,"status":114,"phases":7381,"primaryCompletion":5543,"completion":5543,"start":4389,"enrollment":34,"conditions":7382,"interventions":7383},[95],[7362],[7343,7364,7365],{"intervention":7365,"totalTrials":147,"cells":7385},{"EARLY_PHASE1":7386,"PHASE1":7388,"PHASE2":7390,"PHASE3":7392,"PHASE4":7394,"NA":7396},{"trials":7387,"activeCount":102},[],{"trials":7389,"activeCount":102},[],{"trials":7391,"activeCount":102},[],{"trials":7393,"activeCount":102},[],{"trials":7395,"activeCount":102},[],{"trials":7397,"activeCount":102},[7398],{"nctId":7358,"briefTitle":7359,"status":114,"phases":7399,"primaryCompletion":5543,"completion":5543,"start":4389,"enrollment":34,"conditions":7400,"interventions":7401},[95],[7362],[7343,7364,7365],{"intervention":7403,"totalTrials":147,"cells":7404},"Nifedipine",{"EARLY_PHASE1":7405,"PHASE1":7407,"PHASE2":7409,"PHASE3":7411,"PHASE4":7413,"NA":7415},{"trials":7406,"activeCount":102},[],{"trials":7408,"activeCount":102},[],{"trials":7410,"activeCount":102},[],{"trials":7412,"activeCount":102},[],{"trials":7414,"activeCount":102},[],{"trials":7416,"activeCount":102},[7417],{"nctId":7418,"briefTitle":7419,"status":137,"phases":7420,"primaryCompletion":1374,"completion":7421,"start":7422,"enrollment":599,"conditions":7423,"interventions":7425},"NCT02090920","Individualized Dosing of Nifedipine For Tocolysis in Preterm Labor",[],"2019-04","2011-07",[7424],"Preterm Labor",[7403],{"intervention":6955,"totalTrials":147,"cells":7427},{"EARLY_PHASE1":7428,"PHASE1":7430,"PHASE2":7432,"PHASE3":7434,"PHASE4":7436,"NA":7438},{"trials":7429,"activeCount":102},[],{"trials":7431,"activeCount":102},[],{"trials":7433,"activeCount":102},[],{"trials":7435,"activeCount":102},[],{"trials":7437,"activeCount":102},[],{"trials":7439,"activeCount":102},[7440],{"nctId":6940,"briefTitle":6941,"status":114,"phases":7441,"primaryCompletion":6943,"start":4445,"enrollment":1327,"conditions":7442,"interventions":7443},[95],[6945,6946,6947,6948,4677,6949,6950,6951,6952,6953],[4695,6955,6956,6957,6958],{"intervention":6956,"totalTrials":147,"cells":7445},{"EARLY_PHASE1":7446,"PHASE1":7448,"PHASE2":7450,"PHASE3":7452,"PHASE4":7454,"NA":7456},{"trials":7447,"activeCount":102},[],{"trials":7449,"activeCount":102},[],{"trials":7451,"activeCount":102},[],{"trials":7453,"activeCount":102},[],{"trials":7455,"activeCount":102},[],{"trials":7457,"activeCount":102},[7458],{"nctId":6940,"briefTitle":6941,"status":114,"phases":7459,"primaryCompletion":6943,"start":4445,"enrollment":1327,"conditions":7460,"interventions":7461},[95],[6945,6946,6947,6948,4677,6949,6950,6951,6952,6953],[4695,6955,6956,6957,6958],{"intervention":6957,"totalTrials":147,"cells":7463},{"EARLY_PHASE1":7464,"PHASE1":7466,"PHASE2":7468,"PHASE3":7470,"PHASE4":7472,"NA":7474},{"trials":7465,"activeCount":102},[],{"trials":7467,"activeCount":102},[],{"trials":7469,"activeCount":102},[],{"trials":7471,"activeCount":102},[],{"trials":7473,"activeCount":102},[],{"trials":7475,"activeCount":102},[7476],{"nctId":6940,"briefTitle":6941,"status":114,"phases":7477,"primaryCompletion":6943,"start":4445,"enrollment":1327,"conditions":7478,"interventions":7479},[95],[6945,6946,6947,6948,4677,6949,6950,6951,6952,6953],[4695,6955,6956,6957,6958],{"intervention":7481,"totalTrials":147,"cells":7482},"Azathioprine",{"EARLY_PHASE1":7483,"PHASE1":7485,"PHASE2":7487,"PHASE3":7489,"PHASE4":7491,"NA":7493},{"trials":7484,"activeCount":102},[],{"trials":7486,"activeCount":102},[],{"trials":7488,"activeCount":102},[],{"trials":7490,"activeCount":102},[],{"trials":7492,"activeCount":102},[],{"trials":7494,"activeCount":102},[7495],{"nctId":7496,"briefTitle":7497,"status":114,"phases":7498,"primaryCompletion":7499,"completion":7499,"start":4177,"enrollment":98,"conditions":7500,"interventions":7503},"NCT02413047","Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator",[95],"2018-02",[7501,7502,6637],"Inflammatory Bowel Disease","Ulcerative Colitis",[7481,7504,7505],"6 mercaptopurine","Methotrexate",{"intervention":7504,"totalTrials":147,"cells":7507},{"EARLY_PHASE1":7508,"PHASE1":7510,"PHASE2":7512,"PHASE3":7514,"PHASE4":7516,"NA":7518},{"trials":7509,"activeCount":102},[],{"trials":7511,"activeCount":102},[],{"trials":7513,"activeCount":102},[],{"trials":7515,"activeCount":102},[],{"trials":7517,"activeCount":102},[],{"trials":7519,"activeCount":102},[7520],{"nctId":7496,"briefTitle":7497,"status":114,"phases":7521,"primaryCompletion":7499,"completion":7499,"start":4177,"enrollment":98,"conditions":7522,"interventions":7523},[95],[7501,7502,6637],[7481,7504,7505],{"intervention":7505,"totalTrials":147,"cells":7525},{"EARLY_PHASE1":7526,"PHASE1":7528,"PHASE2":7530,"PHASE3":7532,"PHASE4":7534,"NA":7536},{"trials":7527,"activeCount":102},[],{"trials":7529,"activeCount":102},[],{"trials":7531,"activeCount":102},[],{"trials":7533,"activeCount":102},[],{"trials":7535,"activeCount":102},[],{"trials":7537,"activeCount":102},[7538],{"nctId":7496,"briefTitle":7497,"status":114,"phases":7539,"primaryCompletion":7499,"completion":7499,"start":4177,"enrollment":98,"conditions":7540,"interventions":7541},[95],[7501,7502,6637],[7481,7504,7505],{"intervention":7543,"totalTrials":147,"cells":7544},"Fish oil",{"EARLY_PHASE1":7545,"PHASE1":7547,"PHASE2":7549,"PHASE3":7551,"PHASE4":7553,"NA":7555},{"trials":7546,"activeCount":102},[],{"trials":7548,"activeCount":102},[],{"trials":7550,"activeCount":102},[],{"trials":7552,"activeCount":102},[],{"trials":7554,"activeCount":102},[],{"trials":7556,"activeCount":102},[7557],{"nctId":7558,"briefTitle":7559,"status":137,"phases":7560,"completion":1936,"start":1740,"enrollment":1364,"conditions":7561,"interventions":7563},"NCT00308295","A Pilot Study of Fish Oil Supplementation in Hemodialysis Patients",[95],[7562],"End-Stage Renal Disease Patients on Hemodialysis",[7543,7564],"matched placebo",{"intervention":7564,"totalTrials":147,"cells":7566},{"EARLY_PHASE1":7567,"PHASE1":7569,"PHASE2":7571,"PHASE3":7573,"PHASE4":7575,"NA":7577},{"trials":7568,"activeCount":102},[],{"trials":7570,"activeCount":102},[],{"trials":7572,"activeCount":102},[],{"trials":7574,"activeCount":102},[],{"trials":7576,"activeCount":102},[],{"trials":7578,"activeCount":102},[7579],{"nctId":7558,"briefTitle":7559,"status":137,"phases":7580,"completion":1936,"start":1740,"enrollment":1364,"conditions":7581,"interventions":7582},[95],[7562],[7543,7564],{"intervention":7584,"totalTrials":147,"cells":7585},"Polymyxin B in Normal Saline",{"EARLY_PHASE1":7586,"PHASE1":7588,"PHASE2":7590,"PHASE3":7592,"PHASE4":7594,"NA":7596},{"trials":7587,"activeCount":102},[],{"trials":7589,"activeCount":102},[],{"trials":7591,"activeCount":102},[],{"trials":7593,"activeCount":102},[],{"trials":7595,"activeCount":102},[],{"trials":7597,"activeCount":102},[7598],{"nctId":7599,"briefTitle":7600,"status":137,"phases":7601,"primaryCompletion":7421,"completion":4600,"start":864,"enrollment":7602,"conditions":7603,"interventions":7605},"NCT02186457","Antibiotic Irrigation for Pancreatoduodenectomy",[95],190,[121,7604],"Infection",[7584],{"intervention":7607,"totalTrials":147,"cells":7608},"COVID-19 Vaccination",{"EARLY_PHASE1":7609,"PHASE1":7611,"PHASE2":7613,"PHASE3":7615,"PHASE4":7617,"NA":7619},{"trials":7610,"activeCount":102},[],{"trials":7612,"activeCount":102},[],{"trials":7614,"activeCount":102},[],{"trials":7616,"activeCount":102},[],{"trials":7618,"activeCount":102},[],{"trials":7620,"activeCount":102},[7621],{"nctId":7622,"briefTitle":7623,"status":114,"phases":7624,"primaryCompletion":7625,"completion":7626,"start":7627,"enrollment":7628,"conditions":7629,"interventions":7631},"NCT04930055","Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)",[],"2021-11-01","2022-03-08","2021-06-30",2206,[7630],"Cancer",[7607],{"intervention":7633,"totalTrials":147,"cells":7634},"Bupropion and intensive behavioral therapy",{"EARLY_PHASE1":7635,"PHASE1":7637,"PHASE2":7639,"PHASE3":7641,"PHASE4":7643,"NA":7645},{"trials":7636,"activeCount":102},[],{"trials":7638,"activeCount":102},[],{"trials":7640,"activeCount":102},[],{"trials":7642,"activeCount":102},[],{"trials":7644,"activeCount":102},[],{"trials":7646,"activeCount":102},[7647],{"nctId":7648,"briefTitle":7649,"status":137,"phases":7650,"completion":1301,"start":7651,"enrollment":4409,"conditions":7652,"interventions":7654},"NCT00236288","A Feasibility Study of Smoking Cessation Program in Radiation Oncology",[95],"2005-10",[7653],"Cancer and Tobacco Abuse",[7633],{"intervention":7656,"totalTrials":147,"cells":7657},"ezetimibe",{"EARLY_PHASE1":7658,"PHASE1":7660,"PHASE2":7662,"PHASE3":7664,"PHASE4":7666,"NA":7668},{"trials":7659,"activeCount":102},[],{"trials":7661,"activeCount":102},[],{"trials":7663,"activeCount":102},[],{"trials":7665,"activeCount":102},[],{"trials":7667,"activeCount":102},[],{"trials":7669,"activeCount":102},[7670],{"nctId":7671,"briefTitle":7672,"status":861,"phases":7673,"primaryCompletion":4994,"completion":4994,"start":4994,"enrollment":102,"conditions":7674,"interventions":7676},"NCT00634140","The Influence of Ezetimibe on Gallbladder Function",[95],[7675],"Chronic Acalculous Cholecystitis",[7656],{"intervention":7678,"totalTrials":147,"cells":7679},"Atorvastatin",{"EARLY_PHASE1":7680,"PHASE1":7682,"PHASE2":7684,"PHASE3":7686,"PHASE4":7688,"NA":7690},{"trials":7681,"activeCount":102},[],{"trials":7683,"activeCount":102},[],{"trials":7685,"activeCount":102},[],{"trials":7687,"activeCount":102},[],{"trials":7689,"activeCount":102},[],{"trials":7691,"activeCount":102},[7692],{"nctId":7693,"briefTitle":7694,"status":114,"phases":7695,"primaryCompletion":1346,"completion":6057,"start":1531,"enrollment":951,"conditions":7696,"interventions":7697},"NCT00979940","Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)",[95],[2928],[7678],{"intervention":7699,"totalTrials":147,"cells":7700},"Administration of montelukast or placebo",{"EARLY_PHASE1":7701,"PHASE1":7703,"PHASE2":7705,"PHASE3":7707,"PHASE4":7709,"NA":7711},{"trials":7702,"activeCount":102},[],{"trials":7704,"activeCount":102},[],{"trials":7706,"activeCount":102},[],{"trials":7708,"activeCount":102},[],{"trials":7710,"activeCount":102},[],{"trials":7712,"activeCount":102},[7713],{"nctId":7714,"briefTitle":7715,"status":861,"phases":7716,"start":4241,"enrollment":102,"conditions":7717,"interventions":7719},"NCT00375232","Effects of Montelukast on Occult Exercise-Induced Bronchospasm in Athletes",[95],[7718],"Exercise-Induced Bronchospasm",[7699],{"intervention":7721,"totalTrials":147,"cells":7722},"triamcinolone",{"EARLY_PHASE1":7723,"PHASE1":7725,"PHASE2":7727,"PHASE3":7729,"PHASE4":7731,"NA":7733},{"trials":7724,"activeCount":102},[],{"trials":7726,"activeCount":102},[],{"trials":7728,"activeCount":102},[],{"trials":7730,"activeCount":102},[],{"trials":7732,"activeCount":102},[],{"trials":7734,"activeCount":102},[7735],{"nctId":7736,"briefTitle":7737,"status":137,"phases":7738,"primaryCompletion":1436,"completion":1436,"start":7739,"enrollment":7740,"conditions":7741,"interventions":7742},"NCT00583271","A Prospective Study of EUS Guided Celiac Block",[],"2002-06",127,[847,2447],[7721,7743],"98% dehydrated alcohol",{"intervention":7743,"totalTrials":147,"cells":7745},{"EARLY_PHASE1":7746,"PHASE1":7748,"PHASE2":7750,"PHASE3":7752,"PHASE4":7754,"NA":7756},{"trials":7747,"activeCount":102},[],{"trials":7749,"activeCount":102},[],{"trials":7751,"activeCount":102},[],{"trials":7753,"activeCount":102},[],{"trials":7755,"activeCount":102},[],{"trials":7757,"activeCount":102},[7758],{"nctId":7736,"briefTitle":7737,"status":137,"phases":7759,"primaryCompletion":1436,"completion":1436,"start":7739,"enrollment":7740,"conditions":7760,"interventions":7761},[],[847,2447],[7721,7743],{"intervention":7763,"totalTrials":147,"cells":7764},"liraglutide",{"EARLY_PHASE1":7765,"PHASE1":7767,"PHASE2":7769,"PHASE3":7771,"PHASE4":7773,"NA":7775},{"trials":7766,"activeCount":102},[],{"trials":7768,"activeCount":102},[],{"trials":7770,"activeCount":102},[],{"trials":7772,"activeCount":102},[],{"trials":7774,"activeCount":102},[],{"trials":7776,"activeCount":102},[7777],{"nctId":7778,"briefTitle":7779,"status":137,"phases":7780,"primaryCompletion":7781,"completion":7781,"start":1771,"enrollment":579,"conditions":7782,"interventions":7783},"NCT01232946","Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake",[95],"2017-09-08",[4616],[7763,7784,7785],"insulin detemir","liraglutide plus insulin detemir",{"intervention":7784,"totalTrials":147,"cells":7787},{"EARLY_PHASE1":7788,"PHASE1":7790,"PHASE2":7792,"PHASE3":7794,"PHASE4":7796,"NA":7798},{"trials":7789,"activeCount":102},[],{"trials":7791,"activeCount":102},[],{"trials":7793,"activeCount":102},[],{"trials":7795,"activeCount":102},[],{"trials":7797,"activeCount":102},[],{"trials":7799,"activeCount":102},[7800],{"nctId":7778,"briefTitle":7779,"status":137,"phases":7801,"primaryCompletion":7781,"completion":7781,"start":1771,"enrollment":579,"conditions":7802,"interventions":7803},[95],[4616],[7763,7784,7785],{"intervention":7785,"totalTrials":147,"cells":7805},{"EARLY_PHASE1":7806,"PHASE1":7808,"PHASE2":7810,"PHASE3":7812,"PHASE4":7814,"NA":7816},{"trials":7807,"activeCount":102},[],{"trials":7809,"activeCount":102},[],{"trials":7811,"activeCount":102},[],{"trials":7813,"activeCount":102},[],{"trials":7815,"activeCount":102},[],{"trials":7817,"activeCount":102},[7818],{"nctId":7778,"briefTitle":7779,"status":137,"phases":7819,"primaryCompletion":7781,"completion":7781,"start":1771,"enrollment":579,"conditions":7820,"interventions":7821},[95],[4616],[7763,7784,7785],{"intervention":7823,"totalTrials":147,"cells":7824},"Atazanavir",{"EARLY_PHASE1":7825,"PHASE1":7827,"PHASE2":7829,"PHASE3":7831,"PHASE4":7833,"NA":7835},{"trials":7826,"activeCount":102},[],{"trials":7828,"activeCount":102},[],{"trials":7830,"activeCount":102},[],{"trials":7832,"activeCount":102},[],{"trials":7834,"activeCount":102},[],{"trials":7836,"activeCount":102},[7837],{"nctId":7838,"briefTitle":7839,"status":137,"phases":7840,"primaryCompletion":6128,"completion":4241,"start":1445,"enrollment":579,"conditions":7841,"interventions":7842},"NCT00720590","Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir\u002FRitonavir on Cardiovascular Disease Risk Factors",[95],[7014],[7823,7843],"Lopinavir\u002Fritonavir",{"intervention":7843,"totalTrials":147,"cells":7845},{"EARLY_PHASE1":7846,"PHASE1":7848,"PHASE2":7850,"PHASE3":7852,"PHASE4":7854,"NA":7856},{"trials":7847,"activeCount":102},[],{"trials":7849,"activeCount":102},[],{"trials":7851,"activeCount":102},[],{"trials":7853,"activeCount":102},[],{"trials":7855,"activeCount":102},[],{"trials":7857,"activeCount":102},[7858],{"nctId":7838,"briefTitle":7839,"status":137,"phases":7859,"primaryCompletion":6128,"completion":4241,"start":1445,"enrollment":579,"conditions":7860,"interventions":7861},[95],[7014],[7823,7843],{"intervention":7863,"totalTrials":147,"cells":7864},"Brimonidine Purite",{"EARLY_PHASE1":7865,"PHASE1":7867,"PHASE2":7869,"PHASE3":7871,"PHASE4":7873,"NA":7875},{"trials":7866,"activeCount":102},[],{"trials":7868,"activeCount":102},[],{"trials":7870,"activeCount":102},[],{"trials":7872,"activeCount":102},[],{"trials":7874,"activeCount":102},[],{"trials":7876,"activeCount":102},[7877],{"nctId":7878,"briefTitle":7879,"status":137,"phases":7880,"completion":4901,"start":5868,"enrollment":3017,"conditions":7881,"interventions":7882},"NCT00352807","Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract Patients",[95],[1940],[7863],{"intervention":7884,"totalTrials":147,"cells":7885},"The MedMilk study",{"EARLY_PHASE1":7886,"PHASE1":7888,"PHASE2":7890,"PHASE3":7892,"PHASE4":7894,"NA":7896},{"trials":7887,"activeCount":102},[],{"trials":7889,"activeCount":102},[],{"trials":7891,"activeCount":102},[],{"trials":7893,"activeCount":102},[],{"trials":7895,"activeCount":102},[],{"trials":7897,"activeCount":102},[7898],{"nctId":7899,"briefTitle":7900,"status":137,"phases":7901,"primaryCompletion":7902,"completion":7902,"start":7903,"enrollment":579,"conditions":7904,"interventions":7905},"NCT05099484","Medications in Breast Milk: A Convenience Pharmacokinetic Study",[],"2022-09-01","2021-01-15",[1269],[7884],{"intervention":7907,"totalTrials":147,"cells":7908},"Losartan",{"EARLY_PHASE1":7909,"PHASE1":7911,"PHASE2":7913,"PHASE3":7915,"PHASE4":7917,"NA":7919},{"trials":7910,"activeCount":102},[],{"trials":7912,"activeCount":102},[],{"trials":7914,"activeCount":102},[],{"trials":7916,"activeCount":102},[],{"trials":7918,"activeCount":102},[],{"trials":7920,"activeCount":102},[7921],{"nctId":7922,"briefTitle":7923,"status":137,"phases":7924,"primaryCompletion":7925,"completion":1707,"start":7926,"enrollment":28,"conditions":7927,"interventions":7929},"NCT00402194","Treating the Endothelium to Restore Insulin Sensitivity",[95],"2011-11","2005-06",[6397,4618,7928,6396],"Impaired Glucose Tolerance",[7907],{"intervention":7931,"totalTrials":147,"cells":7932},"[13C]Pantoprazole",{"EARLY_PHASE1":7933,"PHASE1":7935,"PHASE2":7937,"PHASE3":7939,"PHASE4":7941,"NA":7943},{"trials":7934,"activeCount":102},[],{"trials":7936,"activeCount":102},[],{"trials":7938,"activeCount":102},[],{"trials":7940,"activeCount":102},[],{"trials":7942,"activeCount":102},[],{"trials":7944,"activeCount":102},[7945],{"nctId":7946,"briefTitle":7947,"status":137,"phases":7948,"primaryCompletion":6347,"completion":4390,"start":1764,"enrollment":1290,"conditions":7949,"interventions":7950},"NCT00668902","Rapid Screening Phenotype Test To Evaluate CYP 2C19 Enzyme Activity Using Stable Isotope [13C]Pantoprazole",[95],[754],[7931],{"intervention":7952,"totalTrials":147,"cells":7953},"gene expression analysis",{"EARLY_PHASE1":7954,"PHASE1":7956,"PHASE2":7958,"PHASE3":7960,"PHASE4":7962,"NA":7964},{"trials":7955,"activeCount":102},[],{"trials":7957,"activeCount":102},[],{"trials":7959,"activeCount":102},[],{"trials":7961,"activeCount":102},[],{"trials":7963,"activeCount":102},[],{"trials":7965,"activeCount":102},[7966],{"nctId":7967,"briefTitle":7968,"status":137,"phases":7969,"primaryCompletion":2360,"completion":2360,"start":4390,"enrollment":7215,"conditions":7970,"interventions":7974},"NCT00898378","Study of Biomarkers in Blood & Tissue Samples From Patients With Colorectal Cancer or Polyps & Patients Without Polyps",[],[7971,7972,7973],"Colorectal Cancer","Healthy, no Evidence of Disease","Precancerous Condition",[7952,7975,7976,7977,7978],"polymerase chain reaction","polymorphism analysis","protein expression analysis","proteomic profiling",{"intervention":7975,"totalTrials":147,"cells":7980},{"EARLY_PHASE1":7981,"PHASE1":7983,"PHASE2":7985,"PHASE3":7987,"PHASE4":7989,"NA":7991},{"trials":7982,"activeCount":102},[],{"trials":7984,"activeCount":102},[],{"trials":7986,"activeCount":102},[],{"trials":7988,"activeCount":102},[],{"trials":7990,"activeCount":102},[],{"trials":7992,"activeCount":102},[7993],{"nctId":7967,"briefTitle":7968,"status":137,"phases":7994,"primaryCompletion":2360,"completion":2360,"start":4390,"enrollment":7215,"conditions":7995,"interventions":7996},[],[7971,7972,7973],[7952,7975,7976,7977,7978],{"intervention":7976,"totalTrials":147,"cells":7998},{"EARLY_PHASE1":7999,"PHASE1":8001,"PHASE2":8003,"PHASE3":8005,"PHASE4":8007,"NA":8009},{"trials":8000,"activeCount":102},[],{"trials":8002,"activeCount":102},[],{"trials":8004,"activeCount":102},[],{"trials":8006,"activeCount":102},[],{"trials":8008,"activeCount":102},[],{"trials":8010,"activeCount":102},[8011],{"nctId":7967,"briefTitle":7968,"status":137,"phases":8012,"primaryCompletion":2360,"completion":2360,"start":4390,"enrollment":7215,"conditions":8013,"interventions":8014},[],[7971,7972,7973],[7952,7975,7976,7977,7978],{"intervention":7977,"totalTrials":147,"cells":8016},{"EARLY_PHASE1":8017,"PHASE1":8019,"PHASE2":8021,"PHASE3":8023,"PHASE4":8025,"NA":8027},{"trials":8018,"activeCount":102},[],{"trials":8020,"activeCount":102},[],{"trials":8022,"activeCount":102},[],{"trials":8024,"activeCount":102},[],{"trials":8026,"activeCount":102},[],{"trials":8028,"activeCount":102},[8029],{"nctId":7967,"briefTitle":7968,"status":137,"phases":8030,"primaryCompletion":2360,"completion":2360,"start":4390,"enrollment":7215,"conditions":8031,"interventions":8032},[],[7971,7972,7973],[7952,7975,7976,7977,7978],{"intervention":7978,"totalTrials":147,"cells":8034},{"EARLY_PHASE1":8035,"PHASE1":8037,"PHASE2":8039,"PHASE3":8041,"PHASE4":8043,"NA":8045},{"trials":8036,"activeCount":102},[],{"trials":8038,"activeCount":102},[],{"trials":8040,"activeCount":102},[],{"trials":8042,"activeCount":102},[],{"trials":8044,"activeCount":102},[],{"trials":8046,"activeCount":102},[8047],{"nctId":7967,"briefTitle":7968,"status":137,"phases":8048,"primaryCompletion":2360,"completion":2360,"start":4390,"enrollment":7215,"conditions":8049,"interventions":8050},[],[7971,7972,7973],[7952,7975,7976,7977,7978],{"intervention":8052,"totalTrials":147,"cells":8053},"Serum Zn",{"EARLY_PHASE1":8054,"PHASE1":8056,"PHASE2":8058,"PHASE3":8060,"PHASE4":8062,"NA":8064},{"trials":8055,"activeCount":102},[],{"trials":8057,"activeCount":102},[],{"trials":8059,"activeCount":102},[],{"trials":8061,"activeCount":102},[],{"trials":8063,"activeCount":102},[],{"trials":8065,"activeCount":102},[8066],{"nctId":8067,"briefTitle":8068,"status":137,"phases":8069,"primaryCompletion":8070,"completion":8070,"start":8071,"enrollment":8072,"conditions":8073,"interventions":8076},"NCT04302428","Zinc Status and Growth in Cystic Fibrosis",[],"2021-03-30","2019-08-29",35,[8074,8075],"Cystic","Fibrosis",[8052,8077],"Red Blood Cell Zn",{"intervention":8077,"totalTrials":147,"cells":8079},{"EARLY_PHASE1":8080,"PHASE1":8082,"PHASE2":8084,"PHASE3":8086,"PHASE4":8088,"NA":8090},{"trials":8081,"activeCount":102},[],{"trials":8083,"activeCount":102},[],{"trials":8085,"activeCount":102},[],{"trials":8087,"activeCount":102},[],{"trials":8089,"activeCount":102},[],{"trials":8091,"activeCount":102},[8092],{"nctId":8067,"briefTitle":8068,"status":137,"phases":8093,"primaryCompletion":8070,"completion":8070,"start":8071,"enrollment":8072,"conditions":8094,"interventions":8095},[],[8074,8075],[8052,8077],{"intervention":7164,"totalTrials":147,"cells":8097},{"EARLY_PHASE1":8098,"PHASE1":8100,"PHASE2":8102,"PHASE3":8104,"PHASE4":8106,"NA":8108},{"trials":8099,"activeCount":102},[],{"trials":8101,"activeCount":102},[],{"trials":8103,"activeCount":102},[],{"trials":8105,"activeCount":102},[],{"trials":8107,"activeCount":102},[],{"trials":8109,"activeCount":102},[8110],{"nctId":7158,"briefTitle":7159,"status":114,"phases":8111,"primaryCompletion":4970,"completion":4970,"start":2384,"enrollment":699,"conditions":8112,"interventions":8113},[95],[33,7162],[7135,1448,7164],{"intervention":8115,"totalTrials":147,"cells":8116},"Immunotherapy",{"EARLY_PHASE1":8117,"PHASE1":8119,"PHASE2":8121,"PHASE3":8123,"PHASE4":8125,"NA":8127},{"trials":8118,"activeCount":102},[],{"trials":8120,"activeCount":102},[],{"trials":8122,"activeCount":102},[],{"trials":8124,"activeCount":102},[],{"trials":8126,"activeCount":102},[],{"trials":8128,"activeCount":102},[8129],{"nctId":8130,"briefTitle":8131,"status":114,"phases":8132,"primaryCompletion":8133,"completion":8133,"start":8134,"enrollment":147,"conditions":8135,"interventions":8136},"NCT06084676","Organoid Model Predictive of Response to Immunotherapies",[],"2024-02-26","2024-01-22",[24],[8115],{"intervention":8138,"totalTrials":147,"cells":8139},"doxercalciferol",{"EARLY_PHASE1":8140,"PHASE1":8142,"PHASE2":8144,"PHASE3":8146,"PHASE4":8148,"NA":8150},{"trials":8141,"activeCount":102},[],{"trials":8143,"activeCount":102},[],{"trials":8145,"activeCount":102},[],{"trials":8147,"activeCount":102},[],{"trials":8149,"activeCount":102},[],{"trials":8151,"activeCount":102},[8152],{"nctId":8153,"briefTitle":8154,"status":137,"phases":8155,"primaryCompletion":2635,"completion":2635,"start":7046,"enrollment":8156,"conditions":8157,"interventions":8159},"NCT00285467","Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease",[95],55,[8158],"Renal Osteodystrophy",[8138,8160],"Cholecalciferol",{"intervention":8160,"totalTrials":147,"cells":8162},{"EARLY_PHASE1":8163,"PHASE1":8165,"PHASE2":8167,"PHASE3":8169,"PHASE4":8171,"NA":8173},{"trials":8164,"activeCount":102},[],{"trials":8166,"activeCount":102},[],{"trials":8168,"activeCount":102},[],{"trials":8170,"activeCount":102},[],{"trials":8172,"activeCount":102},[],{"trials":8174,"activeCount":102},[8175],{"nctId":8153,"briefTitle":8154,"status":137,"phases":8176,"primaryCompletion":2635,"completion":2635,"start":7046,"enrollment":8156,"conditions":8177,"interventions":8178},[95],[8158],[8138,8160],{"intervention":8180,"totalTrials":147,"cells":8181},"Intravenous antibiotics",{"EARLY_PHASE1":8182,"PHASE1":8184,"PHASE2":8186,"PHASE3":8188,"PHASE4":8190,"NA":8192},{"trials":8183,"activeCount":102},[],{"trials":8185,"activeCount":102},[],{"trials":8187,"activeCount":102},[],{"trials":8189,"activeCount":102},[],{"trials":8191,"activeCount":102},[],{"trials":8193,"activeCount":102},[8194],{"nctId":8195,"briefTitle":8196,"status":137,"phases":8197,"primaryCompletion":2901,"completion":4854,"start":1288,"enrollment":776,"conditions":8198,"interventions":8200},"NCT00596167","Intradialytic Drug Removal by Short-daily Hemodialysis",[95],[8199,7604],"End Stage Renal Disease",[8180],{"intervention":8202,"totalTrials":147,"cells":8203},"IC Green",{"EARLY_PHASE1":8204,"PHASE1":8206,"PHASE2":8208,"PHASE3":8210,"PHASE4":8212,"NA":8214},{"trials":8205,"activeCount":102},[],{"trials":8207,"activeCount":102},[],{"trials":8209,"activeCount":102},[],{"trials":8211,"activeCount":102},[],{"trials":8213,"activeCount":102},[],{"trials":8215,"activeCount":102},[8216],{"nctId":8217,"briefTitle":8218,"status":137,"phases":8219,"primaryCompletion":8220,"completion":8220,"start":4852,"enrollment":8221,"conditions":8222,"interventions":8224},"NCT01673022","Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging",[95],"2017-01",430,[8223,1112],"Endometrial Cancer",[8202],{"intervention":8226,"totalTrials":147,"cells":8227},"Vaginal acidifying gel",{"EARLY_PHASE1":8228,"PHASE1":8230,"PHASE2":8232,"PHASE3":8234,"PHASE4":8236,"NA":8238},{"trials":8229,"activeCount":102},[],{"trials":8231,"activeCount":102},[],{"trials":8233,"activeCount":102},[],{"trials":8235,"activeCount":102},[],{"trials":8237,"activeCount":102},[],{"trials":8239,"activeCount":102},[8240],{"nctId":8241,"briefTitle":8242,"status":137,"phases":8243,"primaryCompletion":8244,"completion":8244,"start":1288,"enrollment":8156,"conditions":8245,"interventions":8247},"NCT00545181","Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial",[95],"2009-07",[8246],"Bacterial Vaginosis",[8226,8248],"Metronidazole control",{"intervention":8248,"totalTrials":147,"cells":8250},{"EARLY_PHASE1":8251,"PHASE1":8253,"PHASE2":8255,"PHASE3":8257,"PHASE4":8259,"NA":8261},{"trials":8252,"activeCount":102},[],{"trials":8254,"activeCount":102},[],{"trials":8256,"activeCount":102},[],{"trials":8258,"activeCount":102},[],{"trials":8260,"activeCount":102},[],{"trials":8262,"activeCount":102},[8263],{"nctId":8241,"briefTitle":8242,"status":137,"phases":8264,"primaryCompletion":8244,"completion":8244,"start":1288,"enrollment":8156,"conditions":8265,"interventions":8266},[95],[8246],[8226,8248],{"intervention":8268,"totalTrials":147,"cells":8269},"dexlansoprazole",{"EARLY_PHASE1":8270,"PHASE1":8272,"PHASE2":8274,"PHASE3":8276,"PHASE4":8278,"NA":8280},{"trials":8271,"activeCount":102},[],{"trials":8273,"activeCount":102},[],{"trials":8275,"activeCount":102},[],{"trials":8277,"activeCount":102},[],{"trials":8279,"activeCount":102},[],{"trials":8281,"activeCount":102},[8282],{"nctId":8283,"briefTitle":8284,"status":114,"phases":8285,"primaryCompletion":6971,"completion":6971,"start":4434,"enrollment":4435,"conditions":8286,"interventions":8288},"NCT01317472","The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux",[95],[8287],"Laryngopharyngeal Reflux",[8268],{"intervention":8290,"totalTrials":147,"cells":8291},"HPV vaccine, Merck",{"EARLY_PHASE1":8292,"PHASE1":8294,"PHASE2":8296,"PHASE3":8298,"PHASE4":8300,"NA":8302},{"trials":8293,"activeCount":102},[],{"trials":8295,"activeCount":102},[],{"trials":8297,"activeCount":102},[],{"trials":8299,"activeCount":102},[],{"trials":8301,"activeCount":102},[],{"trials":8303,"activeCount":102},[8304],{"nctId":8305,"briefTitle":8306,"status":137,"phases":8307,"primaryCompletion":8308,"completion":8308,"start":8309,"enrollment":3768,"conditions":8310,"interventions":8312},"NCT04774887","ERADICATING CERVICAL CANCER IN KENYA",[95],"2023-10-18","2021-11-13",[8311,4401],"Human Papilloma Virus",[8290],{"intervention":8314,"totalTrials":147,"cells":8315},"Human Papillomavirus Vaccine",{"EARLY_PHASE1":8316,"PHASE1":8318,"PHASE2":8320,"PHASE3":8322,"PHASE4":8324,"NA":8326},{"trials":8317,"activeCount":102},[],{"trials":8319,"activeCount":102},[],{"trials":8321,"activeCount":102},[],{"trials":8323,"activeCount":102},[],{"trials":8325,"activeCount":102},[],{"trials":8327,"activeCount":102},[8328],{"nctId":8329,"briefTitle":8330,"status":137,"phases":8331,"primaryCompletion":8332,"completion":8332,"start":7925,"enrollment":8333,"conditions":8334,"interventions":8336},"NCT00767897","The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients",[],"2018-12",72,[1606,8335],"Dialysis",[8314],{"intervention":7132,"totalTrials":147,"cells":8338},{"EARLY_PHASE1":8339,"PHASE1":8341,"PHASE2":8343,"PHASE3":8345,"PHASE4":8347,"NA":8349},{"trials":8340,"activeCount":102},[],{"trials":8342,"activeCount":102},[],{"trials":8344,"activeCount":102},[],{"trials":8346,"activeCount":102},[],{"trials":8348,"activeCount":102},[],{"trials":8350,"activeCount":102},[8351],{"nctId":7126,"briefTitle":7127,"status":137,"phases":8352,"primaryCompletion":2445,"completion":2445,"start":7129,"enrollment":25,"conditions":8353,"interventions":8354},[95],[2662],[7132,4030,7133],{"intervention":7133,"totalTrials":147,"cells":8356},{"EARLY_PHASE1":8357,"PHASE1":8359,"PHASE2":8361,"PHASE3":8363,"PHASE4":8365,"NA":8367},{"trials":8358,"activeCount":102},[],{"trials":8360,"activeCount":102},[],{"trials":8362,"activeCount":102},[],{"trials":8364,"activeCount":102},[],{"trials":8366,"activeCount":102},[],{"trials":8368,"activeCount":102},[8369],{"nctId":7126,"briefTitle":7127,"status":137,"phases":8370,"primaryCompletion":2445,"completion":2445,"start":7129,"enrollment":25,"conditions":8371,"interventions":8372},[95],[2662],[7132,4030,7133],{"intervention":8374,"totalTrials":147,"cells":8375},"Buprenorphine",{"EARLY_PHASE1":8376,"PHASE1":8378,"PHASE2":8380,"PHASE3":8382,"PHASE4":8384,"NA":8386},{"trials":8377,"activeCount":102},[],{"trials":8379,"activeCount":102},[],{"trials":8381,"activeCount":102},[],{"trials":8383,"activeCount":102},[],{"trials":8385,"activeCount":102},[],{"trials":8387,"activeCount":102},[8388],{"nctId":8389,"briefTitle":8390,"status":137,"phases":8391,"primaryCompletion":8392,"completion":8392,"start":3351,"enrollment":8393,"conditions":8394,"interventions":8396},"NCT06008990","Maternal Brain Imaging in Opioid Use Disorder",[],"2025-10-31",45,[849,1268,8395,1269,1270,1271],"Substance Use",[8374],{"intervention":8398,"totalTrials":147,"cells":8399},"Inhaled primatene will be given as a breathing treatment",{"EARLY_PHASE1":8400,"PHASE1":8402,"PHASE2":8404,"PHASE3":8406,"PHASE4":8408,"NA":8410},{"trials":8401,"activeCount":102},[],{"trials":8403,"activeCount":102},[],{"trials":8405,"activeCount":102},[],{"trials":8407,"activeCount":102},[],{"trials":8409,"activeCount":102},[],{"trials":8411,"activeCount":102},[8412],{"nctId":8413,"briefTitle":8414,"status":137,"phases":8415,"primaryCompletion":1708,"completion":1436,"start":3304,"enrollment":8416,"conditions":8417,"interventions":8420},"NCT00435994","Assessment of Airway Obstruction in Infants With Lower Respiratory Infections",[95],59,[8418,8419],"Bronchiolitis","Respiratory Syncytial Virus Infections",[8398],{"intervention":8422,"totalTrials":147,"cells":8423},"lapatinib",{"EARLY_PHASE1":8424,"PHASE1":8426,"PHASE2":8428,"PHASE3":8430,"PHASE4":8432,"NA":8434},{"trials":8425,"activeCount":102},[],{"trials":8427,"activeCount":102},[],{"trials":8429,"activeCount":102},[],{"trials":8431,"activeCount":102},[],{"trials":8433,"activeCount":102},[],{"trials":8435,"activeCount":102},[8436],{"nctId":8437,"briefTitle":8438,"status":114,"phases":8439,"primaryCompletion":3504,"completion":3504,"start":2901,"enrollment":147,"conditions":8440,"interventions":8442},"NCT00857714","Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast",[95],[8441],"Ductal Carcinoma in Situ",[8422],{"intervention":6848,"totalTrials":147,"cells":8444},{"EARLY_PHASE1":8445,"PHASE1":8447,"PHASE2":8449,"PHASE3":8451,"PHASE4":8453,"NA":8455},{"trials":8446,"activeCount":102},[],{"trials":8448,"activeCount":102},[],{"trials":8450,"activeCount":102},[],{"trials":8452,"activeCount":102},[],{"trials":8454,"activeCount":102},[],{"trials":8456,"activeCount":102},[8457],{"nctId":6841,"briefTitle":6842,"status":137,"phases":8458,"primaryCompletion":2384,"completion":1347,"start":1300,"enrollment":6844,"conditions":8459,"interventions":8460},[95],[6846],[1675,6848],{"intervention":8462,"totalTrials":147,"cells":8463},"Mifepristone 200 MG",{"EARLY_PHASE1":8464,"PHASE1":8466,"PHASE2":8468,"PHASE3":8470,"PHASE4":8472,"NA":8474},{"trials":8465,"activeCount":102},[],{"trials":8467,"activeCount":102},[],{"trials":8469,"activeCount":102},[],{"trials":8471,"activeCount":102},[],{"trials":8473,"activeCount":102},[],{"trials":8475,"activeCount":102},[8476],{"nctId":8477,"briefTitle":8478,"status":861,"phases":8479,"primaryCompletion":8480,"completion":8481,"start":7625,"enrollment":102,"conditions":8482,"interventions":8486},"NCT05062174","Breast Cancer BRCA1 Carriers: a Pilot Study",[],"2023-12-31","2024-12-31",[8483,8484,8485],"BRCA1 Mutation","High-grade Serous Ovarian Cancer","TNBC - Triple-Negative Breast Cancer",[8462]]